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ABSTRACT 
A unique characteristic of the biotechnology industry is its heavy reliance on 
continuous research & development (R&D). To explore the interdependence of 
science and commercialisation in the context of the biotechnology industry, this thesis 
built on expertise within the University of Queensland’s Institute for Molecular 
Bioscience and the UQ Business School. It used a interdisciplinary approach, 
undertaking both (1) scientific discovery, in the area of disulfide-rich peptide based 
molecules with therapeutic potential, and (2) a longitudinal analysis of Business 
Model (BM) framework components, to better understand the research underpinning, 
and successful commercialisation of, novel therapeutics.  
 
Chapters 2 to 5 of the thesis describe research on naturally occurring cyclic (plant) 
and open - chain (Anuran) disulfide rich molecules, with serine protease inhibitory 
(primarily, trypsin) activity. MCoTI-II and SFTI-1 are ultra-stable cyclic peptides 
derived from plants seeds and are potent trypsin inhibitors. In Chapter 2, these 
peptides were studied for their inhibitory activity against another serine protease, 
matriptase. Matriptase is over-expressed in several carcinomas, and has been reported 
to play a role in cancer progression. Mutagenesis studies on MCoTI-II and SFTI-1 
have provided insight into their structure-activity relationship, resulting in the design 
of the most potent matriptase inhibitor reported to date, with sub-nanomolar activity.  
  
In Chapter 3, open chain peptides, from frog skin secretions, with high sequence and 
structural similarity to SFTI-1, termed SFTI-1 like frog (SLF) peptides, were 
investigated. They have been reported to have both trypsin inhibitory and 
antimicrobial activity, which inspired us to further validate their antimicrobial 
properties in an animal model to treat Staphylococcal skin infection. Three SLF 
peptides (ORB, ORB2K and pYR) were found to have promising activity. Although 
cyclization of the SLF peptides was found to improve serum stability, it resulted in 
decreased efficacy against S. aureus. Nonetheless, this study opened doors to apply 
serine protease inhibitors to treat infections. Chapter 4 explored the used of related 
molecules in the inhibition of melanocortin (1 - 5) receptors (MCR), which are 
recognised as drug targets because of their role in diseases such as inflammation, 
obesity and skin disease. Here, I showed that SFTI-1 had moderate activity against 
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MCRs and, based on this result, I subsequently tested SLF peptides against MCR 
subtypes. Three novel SFL peptides (ORB, ORB2K and ranacyclin-T) exhibited 
promising antagonistic subtype selectivity.  
 
One of the limitations of peptides as drugs is high manufacturing costs, but their 
production in plants could potentially resolve this issue. Understanding the 
biosynthesis of MCoTI-II and SFTI-1 could facilitate the production of designer 
peptides in genetically modified plants. In Chapter 5, the biosynthesis of MCoTI-II 
was investigated. The enzyme, Asparaginyl endopeptidase (AEP) was found to play a 
crucial role, such that optimisation of AEP activity has been identified as a future goal, 
for significantly improving peptide production. 
 
Recently, the biotechnology industry has witnessed a decline in the number of drugs 
reaching the market. This reduction is largely due to the many hurdles in the process 
of transforming potential molecules into drugs, including inadequate capability on the 
industry front and increasing stringent clinical regulations. Understanding and 
evaluating the longitudinal performance outcome of a firm, through the identification 
of the business model (BM) deployed, provides an instructive tool to mitigate 
business risks and thus improve chances of success. We, therefore, sought to develop 
a tool, for bio-entrepreneurs, to help them better align their organisations with core 
business objectives and a dynamic market environment. Prior to developing the tool, I 
conducted an extensive and systematic review of the Biotechnology BM research area, 
which is reported in Chapter 6.  
 
The prevalent BMs in other technology-based industries are not directly applicable in 
the biotechnology context, primarily due to lengthy product pipeline times, high cash 
burn rates, and the intensiveness of research involved. As described in Chapter 7, I 
developed a BM framework specifically tailored to the biotechnology industry and 
used it to analyse the impact of BM framework components on firms since 1985, 
resulting in an evolutionary analysis of BM profiles. Irrespective of the era in which 
firms were founded, they tended to move from “research intensive” to “revenue 
oriented” and attain a stable BM, most likely due to longitudinal capability learning, 
and improved monetary availability. I noted that the performance of the 
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biotechnology industry could be improved by the application of better decision-
making tools such as BM in their organisational structure and development cycle. 
The nascent medical biotechnology industry has seen more failures than successes 
and has struggled on both R&D and economic fronts. Attempts to improve the current 
state by addressing the science and business issues in isolation have achieved limited 
success. A systems-thinking approach that studies science and business issues in an 
integrated framework is likely to generate insights which is less widespread among 
small biotechnology firms. This thesis provides both novel scientific discoveries, and 
also explores ways in which biotechnology companies can be better prepared to 
capitalise on these research outcomes.  
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CHAPTER 1 
 
 
 
1 INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
कमर् णे्यवािधकारसे्त मा फलेषु कदाचन। मा कमर् फलहेतुभूर् मार् ते सङ्गोऽस्त्वकमर् िण॥ 
You have the right to perform your actions, but you are not entitled to the fruits of the actions. Do not 
let the fruit be the purpose of your actions, and therefore you won’t be attached to not doing your duty. 
 
Bhagavad Gita, Chapter 2, Verse: 47
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1.1 DRUG DEVELOPMENT AND BIOTECHNOLOGY INDUSTRY 
 
Biotechnology as a science has existed for centuries, but modern biotechnology has 
only been in existence since the 1970s and the United States and Europe have 
dominated the industry. The biotechnology industry is a science based, yet market 
driven industry (Pisano, 2006a; Pisano, 2006b), which is the result of the effort and 
risks taken by a generation of molecular biologists and risk-taking venture capitalists. 
These people successfully triumphed over obstacles between academia and industry 
and delivered life-changing drugs to the market (Bud, 1991). In the wake of this, 
many breakthroughs in drugs, vaccines and therapies were delivered to the market. 
Biotechnology industry has been defined as “any technique that uses living organisms 
or parts of organisms to make/modify products, improve plants or animals, or develop 
microorganisms for specific use” (Goetz et. al., 1995). Figure 1.1 shows the life cycle 
of a therapeutic from its discovery in the laboratory to its availability in the market.  
 
 
Figure 1.1 Schematic diagram of drug development cycle.  
The development of novel therapeutics depends upon the availability of a continuous 
discovery of novel molecules.  
 
In the past half-century there have been great scientific, technological and managerial 
advances, which should have increased the efficiency of the drug pipeline. On the 
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contrary, there has been a decline in the number of new drugs reaching market while 
more money is being put into research and development (Munos, 2009; Scannell et. 
al., 2012). The reasons reported for this relate to the ‘better than the Beatles’ problem 
i.e. development of better drugs than those already on the market. In addition, 
stringent regulations and over estimation of science abilities have had an impact 
(Scannell et. al., 2012). Overall science has been blamed for the failures of drug 
development. However, the competency of biotechnology firms to take drugs to 
market has been overlooked, and limited knowledge about the business models of 
biotechnology firms has constrained the knowledge transfer between the firms.  
 
A major characteristic of a biotechnology industry is its heavy investment in R&D 
that makes it different from other closely related technology driven industries. Due to 
these high investments, this industry is often categorized into high risk-high return 
making its stocks highly risky and volatile (Tan et. al., 2007). Also, unlike other 
industries the investment in a biotechnology firm is mainly based on intangibles such 
as intellectual human capital, strategic alliances, patents and scientific expertise (Tan 
et. al., 2007; Wolff, 2001). These intangibles make it harder for experts to predict the 
future of this industry or of an individual firm.  As stated by Adelene Q. Perkins, 
President of Infinity Pharmaceuticals, Inc the principles from other kinds of 
successful industries cannot be applied to biotechnology as the product development 
is slow, expensive and risky (Young, 2009). Financial scepticism is not the only 
hurdle that a biotechnology firms faces to survive and grow. The industry as a whole 
is being stressed by several threats and challenges ranging from stringent FDA 
approval process to financial scarcity. Overall from a technological perspective, 
biology has not yet been considered a mature science (Munos, 2009). Nonetheless as 
compared to other industries, biotechnology is expected to face the challenges of large 
R&D costs and long timelines for product development. 
1.1.1 The reality of novel therapeutics 
 
Although the modern medical biotechnology industry has been in existence for more 
than three decades, and despite some prominent drug discoveries, a concern remains 
that as an industry it is yet to deliver on its promise. Declining drugs approvals does 
not bode well for the future (Scannell et. al., 2012). Figure 1.2 shows the number of 
                                                                                                                                                    Chapter 1  
 4 
drugs approved in various therapeutic areas since 2004. There are various reasons 
behind the decline of approved drugs including increased regulatory vigilance on 
clinical trials, drug toxicity, side effects, lack of selectivity, lower clinical efficacy 
and even a lack of money to make them better (Giuliano et. al., 1997; Hopkins, 2008). 
Also, the biotechnology industry is so young that it does not have a roadmap to learn 
from and deal with those failures. There is an utmost need to identify the reasons and 
solutions towards the failure of drugs and biotechnology firms from both science and 
business perspectives. 
 
 
Figure 1.2 Number of drugs approved in various therapeutic areas in last decade. 
 ‘Others’ include therapeutic areas with less than 30 drugs in last 10 years; pulmonary 
diseases, neonatology, gynecology, musculoskeletal, gastroenterology, hematology, 
nephrology, dermatology, psychiatry, genetic disease, urology, rheumatology, ophthalmology, 
hepatology, vaccines, toxicology, otolaryngology, podiatry, trauma, dental and oral health, 
nutrition and weight loss, orthopedics, sleep, devices and healthy volunteers. 
 
In 2008, 4,300 companies had been engaged in the area of drug discovery, yet only 
261 (6%) had registered new biologics. It is not surprising that of these 261 firms, 
only 105 survived until 2009. The other 137 have vanished through merger and 
acquisition (M&A), while the remaining 19 were liquidated. Consequently, only 21 
companies that have produced half of all the approved new molecular entities (Munos, 
2009). Despite the distressing situation that these statistics present, 1,220 new drugs 
have been approved in the past 60 years and they have resulted in an increase in life 
expectancy by an average of two months each year (Arias, 2007).  
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1.2 THESIS OVERVIEW – The need for a complete picture 
 
This inter-disciplinary thesis amalgamates the two components of drug discovery in 
the biotechnology industry – the science behind the creation of a drug in the 
laboratory and beyond, and the business that seeks to deliver the drug to its market; 
each in an attempt to provide solutions to health and medical issues. Figure 1.3 shows 
the schematic representation of various components of this thesis. As such my PhD 
project has two distinct, but interlocking objectives: to develop potential novel drug 
leads in the laboratory; and propose an efficient business model that is tailored for the 
biotechnology industry to understand the evolution of business model that deliver 
performance in the biotechnology industry.  
 
Figure 1.3 Thesis outline.  
This interdisciplinary of PhD thesis is designed to address the gaps in different stages 
of drug development process. The schematic representation of the thesis shows the 
two interconnected component of biotechnology. 
 
Investigating these problems across the science and business area, brought forward 
some of the key gaps that need to be addressed for holistic growth in this field. 
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Therefore Chapters 2 - 4 describe the discovery of novel drug leads with potential for 
treating cancer, bacterial infections, acne and obesity and Chapter 5 presents the 
insight into the biosynthesis of a cyclic peptide with the aim to contribute towards 
economical production in plants, and finally understanding the business model of 
biotechnology companies for better firm performance.  
1.2.1 The science of novel therapeutics 
 
The reasons for the decline in approved drugs are largely due to the inability of the 
sector to develop molecules that improve on existing drugs and vaccines, and a lack 
of novel discoveries that reach the market. This causes the further obstacles for 
approval, adoption and return on investment of a drug. In this PhD, an attempt has 
been made to discover novel peptide-based drug leads against the diseases that have 
been of particular interest to biotechnology companies and society due to their wide 
spread implications. In the field of drug development, the few diseases that have been 
of particular interest for biotechnology and pharmaceutical industry is the 
development of molecules of therapeutic significance against cancer and bacterial 
infection.  
 
Serine proteases have importance in both basic and applied research because they are 
involved in a range of physiologically significant processes such as digestive 
processes, blood clotting, degradative processes, cellular and humoral immunity, 
fertilization, embryonic development, fibrinolysis, protein processing and tissue 
remodelling (Krem et. al., 2001a; Stoop et. al., 2000).  Although inhibitors of serine 
proteases have potential in the development of novel drugs, many have failed to reach 
the market because of two main reasons: lack of specificity or our limited 
understanding of their biological roles (Deu et. al., 2012).  Four main strategies have 
been employed by researchers to develop inhibitors for this class of enzymes: 
discovering natural products ranging from proteins to small molecules; converting 
endogenous substrates into inhibitors; screening large compound libraries; and 
modifying compounds that contain mechanism based electrophiles which can reach 
covalently to the serine nucleophile in the active sites (Bachovchin et. al., 2012). 
 
A promising approach in the development of such therapeutics involves exploring 
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nature’s repositories of disulfide-rich cyclic peptides that are either naturally cyclic or 
chemically cyclized and investigating their biological and structural characteristics. 
Peptides are generally defined as molecules containing less than 50 amino acids and 
this differentiates them from proteins (Craik et. al., 2013a). One of the most common 
post-translational modifications in peptides is disulfide bond formation. It plays a 
critical role in stabilising the three dimensional structure and peptides may contain 
multiple disulfide bonds. A disulfide bond  (-S-S-) is a covalent linkage formed by the 
oxidation of sulfhydryl (SH) groups on two cysteines or other SH containing groups 
(Saito et. al., 2003). One of the key characteristics of disulfide bond containing 
peptides that make them attractive in designing drug leads is their relative stability in 
plasma (Klink et. al., 2000). Another intriguing post-translational modification is 
head-to-tail cyclization. Numerous peptides have been discovered in the last few 
decades that are head-to-tail cyclic and contain disulfide bonds and together these two 
characteristics contribute towards their exceptional thermal, chemical and enzymatic 
stability (Craik et. al., 2012). Disulfide-rich cyclic peptides have been used in several 
recent studies for the design of novel compounds with potential in drug design (Chan 
et. al., 2011; Northfield et. al., 2014; Schroeder et. al., 2013). 
 
The peptides that will be further explored for their potential to deliver drug leads are 
disulfide-rich serine protease inhibitors – 1) cyclic peptides from plant (SFTI-1 and 
MCoTI-II) and 2) SFTI-1 like peptides from Anuran skin secretion (Figure 1.4). A 
major focus of this PhD thesis is the development of peptide based drug leads, 
primarily based on naturally cyclic peptides from plants. Plant-produced 
pharmaceuticals could provide a cost-effective method of manufacturing drugs as 
compared to chemical synthesis. To successfully produce cyclic peptide based drugs 
that are altered for therapeutic purposes in cyclic peptide producing plants it is 
important to understand their synthesis inside the cell. Therefore, another objective of 
my PhD was to study the processing of a cyclic peptide to advance our understanding 
of the biosynthesis of cyclic peptides (Gillon et. al., 2008; Saska et. al., 2007). These 
studies involved analysis of the role of an enzyme, asparaginyl endopeptidase (AEP) 
in the processing. AEP had been suggested to be involved in the processing but direct 
evidence was not available at the start of these studies. 
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Figure 1.4 Disulfide rich peptide used for the development of molecules with 
therapeutic significance.  
A) Sequence and B) structure of the disulfide rich peptides consisting of six and two 
cysteines plant peptide, MCoTI-II (orange) and SFTI-1 (orange-red), respectively, 
and SFTI-1 like peptide (green) derived from frog skin secretions.  
 
1.2.1.1 Cyclic plant peptides as matriptase inhibitors 
1.2.1.1.1 Background, discovery and applications of cyclic peptides 
 
In the last two decades, very unique and fascinating classes of cysteine rich peptides 
have been discovered which have head to tail cyclised backbones. These structurally 
and functionally diverse cyclic proteins have been discovered across a range of genera 
and families from the plant, bacteria, fungi and animal kingdoms. Two intriguing and 
potent serine protease inhibitors have been discovered from seeds, MCoTI-II from 
Momordica cochinchinensis and SFTI-1 from Helianthus annuus. 
 
MCoTI-II and SFTI-1 are naturally occurring peptides that are highly stable due to 
their cross-bracing by disulfide bonds coupled with the cyclic backbone which also 
makes them resistant to chemical, thermal and enzymatic degradation (Chan et. al., 
2011; Daly et. al., 2013).  The atypical and pharmaceutically essential properties of 
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these peptides have intrigued various researchers and led to studies aimed at gaining a 
better understanding of their structure stability, gene structure, in-vivo synthesis, 
biological functions and therapeutic applications. One of the potential therapeutic 
applications of cyclic peptides is their use as scaffolds to deliver bioactive sequences 
and therefore it becomes important to investigate the contribution of individual 
residues to the peptide structure and biological activity (Simonsen et. al., 2008; 
Thongyoo et. al., 2007).  
 
1.2.1.1.2 MCoTI II – peptide characteristics 
 
MCoTI-II is a 34-residue long cyclic polypeptide with three disulfide bonds, which is 
potent trypsin inhibitor (Hernandez et. al., 2000). It has high sequence similarity to 
the squash trypsin inhibitors but is one of the first to be discovered with a cyclised 
amino acid backbone. The importance of cyclization and the mechanism behind the 
cyclization observed in MCoTI-II is yet to be determined. It is anticipated that high 
stability, trypsin inhibitory activity and cyclization could have evolved together to 
confer resistance to exopeptidases. Interestingly, both cyclised and acyclic MCoTI 
peptides have been observed in M. cochinchinensis.  
 
The structure of MCoTI-II has been determined using NMR spectroscopy and 
contains a cyclic cystine knot (CCK) motif (Felizmenio-Quimio et. al., 2001; Heitz et. 
al., 2001). This motif involves the disulfide connectivity I-IV, II-V and III-VI coupled 
with a cyclic backbone (Figure 1.4A). The major element of secondary structure is a 
β-hairpin (Cĕmažar et. al., 2008b).  
1.2.1.1.3 SFTI-1 – peptide characteristics 
 
SFTI-1 is a 14 residue long small cyclic peptide, which is a potent trypsin inhibitor 
related to the Bowman-Birk family of inhibitors (BBIs) (Daly et. al., 2006). SFTI -1 
contains one disulfide bond, which connects the two β-strands creating two distinct 
loops. Along with extensive hydrogen bonding network, three proline residues and the 
cyclic backbone SFTI-1 forms a tightly folded scaffold (Figure 1.4A). The two loops 
in SFTI-1, are referred to as the binding loop and secondary loop. The binding loop 
contains Lys 5, the active site residue and the secondary loop is where backbone 
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cyclization occurs (Daly et. al., 2006; Korsinczky et. al., 2001; Mylne et. al., 2011).  
This rigid structure of SFTI-1 appears to be effective in reducing the entropy loss 
when it binds to trypsin and prevents conformational rearrangement. 
 
SFTI-1 has potential to provide potential drug leads as it can accommodate sequence 
variation and still retain its native-like form, thus it can be also be used as a scaffold 
and it could then be potentially trimmed down to make therapeutic molecules (Chan 
et. al., 2011; Daly et. al., 2006; Swedberg et. al., 2009). This concept has been used to 
insert the FCQR residue in its framework to increase its potency to inhibit KLK4 
activation of protease-activated receptor 2 (PAR2), which is a potential target for 
prostate cancer research (Swedberg et. al., 2009). In addition, SFTI-1 has been used 
for the design of novel angiogenic agents (Chan et. al., 2011). Also, as a result of its 
highly optimised framework, SFTI-1 has also been found to inhibit matriptase and 
trypsin with a Ki of 0.92 nM and 0.03 nM, respectively, making it one of the most 
potent naturally occurring trypsin inhibitors. However the structure-activity 
relationships are still not fully understood.  
 
1.2.1.1.4 Cyclic plant peptides and matriptase 
 
Matriptase, also known as TADG-15, ST14/SNC19 and MT-SP1, is a type II 
transmembrane trypsin-like serine protease.  It is an 80-90 kDa cell surface 
glycoprotein with a complex modular structure. Cells of epithelial origin express it 
and it substantially contributes to tumour progression, metastasis and other diseases 
(Sales et. al., 2010; Uhland, 2006).  It is expressed in an unusually high proportion of 
human epithelial tumours and promotes malignant progression (List et. al., 2006). 
Therefore it is essential to discover or synthesize potent and selective matriptase 
inhibitors, which could have therapeutic potential for the treatment of cancer and it 
could also be used to further elucidate the role of matriptase in biological processes 
(Enyedy et. al., 2001). Chapter 2 examines the evaluation of inhibitory activity of 
naturally cyclic peptides, MCoTI-II and SFTI-1 against matriptase and trypsin. This 
study contributes towards understanding the structure activity relationships by 
determining the influence of mutations in MCoTI-II and SFTI-1 on serine protease 
inhibitory activity. 
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1.2.1.2 SFTI-1 like frog peptides to treat Staphylococcal skin infection 
 
SFTI - like frog (SLF) peptides were found in the literature and through blast searches 
that have been reported to have bi-functional properties - antimicrobial and trypsin 
inhibitor. These peptides have a conserved BBI loop (SIPPI/K), and a range of 
biological activities including antimicrobial, anti fungal and immunomodulatory 
effects (Graham et. al., 2004, 2005; Li et. al., 2007; Mangoni et. al., 2003; Salmon et. 
al., 2000). Amphibians live in hostile environments, and are able to survive in 
conditions laden with pathogenic microbes. To help survive in these hostile 
environments, frogs are endowed with an extremely effective chemical defence 
system composed of pharmacologically active antimicrobial peptides (AMPs) (Li et. 
al., 2007). These peptides had been exploited to develop molecules of pharmaceutical 
significance (Andrès, 2012; Eckert, 2011; King et. al., 2012). 
 
In Chapter 3, SLF peptides, were examined for their antimicrobial properties against 
Staphylococcus aureus using in vivo and in vitro antibacterial assays.  S. aureus is one 
of the most notorious and virulent pathogens and its resistance against existing 
antimicrobial drugs is a global concern. Antimicrobial peptides (AMPs) offer a 
potential solution to this problem, as resistance against them is considered improbable 
as they target microbial membranes. Several peptides were found to have potent 
antibacterial activity Staphylococcus skin infection and they were also found to 
modulate the host innate immunity system.  Structure-function relationships provided 
insights towards the development of bi-functional peptides with both potent in vivo 
antimicrobial activity and serine protease inhibitory activity. This work could offer 
therapeutic solutions against clinically resistant microbes. 
 
1.2.1.3 SFTI-1 like frog peptides as melanocortin antagonists 
 
SLF peptides were also tested for their agonist and antagonistic functional activity 
and binding affinity against melanocortin receptors 1, 3, 4 and 5 as described in 
Chapter 4. Melanocortin receptors are members of 7-transmembrane G-protein-
coupled receptors that are known to affect memory, inflammation, obesity, blood 
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pressure and regeneration (Catania et. al., 2004; Schioth et. al., 2005). Studies have 
been conducted to understand the physiological functions of receptors and some 
findings indicate that the agonist and antagonist for the receptors could serve as novel 
drug therapeutics (Wikberg, 1999; Yang, 2011).  
 
Recently, a cyclic peptide from plant, kalata B1 has been used as scaffold for 
melanocortin receptor-activating sequence and this led to the development of a new 
group of selective melanocortin agonist (Eliasen et. al., 2012). Another cyclic plant 
peptide, SFTI-1 was tested for activity and affinity towards MCR. It was found to 
have relatively low activity, however selective binding affinity towards MCRs. Due to 
high sequence and structural similarity of SLF peptides to SFTI-1, they were screened 
for their binding and functional activity towards melanocortin receptors with an 
objective to discover novel selective scaffolds or ligands for one of the MCRs. This 
study resulted in the discovery of a stable and novel class of ligands that have high 
subtype receptor selectivity and thus they could be further optimized for their 
applicability as scaffold to stimulate or block specific melanocortin receptors.  
 
1.2.1.4 Understanding biosynthesis of naturally occurring cyclic plant peptides 
 
Peptide-based drugs had lagged behind small molecules for various reasons including 
large-scale production costs. Plants abundantly produce cyclic peptides and 
unraveling their biosynthetic mechanisms could assist biologists to produce designer 
peptides in genetically modified plants. Chapter 5 sheds light on the processing and 
cyclization of MCoTI-II for which pharmaceutically relevant properties were 
discovered in Chapter 2. Asparaginyl endopeptidase was found to play a crucial role 
in the cyclization and optimization of this enzyme could improve the peptide 
production in both cyclic peptide producing and non-producing plants.  
 
Recently the gene sequences for the precursor of MCoTI-II and related peptides have 
been discovered and they have been referred to as TIPTOP for Two Inhibitor Peptide 
TOPologies. The gene encoding MCoTI-II has eight repeating protein units in tandem 
comprising seven cyclic and two acyclic peptides. This could be the result of 
extensive internal gene amplification (Mylne et. al., 2012). This kind of dual topology 
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within one protein has similarities with the PawS genes that translates to give related 
cyclic and acyclic peptides (Mylne et. al., 2011).  The processing event resulting in 
the excision of mature peptide region and its cyclization is not very well understood 
but it is believed that asparaginyl endopeptidase (AEP), which is a cysteine protease, 
is a key element in the maturation and cyclization of cyclic peptides (Gillon et. al., 
2008; Saska et. al., 2008b; Saska et. al., 2007). It has been suggested that AEP 
mediated cyclization occurs at the same time as the cleavage of the C-terminal 
propeptide in the transpeptidation reaction (Saska et. al., 2007). The precursor protein 
of SFTI-1 has recently been discovered and it does not share sequence similarities 
with other BBIs but rather has a unusual biosynthetic route and is found in the same 
gene as an albumin (Mylne et. al., 2011). Interestingly, SFTI-1 has an Asp at the C-
terminus and it appears that AEP also processes this cyclic peptide.  Most of the 
cyclotides precursors known so far contain a conserved Asp/Asn residue at the C 
terminus of the cyclotide domain, which is consistent with AEP being involved in the 
cyclization (Camarero, 2011). However it is assumed that the oxidative folding occurs 
prior to cyclization and it could be facilitated by biological chaperones (Daly et. al., 
2011; Gruber et. al., 2007; Jennings et. al., 2001). The proposed concept of 
cyclization by AEP will be investigated further by in-vitro techniques in this study. 
Figure 1.5 summarizes the advances made in this field since the discovery of 
cyclotides. 
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Figure 1.5 Schematic representation of the major steps thought to occur in 
cyclotide processing inside a plant cell. 
Panel (A) shows the structure of a generic cyclotide precursor protein (prepropeptide) 
highlights proposed N-terminal and C-terminal enzymatic processing points. A series 
of in vivo mutagenesis and transfection studies (Conlan et. al., 2012; Conlan et. al., 
2011; Gillon et. al., 2008; Qin et. al., 2010; Saska et. al., 2007) is schematically 
illustrated below the precursor, which led to: (b) the hypothesized steps involved in 
the intracellular processing of cyclotides and (c) a proposed mechanism for the AEP-
mediated cyclization reaction. In panel (B) the various steps in the biosynthesis 
pathway are highlighted, including: (i) transcription of cyclotide DNA into RNA and 
translation to the prepropeptide (Jennings et. al., 2001); (ii) targeting of the 
prepropeptide to the ER, removal of the signal sequence and folding of the cyclotide 
precursor, possibly assisted by PDI (Gruber et. al., 2007); (iii) targeting of the 
propeptide to the vacuole, presumably by the NTR (or Nttp) (Conlan et. al., 2011); 
(iv) cleavage at the N-terminus of the cyclotide domain by an unknown enzyme to 
release the NTR and expose a small amino acid (Gly/Ala) as the proto N-terminus of 
the cyclotide domain; (v) transpeptidation to release the Ctpp (Gillon et. al., 2008; 
Saska et. al., 2007); and (vi) form cyclic peptide (Conlan et. al., 2012). The last two 
steps probably occur in a concerted manner. In panel (C) the proposed mechanism of 
cyclization of a cyclotide by AEP is shown: (i) AEP cleaves and releases the CTR or 
Ctpp (depending on whether the cyclotide is from a terminal or internal domain) 
leading to formation of an acyl enzyme intermediate via attack of the AEP active site 
thiol on the carbonyl of the scissile bond; (ii) the excised Cttp exits the enzyme active 
site and is replaced by a sterically homologous region from the N-terminus of the 
cyclotide domain; (iii) the primary amine of the N-terminal Gly (or Ala) acts as a 
nucleophile to attack the acyl enzyme intermediate; and (iv) the enzyme is 
regenerated and the cyclized product (cyclotide) exits the active site. The middle 
panel of the diagram schematically represents the process of mutating selected 
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residues in the cyclotide precursor (a), transfecting the modified genes into model 
plants and detecting the presence of cyclic product using mass spectrometry. A lack 
of production of cyclic peptide can be used to draw conclusions about the importance 
of individual residues in the cyclization process. Examples are shown for transfection 
of two mutants into wild-type plants, leading to cyclic products and into an AEP-null 
plant where no cyclization occurs. Adapted from (Craik et. al., 2013b) 
___________________________________________________________________________ 
 
1.2.2 The business of novel therapeutics 
 
Most of the biotechnology firms carry the huge responsibility of transforming a 
molecular entity discovered in a laboratory to a drug in the market. However, 
bioentrepreneurs have to tackle various hurdles in the process, ranging from securing 
significant funding for projects to changing FDA regulations. Only 10% of the drugs 
that enter clinical trials reach the market and to be sustainable in hostile financial 
environments, biotechnology firms often have to constantly change their business 
model efficiently either to prevent the firm from failing or maintaining their steady 
growth (Bienz-Tadmor et. al., 1992; Herrmann, 2001). Therefore, since the inception 
of the biotechnology industry in 1976 with Genentech, the business model and 
evolution of this industry has remained a hot topic among analysts, pundits and 
scholars alike.  
 
A part of this study aims to understand the application of the business model concept 
to the biotechnology industry and proposes a business model framework that best 
defines the operation of this industry. The dynamic characteristics of the system will 
be looked through the lenses of evolutionary biology and economics concepts and this 
could show us the adaptation and evolution of firms to survive the harsh market and 
financial environment. Drug development and approval is a cash intensive and risky 
process and therefore biotechnology firms have a high cash burn rate; firms are forced 
to use a range of external financing sources. Of all the major sources of funding, 
equity markets and corporate partners play an important role. Therefore, evolution in 
investment patterns in publicly listed biotechnology firms in the US will be studied as 
the cyclical nature of the equity market has an great influence on the availability of 
capital which in turn affects the very survival of a biotech firm (Schiff et. al., 2004).  
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Capital has been the crucial element for the sustainability of the biotechnology firms, 
where a few larger biotechnology firms apparently have access to several billion 
dollars capital reserves (Editor, 2009). Thus as per natural selection and economic 
Darwinism, it is the best fit that survives in science or business (Young, 2009). 
Venture capitalists, who were once manifested as the linchpin of biotechnology 
financing, had showed a declining popularity in last few decades (Klausner et. al., 
1983). The other possible sources of financial support for biotechnology industry are: 
R&D limited partnerships, public venture capital, mutual funds, corporate venture 
capital, public offerings and government strategies (Klausner et. al., 1983). Besides 
these sources, angel investors have also been very helpful for the start-up 
biotechnology firms so as to get the firm going and generate preclinical data 
(Schatzman et. al., 2010). 
 
The starting of a biotech company is tougher than it is for companies in many other 
industries. In the early stages neither the large corporations nor banks typically show 
great interest in offering financial support. In such instances survival of biotechnology 
companies becomes important for the success of the drug portfolio that they attempt 
to transfer from laboratory bench to patient’s bedside. Business model is a powerful 
tool for companies to understand their organisation, maintain sustainability and 
improved output. Even after more than a decade of the business model concept, 
biotechnology industry seems to lack its understanding and application. Therefore in 
Chapter 6, extensive literature screening was conducted systematically with an 
objective to extract enough information to develop an archetypical business model 
framework well suited for research-intensive biotechnology industry. Evolution of 
business model research area was studied and the key contributions by research 
scholars were recognized. The factors were identified that has been reported to 
influence the working of biotech firms and these factors/components were combined 
to propose a tailored business model framework. 
 
The business framework generated for the biotechnology industry was employed to 
observe the changes in the profile of a successful business model over time as a result 
of variation in the key industry factors and this work is presented in Chapter 7. The 
profile of the companies were found to be dependent up on the growth period of the 
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industry and financial conditions of companies was found to be a critical factor for 
firm performance in the early stages of its growth, while later replaced by revenue. 
This study is aimed to create a platform for researchers and entrepreneurs to help 
them understand the functioning of a firm and use the knowledge generated to make 
important strategic decisions. 
 
1.3 OVERVIEW 
 
In this dual science-business PhD, novel classes of peptides were identified with 
potential in the design of leads for treating cancer, bacterial infection and obesity. 
Significant contributions were made to understand cyclic-peptide biosynthesis that 
could result in improved peptide-based drug production in plants. Finally, factors 
contributing towards the performance of biotechnology companies were identified 
and their evolution was studied that could help them function better. A business 
model framework was proposed for the industry that could assist bioentrepreneurs to 
communicate better and learn from each other.  
 
1.4 AIMS AND SCOPE OF THESIS 
 
This thesis builds on the two essential elements of the biotechnology - science and 
business that drive the drug discovery and development process. The aims and scope 
of each research chapter in this thesis is provided below those together tackles few 
problems in the life cycle of drug development process and it is also presented as 
illustration in Figure 1.6. 
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Figure 1.6 Schematic representation showing drug development process and 
complementing layout of the thesis 
 
Chapter 2: Cyclic plant peptides as matriptase inhibitors 
 
Cyclic peptides from plants that are potent trypsin inhibitor, MCoTI-II and SFTI-1 
were studied for their inhibitory activity against another serine protease inhibitor, 
matriptase. Matriptase is over expressed in breast cancer cells and it has been reported 
to contribute towards the progression of cancer. Potent matriptase inhibitors would be 
beneficial for both research purposes to elucidate the role of matriptase in 
physiological processes and their use as therapeutic agent. This work was published in 
The Journal of Biological Chemistry in 2013.  
 
Chapter 3: SFTI-1 like frog peptides to treat Staphylococcal skin infection 
 
SFTI-1 like frog (SLF) peptides were found in literature that had been reported to 
have in vitro antimicrobial property against a range of microbes and trypsin inhibitory 
activity. These peptides were evaluated for their efficacy to treat Staphylococcal skin 
infection in mice. Other corresponding biological properties like trypsin inhibitory 
activity, stability and toxicity were also examined. This work has been submitted to 
Antimicrobial and Chemotherapy Journal, October 2014.  
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During the candidature, antimicrobial property of plant derived cyclic peptide (known 
as cyclotides) - cycloviolacin O2 (CyO2) and  kalata B2 (kB2) were evaluated against 
cutaneous infection by S. aureus. This work has been accepted in Peptides (November, 
2013) and provided in Appendix I as it does not cover the scope of this thesis. 
 
Chapter 4: SFTI-1 like frog peptides as melanocortin antagonists 
 
SFTI-1 has promising activity and affinity against melanocortin receptors. The 
analysis of SLF peptides for their response to melanocortin receptors was driven by 
their similarity to SFTI-1. Several peptides have showed promising selective 
antagonistic affinity towards either MC4R or MC5R and have been reported to play 
an important role in acne and obesity. Therefore, these peptides have potential to be 
used as scaffolds or further developed into more potent and selective antagonist 
against melanocortin receptor. 
 
Chapter 5: Understanding biosynthesis of naturally occurring cyclic plant 
peptides 
 
SFTI-1 and MCoTI-II are macrocyclic peptides that are known for their stability and 
potential application as drug design frameworks and protein engineering. However, 
the mechanism associated with post-translational backbone cyclization is poorly 
understood. AEP has been proposed to process the last step in their biosynthesis i.e. 
ligation of N and C termini. This chapter has provided the in vitro evidence that AEP 
is capable of producing cyclic peptide from its precursor. In future, information 
gained from this study could be used in producing peptide-based therapeutics in 
plants.  
 
During candidature, a review paper on cyclotide biosynthesis was published in 
Current Opinion in Chemical Biology (2013) that provides further background to the 
work presented in this chapter. This review summarizes recent studies on the 
mechanism of cyclotide biosynthesis and it is presented in Appendix II as it does not 
cover the full scope of the thesis. 
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Chapter 6: Understanding the business model concept: from its genesis and 
development to continued reinterpretation 
 Modern medical biotechnology industry has struggled to deliver drugs to the 
market due to large numbers of drug failures and requirement of enormous amount of 
funding. However, this industry has adapted and survived some of the major 
challenges of the economic crisis. Prior to the development of an analytical business 
model tool to measure the performance of biotechnology industry, extensive 
systematic literature research was conducted to understand and utilize the knowledge 
in the field of business model. This chapter provided a robust foundation of the 
subsequent empirical work to observe the dynamics in biotechnology industry.  
 
Chapter 7: Impact of changes in business model of biotechnology industry on 
performance 
To date biotechnology industry lacks a tool that could be used to evaluate 
performance and changes over the years. Analytical tools used for other industries 
would not serve the purpose for this industry due to its atypical nature - R&D 
intensive, high risk and high investment. Therefore, a business model framework 
consisting of four key components was proposed in this thesis to study the change in 
profile of biotechnology industry and their impact on its performance.  
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CHAPTER 2 
 
2 CYCLIC PLANT PEPTIDES AS MATRIPTASE 
INHIBITORS  
 
 
 
 
 
 
 
 
 
 
 
 
“When one door closes, another opens; but we often look so long and so regretfully 
upon the closed door that we do not see the one which has opened for us.”  
Alexander Graham Bell, Inventor and innovator (1914 - 1919)
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2.1 RELEVANCE TO THESIS AND SIGNIFICANCE OF WORK 
 
Serine proteases are valued as potential therapeutic agents because of their 
involvement in many physiologically significant processes such as digestive processes, 
blood clotting, degradative processes, cellular and humoral immunity, fertilization, 
embryonic development, fibrinolysis, protein processing and tissue remodelling 
(Krem et. al., 2001b; Stoop et. al., 2003). Two cyclic peptides discovered from plants, 
MCoTI-II from Momordica cochinchinensis and SFTI-1 from Helianthus annuus, 
have been reported to have potent serine protease inhibitory activity. A mutagenesis 
study was carried out on these two peptides to study the structural-functional 
relationships with trypsin and matriptase with an objective to develop a 
therapeutically relevant molecule. Analysis of the inhibitory activity of the SFTI-1 
and MCoTI-II analogues highlighted the amino acids that were important for 
interaction with the enzymes. Based on sequence and structural characteristics of 
SFTI-1, MCoTI-II V3R was designed which led to the development of one of the 
most potent inhibitors of matriptase known with a 290 nM inhibition constant. 
Matriptase inhibitors have potential in the treatment of cancer as over expression of 
this enzyme has been implicated in the progression of cancer. Figure 2.1 shows the 
context of Chapter 2 in the thesis and its contribution in the drug development and 
commercialisation process. 
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Figure 2.1 Schematic representation of the layout of the thesis showing its 
progression across chapters.  
 
 
2.2 DECLARATION OF AUTHORSHIP 
 
In accordance with the guidelines of the University of Queensland, this chapter is 
presented as a published, peer-reviewed article. 
 
“High-affinity cyclic peptide matriptase inhibitors” 
Quimbar, P., Malik, U., Sommerhoff, C. P., Kaas, Q., Chan, L. Y., Huang, Y. H., 
Grundhuber, M., Dunse, K., Craik, D. J., Anderson, M. A., & Daly, N. L. 
 
The Journal of Biological Chemistry, 2013, published online April 2, 2013, DOI: 
10.1074/jbc.M113.460030 
 
                                                                                   The Science and Business of Novel Therapeutics 
 24 
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High-affinity Cyclic Peptide Matriptase Inhibitors*□S
Received for publication, February 6, 2013, and in revised form, March 21, 2013 Published, JBC Papers in Press, April 2, 2013, DOI 10.1074/jbc.M113.460030
Pedro Quimbar‡1, Uru Malik§, Christian P. Sommerhoff¶, Quentin Kaas§, Lai Y. Chan§, Yen-Hua Huang§,
Maresa Grundhuber¶, Kerry Dunse‡, David J. Craik§2, Marilyn A. Anderson‡, and Norelle L. Daly§!3
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Therapeutics, School of PharmacyandMolecular Sciences, JamesCookUniversity, Cairns,Queensland4878, Australia
Background: Sunflower trypsin inhibitor-1 (SFTI-1) and Momordica cochinchinensis trypsin inhibitor-II (MCoTI-II) are
potent protease inhibitors comprising a cyclic backbone.
Results: Elucidation of structure-activity relationships for SFTI-1 and MCoTI-II was used to design inhibitors with enhanced
inhibitory activity.
Conclusion: An analog of MCoTI-II is one of the most potent inhibitors of matriptase.
Significance: These results provide a solid basis for the design of selective peptide inhibitors of matriptase with therapeutic
potential.
The type II transmembrane serineproteasematriptase is a key
activator of multiple signaling pathways associated with cell
proliferation and modification of the extracellular matrix.
Deregulatedmatriptase activity correlates with a number of dis-
eases, including cancer and hence highly selective matriptase
inhibitors may have therapeutic potential. The plant-derived
cyclic peptide, sunflower trypsin inhibitor-1 (SFTI-1), is a prom-
ising drug scaffold with potentmatriptase inhibitory activity. In
the current study we have analyzed the structure-activity rela-
tionships of SFTI-1 and Momordica cochinchinensis trypsin
inhibitor-II (MCoTI-II), a structurally divergent trypsin inhibi-
tor fromMomordica cochinchinensis that also contains a cyclic
backbone. We show that MCoTI-II is a significantly more
potent matriptase inhibitor than SFTI-1 and that all alanine
mutants of both peptides, generated using positional scanning
mutagenesis, have decreased trypsin affinity, whereas several
mutations either maintain or result in enhanced matriptase
inhibitory activity. These intriguing results were used to design
one of themost potentmatriptase inhibitors known to date with
a 290 pM equilibriumdissociation constant, and provide the first
indication on how tomodulate affinity formatriptase over tryp-
sin in cyclic peptides. This information might be useful for the
design of more selective and therapeutically relevant inhibitors
of matriptase.
Serine proteases are one of the largest known family of pro-
teases (1), and are involved in a range of cellular processes such
as apoptosis, inflammation, blood coagulation, and extracellu-
lar matrix remodeling (2). Several mechanisms are involved in
controlling the activity of serine proteases, including synthesis
as inactive zymogens and production of specific protease inhib-
itors. The deregulation of these endogenous controls has dra-
matic consequences, and can lead to autoimmune and meta-
bolic diseases and to an increased susceptibility to infections
and cancer (3).
Matriptase is a type II transmembrane serine protease that is
expressed strongly in the human epithelia (4). The expression
of this protease, both at the RNA and protein level increases
significantly during the progression of prostate cancer (5). The
oncogenic potential of matriptase has been demonstrated in
transgenic mice where overexpression of matriptase caused
spontaneous squamous cell carcinoma. However, overexpres-
sion together with a matriptase inhibitor counteracted the
oncogenic effects (6), indicating that inhibition of matriptase
has significant potential as a therapeutic strategy. Administra-
tion of inhibitors in a pancreatic tumormodel inmice led to the
inhibition of matriptase in vivo for at least 24 h (7), and in a
prostate tumor mouse model inhibitors reduced primary
tumor growth by 40% as well as reducing the prevalence of
metastases (8). Genetic reduction of matriptase in mice
resulted in reduced tumor growth, invasiveness, and migration
in vitro (9) and correlated with in vivo studies where matrip-
tase-deficient PC3 and DU-145 cells exhibited reduced growth
and development compared with control cells when explanted
into nude mice (10). Overall, these studies highlight the poten-
tial of using matriptase inhibitors as a treatment approach to
halt growth and spread of cancer cells.
A major challenge in the design of protease inhibitors is
selectivity (11). Broad range inhibitors have caused detrimental
effects in clinical trials as a result of interference with signaling
pathways and processes that were not foreseen (12). Therefore,
when designing inhibitors for pharmaceutical purposes, it is
essential that they are selective for the desired target, whereas
also having high affinity. Several studies have focused on small
molecules for the design of matriptase inhibitors, and have
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ject SO249/1-1, priority program1394 “Mast cells-promoters of health and
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resulted in potent inhibitors with selectivity over other serine
proteases such as thrombin (8). However, limited information
is available regarding selectivity relative to other closely related
serine proteases, particularly the prototypic trypsin.
The active sites of matriptase and trypsin are very similar in
structure and both enzymes belong to the S1 family and sub-
family A according to the MEROPS database (13). However,
there are some important differences, as shown in Fig. 1, which
could potentially be exploited for the design of novel inhibitors.
The active site of all serine proteases is surrounded by eight
loops (1) that will be referred to as I to VIII in this article. Loop
II of matriptase has 10 more residues than that of trypsin,
resulting in an additional bulge that constitutes the most obvi-
ous topological difference between the two protease active sites
(Fig. 1). Loops I, III, and V also display different sequences
between the two proteases, resulting in slightly different con-
formations. In contrast, loops IV, VI, and VIII, which cluster at
one end of the active site, have similar conformations inmatrip-
tase and trypsin. The active site of matriptase is much more
negatively charged than that of trypsin, mostly because of two
additional aspartate residues in loop IV and three aspartate res-
idues in the extended loop II. The negative charges borne by
matriptase loop II are partly compensated by two positively
charged arginine residues located at the tip of the loop.
Naturally occurring peptidic inhibitors are a promising start-
ing point for the design of novel matriptase inhibitors as they
can provide a relatively large surface area to enhance the poten-
tial of designing selective analogs. The use of naturally occur-
ring amino acids also leaves open the possibility of using plants
as “factories” for producing the modified inhibitors via a low
cost route (14). Sunflower trypsin inhibitor-1 (SFTI-1)4 is a
14-residue sunflower peptide that is a potent inhibitor of both
trypsin and matriptase, with an inhibition constant against
matriptase of 0.92 nM (15). However, SFTI-1 is also active
against other serine proteases within the trypsin clan, which
limits its therapeutic application. Despite this limitation, the
size, versatility, and stability of the SFTI-I backbonemakes it an
appealing scaffold for the design of drugs (16). Swedberg et al.
(17), for example, enhanced both the affinity and specificity of
the SFTI-1 backbone against kallikrein 4 (KLK4) throughmod-
ifications of the inhibitor. They used positional scanning of a
synthetic combinatorial library to study protease specificity and
generated a mutant of SFTI-1 with an inhibition constant of
3.59 nM against KLK4 compared with no inhibition by native
SFTI-1 (17). Although this mutant was not tested in vivo it
retained high inhibitory potential against KLK4 after days of
incubation in serum, highlighting the advantages of the SFTI-1
scaffold in the design of drugs.
Several other researchers have also explored the structure-
activity relationships of SFTI-1 and shown the importance of
particular residues for a range of proteases. The introduction of
naturally and non-naturally occurring residues has been
explored, as have the roles of the disulfide bonds in activity
(18–22). Enhancements in activity and selectivity have been
obtained, highlighting the potential of this cyclic scaffold. How-
ever, further study is required to determine whether significant
selectivity between trypsin and matriptase is achievable.
The stability and versatility of cyclic peptides is not limited to
SFTI-1. Other cyclic peptides, such asmembers of the cyclotide
family, have functions as diverse as insecticidal activity (23),
HIV inhibition (24), and hemolytic activity (25). Their extraor-
dinary stability to pH, heat, and biological fluids also makes
4 The abbreviations used are: SFTI-1, sunflower trypsin inhibitor-1; COSY, cor-
relation spectroscopy; MCoTI-II,Momordica cochinchinensis trypsin inhibi-
tor II;MD,molecular dynamics; NOESY, nuclearOverhauser effect spectros-
copy; RP-HPLC, reverse phase high performance liquid chromatography;
TOCSY, total correlation spectroscopy; PDB, Protein data bank; Boc,
t-Butyloxycarbonyl.
FIGURE 1. Comparison of trypsin and matriptase active sites. The crystallographic structures of SFTI-1 in complex with trypsin (PDB code 1sfi) and in
complexwithmatriptase (PDB code 3p8f) are represented. The protein backbone of SFTI-1 is in cyan and the functional Lys is displayed in stick representation.
The eight loops that surround the active sites are named loops I to VIII. The solvent accessible surfaces of the proteases are colored according to the
Poisson-Boltzmannelectrostatic potential they generate, as computedby theAPBS software (49), with a scale ranging from!5 kT/e (red) to"5 kT/e (blue). The
charged positions in each loop are highlighted. The numberings of trypsin andmatriptase positions are according to the sequence of bovine trypsin (UniProt
P00760) and human matriptase SP1 (Q9Y5Y6), respectively. The figure was generated using PyMol.
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them ideal scaffolds for pharmaceutical design (14, 17). In the
current study we have discovered that a member of the trypsin
inhibitory subfamily of cyclotides,Momordica cochinchinensis
trypsin inhibitor-II (MCoTI-II) (26), a 34-residue cyclic pep-
tide, is also a potent inhibitor of matriptase. Furthermore, we
have used alanine scanning and point mutations to design
inhibitors, based on SFTI-1 and MCoTI-II, which have
enhanced potency and modified selectivity against matriptase.
The sequences and structures of SFTI-1 and MCoTI-II are
given in Fig. 2 and highlight the sequence and structural diver-
sity of these cyclic peptidic trypsin inhibitors.
EXPERIMENTAL PROCEDURES
Peptide Synthesis and Purification
Peptides were synthesized on a 0.5-mmol scale usingmanual
solid-phase peptide synthesis with Boc chemistry. A phenylac-
etamidomethyl-Gly-Boc resinwas usedwith an S-tritylmercap-
topropionic acid linker to facilitate cyclization, as described
previously (27, 28). Crude peptides were purified using a series
of Phenomenex C18 columns on RP-HPLC. Gradients of 1%
min!1 of 0–80% solvent B (90% acetonitrile in 0.045% TFA in
H2O) and solvent A (aqueous 0.05% TFA in H2O) were
employed and the eluant was monitored at 215 and 280 nm.
The purity of the peptides was examined by analytical
RP-HPLC on a Phenomenex Jupiter 5! C18 300 Å 150 "
2.0-mm column and masses were determined by electrospray
mass spectrometry. Grafted and native SFTI-1 peptides were
folded in solution at 0.1 mg/ml using a range of buffer condi-
tions. Synthetic native SFTI-1 peptide was cyclized and oxi-
dized in a two-step process. Cyclization was achieved in the
presence of 0.1 M tris(2-carboxyethyl)phosphine incubated for
24 h and the cyclic product then purified by RP-HPLC. The
cyclic reduced peptide was oxidized in 0.1 M ammonium bicar-
bonate (pH 8.0). By contrast, cyclization and oxidation of
MCoTI-II grafted peptides was done in a single step reaction
with 0.1 M ammonium bicarbonate (pH 8.5) for 12 h. SFTI-1
grafted peptideswere oxidized in 0.1 M ammoniumbicarbonate
(pH 8.5).
NMRAnalysis
Peptides were dissolved in 90% H2O, 10% D2O (v/v) (1 mM).
D2O (99.9%) was obtained from Cambridge Isotope Laborato-
ries, Woburn, MA, for 1H NMR measurements. Spectra were
recorded at 290–298 K on Bruker Avance 500 and 600 MHz
spectrometers. Two-dimensional spectra included TOCSY,
NOESY, and COSY. NOESYmixing times of 200–300ms were
used. Spectra were analyzed using SPARKY (29). The sequen-
tial assignment procedure pioneered by Wüthrich (30) was
used to sequence specifically assign the amino acids, using
TOCSY and NOESY spectra.
Enzyme Kinetics
Titration—The concentrations of active inhibitors were
determined by titration against burst-titrated bovine trypsin
assuming a one to one interaction between the enzyme and the
inhibitor. Reactions were conducted in 96-well plates using
buffer (50 mM Tris-HCl, 150 mM NaCl, 0.01% Triton X-100,
0.01% sodium azide, pH 7.6) and serial dilutions of each inhib-
itor with trypsin (25 nM). After preincubation at 37 °C the fluo-
rogenic substrate Benzoyl-L-arginine-4-methylcoumaryl-7-
amide (75 !M) was added. Hydrolysis of the substrate was then
measured over 10 min with "em and "ex of 360 and 465 nm,
respectively, on a HTS 7000 Bio assay reader (PerkinElmer Life
Sciences). The concentrations of inhibitors with a large Ki,app
could not be determined by titration.
Ki Determination—Inhibition constants of the inhibitors
against matriptase and trypsin were calculated by preincubat-
ing the recombinant humanmatriptase catalytic domain (2 pM,
R&D systems, Inc.) and bovine trypsin (10 pM), respectively,
with serial dilutions of the inhibitors in buffer (50mMTris-HCl,
150 mM NaCl, 0.01% Triton X-100, 0.01% sodium azide, pH
8.0). After preincubation of 60 min the substrate Boc-QAR-
AMC (5 !M) or tos-GPR-AMC (5 !M), respectively, was added
to the reaction mixture and hydrolysis was quantified as
described above. Additional experiments were performed with
preincubation times between 60 and 180min to verify that each
inhibitor was in equilibrium with the protease. The inhibition
curves generated were fitted to Morrison’s equation (31), to
obtain the inhibition constant for each of the tested peptides.
The results presented are mean # S.E. of #4 independent
experiments.
Three-dimensional Structure Calculations
Preliminary three-dimensional structures were calculated
using automated nuclear Overhauser effect assignment within
CYANA (32). A final set of 100 structures was calculated and
the 20 lowest energy structures were selected for further anal-
ysis. Structures were analyzed using MolProbity, and MolMol
(33) and PyMol (The PyMOLMolecular Graphics System, ver-
sion 1.5.0.4, Schrödinger, LLC) were used to display the struc-
tural ensembles and surfaces of the peptides, respectively.
Molecular Modeling
The three-dimensional structures of the complexes between
SFTI-1 and trypsin (PDB identifier 1sfi), between SFTI and the
protease domain of matriptase (PDB identifier 3p8f), and
between MCoTI-II and trypsin5 were determined experimen-
tally using x-ray crystallography independently by different
research groups (16, 34). The three-dimensional structure of
MCoTI-II in complex with the protease domain of matriptase
5 N. L. Daly, L. Thorstholm, K. P. Greenwood, G. K. King, K. J. Rosengren, B.
Heras, J. L. Martin, and D. J. Craik, unpublished data.
FIGURE 2. Comparison of the sequences and structures of SFTI-1 and
MCoTI-II. The structures were determined based on NMR spectroscopy (PDB
codes 1jbl and 1ib9, respectively) and drawn using MolMol.
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was built in this study by homology using Modeler9v11 (35).
The three previously mentioned x-ray structures were used as
structural templates to generate 100 models of the
matriptase!MCoTI-II complex. The model with the lowest
DOPE score (36) was selected and was then refined using
molecular dynamic (MD) simulations. MD simulations were
performed using the program PMEMD from the AMBER 12
packagewith the ff12SB force field (37). The protease domain of
the matriptase!MCoTI-II complex (274 residues) was solvated
in a truncated octahedral periodic boxwith!4900TIP3Pwater
molecules. Three sodium ions were added to neutralize the sys-
tem. The system was then equilibrated using a similar strategy
to Cerutti et al. (38). A steepest descent minimization of 2000
steps was first carried out with the solute restrained to its posi-
tions and then a further 2000 steps of steepest descent minimi-
zationwas performedwith the solvent restrained to its position.
MD simulations were then performed with the solute atoms
restrained to their position by a harmonic potential whose
spring constant was progressively decreased from 16 to 1 kcal/
mol Å2 over 150 ps in theNVT ensemble, before it was progres-
sively decreased from 1 to 0 over 300 ps of standard NPT sim-
ulations (300 K, 1 atm). AnMD simulation of 300 ps with a 1-fs
time step was performed followed by a production run of 20 ns
with a 2-fs time step. All bonds involving hydrogen atoms were
constrained with the SHAKE algorithm (39). Long-range elec-
trostatic interactions were simulated with the particle-mesh
Ewald method (40). Similarly prepared 20-ns MD simulations
starting from the crystallographic structures of SFTI-1/matrip-
tase (3p8f), SFTI-1/trypsin (1sfi), and MCoTI-II/trypsin were
also performed. These simulations gave information on the
dynamics of the interactions at the interface. All simulations
were performed in triplicates using different random seeds.
The three-dimensional structures of complexes involving
mutants of SFTI-1 and MCoTI-II were modeled using the
mutation procedure implemented in Modeler9v11. Each
homology model was subjected to 4000 steps of minimization
using PMEMD. The dynamics of complexes involving a
selection of mutants, including [I10R]SFTI-1 [I10D]SFTI-
1, [I10K]SFTI-1, [I10R]SFTI-1, [I7A"I10R]SFTI-1, [V3R]-
MCoTI-II, [I7A]MCoTI-II, and [V3R " I7A]MCoTI-II, were
studied using 5-ns MD.
RESULTS
Synthesis and Characterization of Peptides—Variants of
SFTI-1 andMCoTI-IIwere synthesized to identify residues that
are essential for inhibition of matriptase or trypsin. The
mutants were synthesized using Boc chemistry and thioester-
mediated backbone cyclization and included alanine substitu-
tions as well as several other single or double amino acid
changes. In general, the SFTI-1 mutants were cyclized and oxi-
dized in separate steps as cyclization occurs more efficiently in
the presence of a reducing agent. By contrast, the MCoTI-II
analogs could be cyclized and oxidized in a single step. It is
possible that the presence of three disulfide bonds inMCoTI-II
compared with one in SFTI-1 facilitates the cyclization process
via a thia-zip mechanism (41). All peptides were purified by
RP-HPLC and analyzed by mass spectrometry. The structures
of the peptides were analyzed using NMR chemical shift anal-
ysis (Fig. 3A) to confirm the native fold was present, as shown
for [R2A]SFTI-1 and [I10R]-SFTI-1 in Fig. 3B. The similarity in
!H chemical shifts with the native peptides indicates that the
overall fold was maintained despite the mutations.
Enzyme Kinetics—Inhibition constants for the SFTI-1 and
MCoTI-II mutants against matriptase and trypsin are given in
Table 1, and graphically presented in Fig. 4. Several mutations
had selective influences on the inhibitory activity as outlined
below for the SFTI-1 and MCoTI-II mutants.
SFTI-1 Mutants—The trypsin inhibitory activity for the
SFTI-1 alanine mutants was consistent with our previous
results (27). Several of the alanine mutants displayed decreased
potency compared with the native peptide for both trypsin and
matriptase. For example, the alanine substitutions at positions
2, 4, 5, 6, and 14 led to a 7.5–50-fold increase in the Ki against
matriptase. Although the R2A mutant had significant loss of
inhibition against matriptase, it was still a potent inhibitor of
trypsin (Ki 160 pM compared with 1.7 pM for the native mole-
cule). Substitution of the active site residue, Lys-5, abolished
inhibitory activity for both enzymes. Additional substitutions
were tested to assess the charge requirements at positions 2 and
5. Substitution of Arg-2 with Lys had no effect on trypsin inhib-
FIGURE 3. A, comparison of the secondary shifts of selected SFTI-1 and
MCoTI-IImutants. The shiftsweregeneratedby subtracting the!Hshifts from
random coil shifts (50). B, alignment of NMR structures of SFTI-1 backbone
with the SFTI-1 variants I10R (left) and R2A (right). The parent peptide SFTI-1 is
displayed in pale cyan. The variants I10R and R02A are displayed in green and
purple respectively.
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itory activity although the Ki for matriptase increased 6-fold.
Substitution of Lys-5 with Arg had little effect on trypsin or
matriptase inhibition.
[I7A]SFTI-1 exhibited a 700-fold decrease in potency re-
lative to the native peptide against trypsin but was 2-fold more
potent against matriptase than the native peptide. Similarly,
[P8A]SFTI-1 had a 20-fold decreased trypsin activity but a
7-fold increase in matriptase activity, and [I10A]SFTI-1 a
!100-fold decrease in potency against trypsin but a 2-fold
increase in activity againstmatriptase. The contrasting effect of
these mutations against trypsin and matriptase indicated that
these positions are potential sites for exploring selectivity.
Additional point mutations were made and the selectivity for
matriptasewasmodulated in [I10R]SFTI-1,which had a 30-fold
increase in activity against matriptase and a decrease in trypsin
inhibitory activity of 2-fold.Mutating position 10 to an aspartic
acid or glycine significantly decreased activity against both
matriptase and trypsin. A combination of the I7A and I10R
mutations resulted in a peptidewith a 700-fold decrease in tryp-
sin inhibitory activity and a 4-fold increase in matriptase
activity.
MCoTI-II Mutants—Analysis of the matriptase inhibitory
activity ofMCoTI-II revealed it is amore potent inhibitor (Ki"
2.8 nM) than SFTI-1 (Ki" 200 nM) (Table 1). In contrast, both
inhibitors had similar Ki values against trypsin, consistent with
previous studies (27, 42). Alaninemutants in the active site loop
of MCoTI-II (loop 1) were synthesized to determine the role
each residue plays in enzyme inhibitory activity. Additional ala-
nine substitutions were generated for residues in loops 5 and 6
that were predicted to be in close proximity to the enzyme
based on modeling studies using the crystal structure of
MCoTI-II in complexwith trypsin. Sites from loops 5 and 6 that
weremutated included residues 2, 3, 26, 28, 30, and 31 (Table 1).
In general, most of the alanine substitutions led to decreased
inhibitory activity, but the influence of the substitutions varied
for trypsin and matriptase. As expected, substitution of the
trypsin active site residue (Lys-6) with an alanine abolished
inhibitory activity for both trypsin and matriptase. Preference
for lysine in this position was confirmed with the K6R substitu-
tion, which decreased the inhibitory activity against both tryp-
sin and matriptase relative to the native peptide. Interestingly,
the mutation of Val-3 in MCoTI-II to an alanine maintained
potency againstmatriptase and decreased potency against tryp-
sin. Based on the selective influence of this mutation at the P4
position of MCoTI-II and the importance of Arg-2 in the P4
position in SFTI-1 for potency against matriptase, aMCoTI-II-
V3R mutant was synthesized. Analysis of the kinetics of this
mutant indicated that it did improve inhibitory activity against
matriptase and resulted in one of the most potent matriptase
inhibitors known, with a Ki of 290 pM.
The mutation I7A of MCoTI-II significantly decreased the
trypsin inhibitory potency but had a lesser impact on matrip-
tase potency. A combination of the I7Amutation with the V3R
mutation resulted in a peptide with a 2-fold decrease inmatrip-
tase inhibitory activity relative to the native peptide but a
#1000-fold decrease in trypsin inhibitory activity.
Hybrids between SFTI-1 and MCoTI-II—Although MCo-
TI-II is amore potentmatriptase inhibitor than SFTI-1, SFTI-1
is smaller, which is potentially advantageous for pharmaceuti-
cal purposes as it is cheaper to synthesize and easier to modify.
A series of grafted peptides was thus generated to investigate
the relative importance of the SFTI-1 and MCoTI-II scaffolds
and the respective binding loops for the inhibitory activity. Two
grafted peptides were generated for the SFTI-1 loop in the
MCoTI-II scaffold to investigate the role of the binding loop
and loop 5 in interacting with the enzymes. The latter peptide
also included the substitution of Lys-6 into alanine to prevent
interference ofMCoTI-II native loop in our studies. These pep-
tides,MCoTI-II-S1 andMCoTI-II-S5, displayed poor inhibition
of both enzymes. The peptide SFMC, which had the MCoTI-II
binding loop grafted onto the SFTI-1 scaffold, was as efficient as
native SFTI-1 in inhibition of both trypsin and matriptase, as
shown in Table 2. However, the SFMCmutant was not as active
as native MCoTI-II against matriptase and the additional pep-
tide/enzyme interactions that occur with the larger MCoTI-II
scaffold may be important for enhanced enzyme inhibitory
activity.
TABLE 1
Equilibrium dissociation constant Ki for the inhibition of trypsin and
matriptase by SFTI-1, MCoTI-II, andmutants (mean! S.E., n>4)
Ki
Inhibitor name Trypsin Matriptase
nM
SFTI-1 native 0.0017$ 0.00026 200$ 22
SFTI-1 alanine mutants
G1A 0.0048$ 0.00032 190$ 26
R2A 0.16$ 0.016 !10,000
T4A 0.16$ 0.016 1,500$ 170
K5A #1000 #10,000
S6A 0.15$ 0.018 1600$ 390
I7A 0.89$ 0.21 84$ 15
P8A 0.035$ 0.0044 27$ 1.4
P9A 0.0017$ 0.0001 370$ 58
I10A 0.086$ 0.016 73$ 11
F12A 0.21$ 0.031 320$ 35
P13A 0.0037$ 0.0003 240$ 37
D14A 0.01$ 0.0014 1,500$ 150
SFTI-1 additional mutants
R2K 0.002$ 0.00003 1,200$ 160
K5R 0.0027$ 0.00078 310$ 52
I7R 0.01$ 0.00095 4,500$ 500
I10D 0.051$ 0.006 !10,000
I10G 0.081$ 0.011 3,700$ 490
I10R 0.0038$ 0.00062 6.4$ 1.3
I10K 0.0057$ 0.0015 40$ 5.8
I7A% I10R 1.2$ 0.25 51$ 4.9
MCoTI-II native 0.0023$ 0.0007 2.8$ 0.51
MCoTI-II alanine mutants
G02A 0.38$ 0.043 180$ 17
V03A 0.15$ 0.028 2.3$ 0.12
P05A 0.056$ 0.0076 39$ 5.4
K06A #1,000 #10,000
I07A 1.2$ 0.22 9.8$ 1.9
L08A 0.13$ 0.011 12$ 1.9
K09A 0.0034$ 0.0048 76$ 14
K10A 0.051$ 0.0095 4.1$ 1
N26A 0.008$ 0.0027 12$ 0.41
Y28A 0.15$ 0.021 11$ 1.3
G30A 0.0032$ 0.00036 3.7$ 0.033
S31A 0.069$ 0.0079 98$ 10
MCoTI-II additional mutants
V03R 0.01$ 0.0025 0.29$ 0.054
K6R 0.13$ 0.0055 39$ 4.4
I7R 5.2$ 0.62 110$ 8.5
V3R% I7A 2.8$ 0.23 3.5$ 0.32
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Structure Determination Using Nuclear Magnetic Resonance
Spectroscopy—NMR structures were determined for selected
SFTI-1 variants to enhance the understanding of the structure-
activity relationships and for use in molecular modeling of
inhibitor!enzyme complexes. [I10R]SFTI-1was chosen because
it is the most potent SFTI-1 mutant against matriptase, and
R2A was chosen because it was one of the least active analogs
againstmatriptase, aside from theK5Amutant. Structureswere
determined using torsion angle dynamics in the program
CYANA and the 20 lowest energy structures chosen to repre-
sent the fold. Energetic and geometric statistics are given in
Table 3. The structures were analyzed using PROMOTIF and
revealed that the major element of the secondary structure in
both R2A and I10R is a !-hairpin with the strands involving
residues 2–4 and 10–12. Comparison of the structureswith the
native peptide confirmed the overall fold was maintained and
therefore the observed effects of the mutations on the inhibi-
tion constants are likely to arise from interactions between the
side chains of the substituted amino acids and the proteases
(Fig. 3B). However, several hydrogen bonds were missing from
FIGURE 4.Comparisonof thedifferences in inhibitory activity of the SFTI-1 (A) andMCoTI-II (B)mutants relative to thenativepeptides. The side chains
are highlightedon the structures shownon the rightof thediagram. Thedisulfidebonds are shownas yellow sticks. The surfacediagramsweregeneratedusing
PyMol.
TABLE 2
Equilibrium dissociation constant Ki for the inhibition of trypsin andmatriptase by SFTI-1 andMCoTI-II hybrids
Peptide Sequence
Inhibition constant
Trypsin Matriptase
nM
SFTI-1 GRCTKSIPPICFPD 0.0017! 00026 200! 22
MCoTI-II GGVCPKILKKCRRDSDCPGACICRGNGY--CGSGSD 0.0023! 0.0007 2.8! 0.51
SFMC GRCPKILKKCFPD 0.0023! 0.00018 290! 34
MCoTI-II-S1 GGVCTKSIPPCRRDSDCPGACICRGNGY--CGSGSD 450! 27 3,500! 660
MCoTI-II-S5 GGVCPAILKKCRRDSDCPGACICTKSIPPICGSGSD 68! 4.5 "10,000
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the mutant structures compared with the native peptide, sug-
gesting that the overall fold had been destabilized, whichmight
also influence the inhibitory activity.
Molecular Modeling—The three-dimensional structures of
complexes involving matriptase or trypsin were used to pro-
pose explanations for the activity of SFTI-1 andMCoTI-II vari-
ants. The structures of complexes between SFTI-1 and trypsin,
SFTI-1 and matriptase, and MCoTI-II and trypsin have been
determined experimentally by x-ray crystallography (16, 34)
and were used here to model the structure of the
matriptase!MCoTI-II complex by homology with refinement
using 20-ns MD simulations (Fig. 5A). The three other com-
plexes involving wild-type SFTI-1 or MCoTI-II were also sim-
ulated for 20 ns by MD (Fig. 5A), and these simulations were
used to compare the dynamics of the molecular interactions at
the interface. All simulations quickly converged, as indicated by
the stabilization of the C! atoms root mean square deviations
from the initial homology model (matriptase!MCoTI-II com-
plex) or from the crystal structures (supplemental Fig. S1).
Structural models of the complexes between the peptide vari-
ants and the proteases were modeled by comparison based on
the wild-type models and refined by 5-ns MD. These simula-
tions allow local conformational change to occur and also pro-
vide information on the structural dynamics of the complexes.
Position 10 of SFTI-1 faces loop II of the proteases (Fig. 5A),
which is 10 residues longer in matriptase than trypsin. Several
SFTI-1 variants at position 10 were prepared and investigated
for their ability to discriminate between the two proteases. The
I10A substitution caused small shifts of the positions of SFTI-1
side chains Arg-2, Phe-12, and Asp-14 in both protease com-
plexes, decreasing the distance by!2 Å between the positively
charged guanidinium group fromArg-2 of SFTI-1 and the neg-
atively charged carboxylic group of matriptase Asp-709 com-
pared with wild-type SFTI-1 (Fig. 6 and supplemental Fig. S2).
As a result the electrostatic interactions were improved and at
the same time the buried surface area remained globally similar
(Table 4). The introduction of a negatively charged residue at
position 10 of SFTI-1 (I10D) dramatically decreased the
potency for matriptase, and in the corresponding model the
substituted aspartate at position 10 hadmoved away from loops
II and IV of matriptase relative to the position of isoleucine 10
in wild-type SFTI-1 (Fig. 6). This probably arose from charge
repulsions between Asp-10 of SFTI-1 and Asp-660, Asp-661,
andAsp-705. Indeed the distance between theC! ofmatriptase
Asp-705 and position 10 in SFTI-1 wild-type and the I10D
mutant had increased slightly by!1Å (Fig. 6 and supplemental
Fig. S2). Furthermore the buried surface area in themutant had
decreased on average by !50 Å2 (Table 4). By contrast, the
substitution of Ile-10 by the positively charged residues, argi-
nine or lysine, resulted in a more potent inhibitor of matriptase
thanwild-type SFTI-1, possibly because of positive electrostatic
interactionswith loop II (Fig. 6). The two variants [I10R]SFTI-1
and [I10K]SFTI-1 exhibited a small decrease in activity for tryp-
sin. The models suggest that [I10R]SFTI-1 is a better inhibitor
of matriptase than [I10K]SFTI-1 because an arginine residue at
position 10 can establish a salt bridge with matriptase Asp-705,
whereas the smaller side chain of lysine does not allow for the
formation of this interaction (Fig. 6 and supplemental Fig. S2).
Duringmost of the 5-ns simulation of the [I10R]SFTI-1!matrip-
tase complex, the guanidinium group of Arg-10 established at
least one hydrogen bond with the carboxylic group of Asp-705
(distance oxygen to nitrogen of !3 Å), whereas over the 5-ns
simulation of [I10K]SFTI-1/matriptase, Lys-10 did not form a
hydrogen bond with Asp-705 (supplemental Fig. S2).
Position 7 of SFTI-1 contacts loops I and V (Fig. 5A), which
has little sequence conservation between matriptase and tryp-
sin, and this position is therefore potentially important in deter-
mining the selectivity for matriptase. According to the model-
ing, the mutation I7A did not change the orientation of SFTI-1
in the trypsin binding site (Fig. 6), but resulted in the largest
decrease in buried surface area (!50 Å2) observed among all
the SFTI-1 variants in complex with trypsin (Table 4). The var-
iant [I7A]SFTI-1 was also amore potent inhibitor ofmatriptase
than the wild-type. Unexpectedly the double mutant [I7A "
I10R]SFTI-1was not amore potent inhibitor ofmatriptase than
[I10R]SFTI-1. The corresponding model suggested that this
doubly mutated peptide had a different binding mode to
[I10R]SFTI-1, and, in this new binding mode, Arg-10 cannot
form a salt bridge with Asp-705 (Fig. 6). By contrast, the effect
of the doublemutation for inhibition of trypsinwas cumulative,
in line with the models of [I7A]SFTI-1, [I10R]SFTI-1, and [I7A
" I10R]SFTI-1 in complex with trypsin that displayed similar
binding modes (Fig. 6). [I7A " I10R]SFTI-1 was the worst
inhibitor for trypsin among all SFTI-1 variants tested in this
study, and the most selective for matriptase among SFTI-1
variants.
Substitution of Arg-2 of SFTI-1 with an alanine resulted in a
loss of potency for both proteases. Arg-2 is involved in charge
interactions with Asp-14 (SFTI-1), and also potentially estab-
lishes cation-" interactions with several aromatic side chains,
including Phe-12 from SFTI-1 and a tryptophan from the pro-
TABLE 3
Structural statistics for SFTI-1 mutant structures
I10R R2A
Experimental restraints
Interproton distances 95 88
Intraresidue 28 28
Sequential 33 36
Medium range, i -- j
#5
9 3
Long range, i -- j#5 25 21
Disulfide bond
restraints
2 2
Dihedral bond ($, %,
&1) restraints
6 8
Root mean square
deviation from
mean coordinate
structure (Å)
Backbone atoms
(residues 1–14)
0.19$ 0.11 0.20$ 0.09
All heavy atoms
(residues 1–14)
1.05$ 0.19 0.70$ 0.09
Stereochemical quality
Residues in most
favored
Ramachandran
region (%)
87.5 85.8
Ramachandran
outliers (%)
12.5 14.2
Overall MolProbity
scorea
1.76$ 0.32 2.15$ 0.47
a Determined using MolProbity.
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teases (Trp-216 for trypsin and Trp-826 for matriptase).
Matriptase has two phenylalanines, i.e. Phe-706 and Phe-708
with proximity to Arg-2 and these residues might also partici-
pate in cation-! interactions with the Arg-2 side chain (Fig. 7).
MCoTI-II globally displayed more flexibility than SFTI-1
during the MD simulations, and the tip of loop 6 (positions 32,
33, 34, and 1) was the most flexible region of MCoTI-II in the
complexes with matriptase and trypsin (supplemental Fig. S3).
By contrast, the inhibitory loop (around Lys-5) was the most
stable region of the peptide and the conformation of this inhib-
itory loop was nearly identical between MCoTI-II and SFTI-1
in complex with the two proteases (Fig. 5B). As a consequence,
the C" at position 3 of MCoTI-II and position 2 of SFTI-1
occupies the same region in the active sites, and because Arg-2
of SFTI-1 was shown to be important for the binding affinity,
the mutant [V3R]MCoTI-II was predicted to have improved
activity. Indeed, the V3R substitution resulted in the best
matriptase inhibitor among MCoTI-II variants. For binding to
matriptase, the V3R substitution resulted in a large increase of
buried surface area (! 180 Å2 on average in Table 4) and, sim-
ilarly to the comments made for the analysis of the mutant
[I7A]SFTI-1, Arg-3 can potentially establish positive electro-
static interactions with Asp-709 in matriptase (Fig. 7).
Every modification to the inhibition loops of MCoTI-II, i.e.
the alanine substitutions in positions 5–8, resulted in a drop of
activity for both proteases, which could be explained by the
tight fit of the inhibition loop in both active sites (Fig. 5B).
Interestingly, the I7A substitution caused a decrease of activity
that was much more dramatic for trypsin than matriptase, and
this substitution resulted in an important loss of !150 Å2 of
buried surface area in the models with trypsin. The double
mutant [V3R" I7A]MCoTI-II was as specific for matriptase as
for trypsin, with each substitution independently contributing
to the loss of activity for trypsin. The models showed that the
substitutions at positions 3 and 7 should have an independent
impact because these residues are distant from each other and
did not cause obvious changes of binding mode. This result
contrasts with the change in binding mode predicted for the
[I7A" I10R]SFTI-1 double mutant.
DISCUSSION
Naturally occurring peptides with cyclic backbones have sig-
nificant promise in drug design (14, 17, 43), and in this studywe
have highlighted the potential of the frameworks of cyclic tryp-
sin inhibitors from seeds. In particular, we have discovered that
MCoTI-II is a potent inhibitor ofmatriptase and also generated
substantial structure-activity data regarding MCoTI-II and
SFTI-1 that has provided insights on how to modulate affinity
toward matriptase over the prototypic trypsin.
Alanine scanning of SFTI-1 against trypsin and matriptase
highlighted enzyme-specific requirements for high affinity
inhibition (Table 1, Fig. 3). In SFTI-1, Arg-2 is indispensable for
inhibition of matriptase, whereas for trypsin there is loss
of inhibition yet the R2A mutant remains a potent inhibitor
with a nanomolar affinity. The importance of this arginine res-
idue was previously highlighted by Long et al. (15) who sug-
gested that it is involved in a cation-! interaction with Phe-706
and Phe-708 of matriptase (15). In addition, It has been
FIGURE 5. A, bindingmodes of SFTI-1 (cyan) andMCoTI-II (green) in the active sites of trypsin (left) andmatriptase (right). The threemajor differences between
the active sites of trypsin andmatriptase are the longest andmore charged loop II ofmatriptase, the different conformation of loop III and themore negatively
charged loop IV of matriptase. The structures in this figure are the final conformations of 20-ns molecular dynamics simulations carried out for each complex.
SFTI-1 and MCoTI-II adopted similar binding modes in the two protease active sites, but MCoTI-II displayed more conformational variability than SFTI-1. The
solvent accessible surfaces of the proteases are colored according to the Poisson-Boltzmann electrostatic potential they generate, as computed by the APBS
software (49), with a scale ranging from#5 kT/e (red) to"5 kT/e (blue). B, comparison of the bindingmodes of the inhibitory loops of SFTI-1 andMCoTI-II when
they are in complexwithmatriptase and trypsin. The backbones of the proteases are shown inwhite using schematic representations, and the inhibitory loops
are in schematic and stick representations. Theproteaseswere superimposedusingPyMol. The remainingparts of the SFTI-1 andMCoTI-II beside the inhibitory
loops are not shown.
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reported that Arg-2 is critical for matriptase inhibitory activity,
with mutation to a phenylalanine derivative resulting in a 900-
fold decrease in potency (20).We further characterized the role
of this residue by substituting it with a lysine to determine
whether the charge is the requirement at this position. How-
ever, this substitution resulted in a significant loss of inhibitory
activity against matriptase suggesting that Arg-2 is an absolute
requirement. These results are consistent with the substrate
specificity of matriptase, as arginine is preferred at the P4 posi-
tion (44), i.e. the position Arg-2 occupies when bound to the
enzyme (Fig. 5).
Mutations in substrate sites P2, P1, and P1! of SFTI-1 had a
major impact on inhibitory activity. As expected, mutation of
Lys-5 (P1) had the most significant effect, consistent with a
previous study (20). Substitution of the adjacent residues
(Thr-4 and Ser-6) also caused a significant loss of affinity
against both enzymes. In general, the mutations had more
detrimental effects on inhibitory activity against trypsin com-
pared withmatriptase, indicating that SFTI-1 has a highly opti-
mized framework in respect to the trypsin inhibitory activity,
reflecting its biological function in plants as a deterrent of insect
and animal predators. Although substitution of Ser-6 with an
alanine has significant effects on trypsin andmatriptase activity
it produces an SFTI-1 variant with potent inhibitory activity
against chymotrypsin (45).
In contrast to the decreased activity observed for themajority
of the SFTI-1 alaninemutants against trypsin, the I7A, P8A, and
I10A substitutions resulted in enhanced inhibitory activity
against matriptase. In addition, F12A had significantly less
activity against trypsin but maintained similar activity to wild-
type SFTI-1 against matriptase. Additional mutations at posi-
tions 7 and 10 were explored, and one, the variant I10R, was
FIGURE 6. Comparison of the bindingmodes of six SFTI-1 variants modeled in thematriptase and trypsin active sites. Themodels of the variants were
generatedby comparisonusing the structureof the complexeswithwild-type SFTI-1 andwere simulatedbymolecular dynamics for at least 5ns. Theproteases
in the mutated complex are shown in green using schematic and stick representations, and the SFTI-1 variants are shown in cyan using schematic and stick
representations. The structuresof the correspondingcomplexesbutwithoutmutations are shown in transparencywith thebackboneof SFTI-1 in violetand the
proteases inwhite. The mutated position is circled, and residues and loops discussed in the text are highlighted.
Development of Cyclic PeptideMatriptase Inhibitors
MAY 10, 2013•VOLUME 288•NUMBER 19 JOURNAL OF BIOLOGICAL CHEMISTRY 13893
 at Univ of Queensland (CAUL) on November 3, 2014
http://www.jbc.org/
Downloaded from 
                                                                                                                                                    Chapter 2 
 33 
 
 
identified to have 30-fold enhanced inhibitory activity against
matriptase compared with the wild-type peptide. The models
generated for the inhibitor [I10R]SFTI-1 in complex with both
enzymes illustrated why this substitution was ineffective in the
trypsin complex as the side chain of Arg-10 is exposed to the
solvent and does not interact with the enzyme. However, in
matriptase, Arg-10 establishes a salt bridge with Asp-705 of
matriptase (3.1 Å) when bound to the enzyme. The additional
electrostatic interaction between these residues is likely to be
responsible for stabilizing the complex, which is reflected in
enhanced inhibition.
Combining the I7A and I10R mutants for SFTI-1 resulted in
a peptidewith significantly decreased trypsin activity (700-fold)
and enhanced matriptase activity (4-fold) relative to the wild-
type peptide. This selective enhancement of matriptase activity
argues well for the design ofmore selective inhibitors using this
framework. In particular, further exploration of mutants at
positions 8 and 12 might provide useful information for subse-
quent design studies.
Initial studies usingmolecularmodeling provided significant
insight into the binding of SFTI-1 tomatriptase and predicted a
role for Arg-2, Lys-5, Ile-10, and Phe-12 in binding (15). The
importance of Arg-2 and Lys-5 has been confirmed experimen-
tally (20) and is consistent with the current study. The impor-
tance of Ile-10 and Phe-12 has also been explored, and both
residues influence activity. For example, replacement of Ile-10
with a glutamine enhanced the selectivity for matriptase versus
thrombin but decreased the potency against matriptase (20).
Ile-10was also highlighted in an analysis of the crystal structure
of SFTI-1 bound to matriptase, and it was suggested that this
residue would be a useful site for mutational analysis to
improve binding (34). However, it was suggested that the
replacement of Ile-10 with a basic residue, arginine or lysine,
would not be beneficial because increasing the flexibility may
result in a loss of entropy upon binding. Our results confirm
that this site is indeed useful for modulating the inhibitory
activity against matriptase and that the increase in potency of
the I10R and I10K variants indicates that the introduction of
more flexible residues does not impact negatively on activity.
Very recently an acyclic SFTI-1 analog has been synthesized
with an I10R substitution in addition to truncation and intro-
duction of a His residue. This peptide also has enhanced
matriptase affinity as well as improved selectivity against tryp-
sin (46).
Consistent with the SFTI-1 alanine mutants, several of the
alanine mutants of MCoTI-II had more significant losses of
activity against trypsin relative to matriptase. Lys-9 and Lys-10
displayed enzyme-specific dependences withmutation of Lys-9
influencing affinity towardmatriptasemore than for trypsin. By
contrast, mutation of Lys-10 influenced inhibition of trypsin
more than that of matriptase. Val-3 was the only MCoTI-II
mutant tomaintain activity againstmatriptase, andmutation of
this residue to an arginine resulted in one of the most potent
inhibitors of matriptase. The model of [V3R]MCoTI-II shows
that the mutated Arg-3 residue sits in the substrate S4 pocket
(Fig. 7) supporting the strong preference for an arginine at this
position. Combining the V3Rmutant with I7A, one of the least
active inhibitors against trypsin, reversed the trend of having
higher trypsin potency relative to matriptase, as a result of a
1200-fold decrease in potency against trypsin, whereas main-
taining potency against matriptase. Based on these results,
MCoTI-II also appears to be a valuable framework for the
development of more selective inhibitors of matriptase.
Analysis of the hybrid peptides of SFTI-1 andMCoTI-II indi-
cates that the SFTI-1 framework is more amenable to substan-
TABLE 4
Average buried surface area in Å2 of SFTI-1 wild-type and variants in
their complex with matriptase and trypsin
The buried surface areas were computed over the last 15 ns of the simulations
involvingwild-type SFTI-1 and over the last 4 ns of the simulations involving SFTI-1
variants using the LCPO approximation implemented in the ccptraj software from
the Amber12 package. Standard deviations are provided for each measure.
Complex with
trypsin
Complex with
matriptase
SFTI-1 wild-type 1340! 49 1483! 55
[I10A]SFTI-1 1465! 52 1476! 54
[I10D]SFTI-1 1413! 60 1431! 62
[I10K]SFTI-1 1384! 59 1417! 55
[I10R]SFTI-1 1407! 64 1538! 81
[I7A]SFTI-1 1295! 44 1428! 52
[I7A" I10R]SFTI-1 1316! 58 1414! 66
[R2A]SFTI-1 1274! 62 1275! 73
MCoTI-II 1550! 64 1971! 124
[V3R]MCoTI-II 1637! 97 2152! 62
[I7A]MCoTI-II 1396! 56 2021! 73
[V3R" I7A]MCoTI-II 1632! 70 2081! 57
FIGURE 7. Comparison of complexes involving matriptase by focusing
around position 2 of SFTI-1 (A), position 3 of MCoTI-II (B), and position 3
of MCoTI-II V3R (C). These three positions occupy equivalent coordinates in
the matriptase active site. SFTI-1, MCoTI-II, and [V3R]MCoTI-II are shown in
cyan, and matriptase is in green. Positions discussed in the text are high-
lighted. The represented structures are the final conformations from molec-
ular dynamics simulations.
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tial sequence changes than MCoTI-II. Grafting the SFTI-1
active site loop into the MCoTI-II resulted in significant losses
in activity against both trypsin and matriptase. By contrast, the
loss of activity for the hybrid with theMCoTI-II active site loop
grafted into the SFTI-1 framework (SFMC) was minimal,
despite having one residue less than the wild-type peptide. A
naturally occurring example of a peptide similar to SFTI-1 has
been found in sunflower (SFT-L2) that comprises only 12 resi-
dues and has significant sequence differences in the bioactive
loop (47). Although only containing 12 residues the structure of
SFT-L2, braced by a disulfide bond and cyclic backbone, is
extremely well defined and has been suggested as a useful
framework in drug design. Theminimized framework of SFMC
might represent a new leadmolecule for the design of inhibitors
against serine proteases.
In summary, the structure-activity data elucidated in this
study are a solid basis for the design of selective peptide inhib-
itors of matriptase and highlights the versatility of cyclic pep-
tides for drug design. The use of disulfide-rich, cyclic peptides
as scaffolds is emerging as a powerful approach for the design of
novel drug leads. Using this approach a cyclic cone snail venom
peptide has been engineered from the naturally occurring acy-
clic peptide, which is orally active in a rat model of pain (48). In
addition, a modified cyclotide has oral activity in an in vivo
mouse model of visceral pain (43). The latter study exemplifies
the potential of the cyclotide scaffold for conferring oral activity
and suggests that selective inhibitors of matriptase, based on
cyclic peptide scaffolds, might hold significant promise for the
treatment of cancer.
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2.4 SUPPLEMENTARY FIGURES 
 
 
 
 
Figure S1: Backbone root mean square deviations (RMSD) to a reference 
conformation measured over 20 ns molecular dynamics simulations of complexes 
between SFTI-1 and trypsin, SFTI-1 and matriptase, MCoTI-II and trypsin and 
MCoTI-II and matriptase. The reference conformations were crystallographic 
structures for the complexes  SFTI-1 and trypsin (pdb identifier 1sfi),  SFTI-1 and 
matriptase (pdb identifier 3p8f), and MCoTI-II and trypsin (JL Martin et al., 
unpublished). The reference structure of the  MCoTI-II and matriptase simulation was 
generated by comparison using the three crystal structures as templates. The four 
systems were simulated in triplicates and the RMSD curves for each simulation 
within each system are shown using different colors. The MD simulations were done 
using the pmemd software from the Amber12 package using the ff12SB forcefield 
and a PBC box filled with TIP3P water molecules. 
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Figure S2 
 
 
 
Figure S2: Distances measured over 5 ns of molecular dynamics simulations of 
SFTI-1 wild-type and variants. In panel A, the distance between the center of mass of 
the atoms NH1 and NH2 of SFTI-1 R2 and the center of mass of the atoms OD1 and 
OD2 of matriptase D95 was monitored to determine if it was influenced by the 
mutation I10A. In panel B, the influence of the mutation of position 10 of SFTI-1 into 
Asp on the proximity of SFTI-1 and loop IV was monitored by measuring the 
distance between the Cα of position 10 and the Cα of matriptase D91. In Panel C, the 
establishment of a salt-bridge between R10 of SFTI I10R and matriptase D91 was 
monitored by measuring the distances between all inter residue distances between the 
atoms NH1, NH2, OD1 and OD2 of R10 and D91. In panel D, the distance between 
the atom NZ of residue K10 of SFTI-1 I10K and the center of mass of the atoms OD1 
and OD2 of matriptase D91 was measured to monitor if these residues directly 
interact. 
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Figure S3 
 
 
 
Figure S3: Root mean square fluctuations of each position of MCoTI-II computed in 
the last 15 ns of molecular dynamics simulations of the complexes between MCoTI-II 
and trypsin (A) and MCoTI-II and matriptase (B). The positions of MCoTI-II are 
numbered according to Figure 6. The root mean square fluctuations were calculated 
using the average conformation over the same molecular dynamics simulations as a 
reference. Computations were performed by the cpptraj software in the Amber12 
package. 
 
 
 
 
 
 
 
  39 
CHAPTER 3 
 
 
3 SFTI-1 LIKE FROG PEPTIDES TO TREAT 
STAPHYLOCOCCAL INFECTION 
 
 
 
 
 
 
 
 
 
 
 
“Once a molecule is asymmetric, its extension proceeds also in an asymmetrical 
sense. This concept completely eliminates the difference between natural and 
artificial synthesis. The advance of science has removed the last chemical hiding 
place for the once so highly esteemed vis vitalis.”   
Hermann Emil Fischer, Chemist (1852 – 1919)
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3.1 RELEVANCE TO THESIS AND SIGNIFICANCE OF WORK 
 
SFTI - like frog (SLF) peptides were found in the literature and through blast searches 
that have been reported to have bi-functional properties - antimicrobial and trypsin 
inhibitor. These peptides have a conserved BBI loop (SIPPI/K), and a range of 
biological activities including antimicrobial, anti fungal and immunomodulatory 
effects (Graham et. al., 2004, 2005; Li et. al., 2007; Mangoni et. al., 2003; Salmon et. 
al., 2000). In this chapter, SLF peptides, were examined for their antimicrobial 
properties against Staphylococcus aureus using in vivo and in vitro antibacterial 
assays.  S. aureus is one of the most notorious and virulent pathogens and its 
resistance against existing antimicrobial drugs is a global concern. Antimicrobial 
peptides (AMPs) offer a potential solution to this problem, as resistance against them 
is considered improbable as they target microbial membranes. Several peptides were 
found to have potent antibacterial activity Staphylococcus skin infection and they 
were also found to modulate the host innate immunity system.  Structure-function 
relationships provided insights towards the development of bi-functional peptides 
with both potent in vivo antimicrobial activity and serine protease inhibitory activity. 
This work could offer therapeutic solutions against clinically resistant microbes. 
Figure 3.1 shows the context of Chapter 3 in the thesis and its contribution in the drug 
development and commercialisation process. 
 
A research paper on antimicrobial property of cyclotide, cycloviolacin 2 and kalata 
B2, co-authored by the candidate was published in Peptides (2014) that is an 
additional work towards the discovery of peptides to treat Staphylococcal infections. 
It is presented in Appendix I as a adjunct to the chapter. 
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Figure 3.1 Schematic representation of the layout of the thesis showing its 
progression across chapters.  
 
 
3.2 DECLARATION OF AUTHORSHIP 
 
In accordance with the guidelines of the University of Queensland, this chapter is 
presented as an accepted article. 
 
“Evaluation of in vivo efficacy of anuran trypsin inhibitory peptides against 
Staphylococcal skin infection and the impact of peptide cyclization” 
Malik, U., Silva, O. N., Fensterseifer, I. C. M., Chan, L. Y., Clark, R. J., Franco, O. L., 
Daly, N. L., & Craik, D. J. 
 
Antimicrobial agent and chemotherapy, published on April 2015, doi: 
10.1128/AAC.04324-14 
                                                                                   The Science and Business of Novel Therapeutics 
 42 
3.3 PUBLICATION 
 
 
 
In Vivo Efficacy of Anuran Trypsin Inhibitory Peptides against
Staphylococcal Skin Infection and the Impact of Peptide Cyclization
U. Malik,a O. N. Silva,b I. C. M. Fensterseifer,b L. Y. Chan,a R. J. Clark,a,c O. L. Franco,b,e N. L. Daly,a,d D. J. Craika
Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australiaa; Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília,
Brasília, Brazilb; School of Biomedical Sciences, The University of Queensland, Brisbane, Australiac; Australian Institute of Tropical Health and Medicine, Centre for
Biodiscovery and Molecular Development of Therapeutics, James Cook University, Cairns, Australiad; S-Inova, Universidade Catolica Dom Bosco, Campo Grande, MS,
Brazile
Staphylococcus aureus is a virulent pathogen that is responsible for a wide range of superficial and invasive infections. Its resis-
tance to existing antimicrobial drugs is a global problem, and the development of novel antimicrobial agents is crucial. Antimi-
crobial peptides from natural resources offer potential as new treatments against staphylococcal infections. In the current study,
we have examined the antimicrobial properties of peptides isolated from anuran skin secretions and cyclized synthetic analogues
of these peptides. The structures of the peptides were elucidated by nuclear magnetic resonance (NMR) spectroscopy, revealing
high structural and sequence similarity with each other and with sunflower trypsin inhibitor 1 (SFTI-1). SFTI-1 is an ultrastable
cyclic peptide isolated from sunflower seeds that has subnanomolar trypsin inhibitory activity, and this scaffold offers pharma-
ceutically relevant characteristics. The five anuran peptides were nonhemolytic and noncytotoxic and had trypsin inhibitory
activities similar to that of SFTI-1. They demonstrated weak in vitro inhibitory activities against S. aureus, but several had
strong antibacterial activities against S. aureus in an in vivomurine wound infection model. pYR, an immunomodulatory pep-
tide from Rana sevosa, was the most potent, with complete bacterial clearance at 3 mg · kg!1. Cyclization of the peptides im-
proved their stability but was associated with a concomitant decrease in antimicrobial activity. In summary, these anuran pep-
tides are promising as novel therapeutic agents for treating infections from a clinically resistant pathogen.
Staphylococcus aureus is one of the most virulent and opportu-nistic pathogens, causing increasing numbers of nosocomial
and community-acquired infections, and is a leading cause of skin
and soft tissue infections (1–3). These Gram-positive cocci pro-
duce amyriad of virulence factors that allow the bacteria to attach
to host cells, to invade tissues, to evade the host immune system,
and to release an array of exoproteins and toxins (4, 5). Conta-
gious S. aureus skin infections can lead to severe muscle or bone
infections that ultimately can spread to the lungs or heart (6). The
primary treatment involves prescription of !-lactam antibiotics
such as penicillins and cephalosporins, alongwith clinical wound-
cleaning procedures (6, 7). Strains resistant to antibiotics have
been emerging since the 1960s, however, especially methicillin-
resistant S. aureus (MRSA), which is most common in nosoco-
mial skin infections (8). Alarmingly, there have been reports of
S. aureus strains that are resistant to the drug of last resort,
vancomycin (9).
Antimicrobial peptides are now recognized as novel alternative
therapeutic agents for infection control (10). Several hypotheses
have been examined regarding the mode of action of antimicro-
bial peptides, including autolysin activation, lipopolysaccharide
(LPS) permeabilization, fatal depolarization of the energized bac-
terial membrane, formation of barrel-stave pores that cause leak-
age of cellular contents, activation of processes that degrade the
cell wall, membrane thinning/thickening, impairment of essential
intracellular targets after internalization, and disturbance of the
distribution of cellular membrane lipids (11–15). Attributes of
antimicrobial peptides that make them viable candidates for de-
velopment as anti-infective therapeutic agents include broad-
spectrum antimicrobial activity, novel mechanisms of action and
ease of manipulation, and synthesis and tailoring of peptide se-
quences (16, 17). Conversely, major obstacles to the successful
development of antimicrobial peptides as therapies include their
potential toxicity, highmanufacturing costs, and degradation due
to proteases, heat, or extremes of pH (10). The design of peptides
that are stable against these processes while maintaining their an-
timicrobial properties would be a breakthrough in this field.
In amphibians, antimicrobial peptides play an important role
in defense against pathogenic microbes. The skin secretions of
anuran frogs contain a cocktail of compounds, with various bio-
logical activities, that have potential for drug development (18).
Among these secreted compounds are the anuran antimicrobial
peptides, which have a broad range of antibacterial and antifungal
activities (19). These ribosomally synthesized peptides of 8 to 63
amino acids have high affinity for microbial cell membranes (20).
They also have serine protease inhibitory activity (21–23).
The amphibian antimicrobial peptides shown in Table 1 con-
tain a conserved Bowman-Birk inhibitor (BBI)-like (24) trypsin
inhibitory loop (CWTKSIPPKPC) and share high sequence ho-
mology and structural similarities with sunflower trypsin inhibi-
tor 1 (SFTI-1), a 14-amino-acid cyclic peptide discovered in sun-
Received 16 September 2014 Returned for modification 16 October 2014
Accepted 21 January 2015
Accepted manuscript posted online 26 January 2015
CitationMalik U, Silva ON, Fensterseifer ICM, Chan LY, Clark RJ, Franco OL, Daly NL,
Craik DJ. 2015. In vivo efficacy of anuran trypsin inhibitory peptides against
staphylococcal skin infection and the impact of peptide cyclization. Antimicrob
Agents Chemother 59:2113–2121. doi:10.1128/AAC.04324-14.
Address correspondence to D. J. Craik, d.craik@imb.uq.edu.au.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.04324-14
April 2015 Volume 59 Number 4 aac.asm.org 2113Antimicrobial Agents and Chemotherapy
 on Septem
ber 10, 2015 by UQ Library
http://aac.asm
.org/
Downloaded from
 
                                                                                                                                                    Chapter 3 
 43 
 
 
 
 
flower seeds (Helianthus annuus) (25). SFTI-1 is the smallest and
one of the most potent BBIs. The structure of SFTI-1 has an ex-
tensive hydrogen bonding network and a disulfide bond connect-
ing two !-strands, which form a tightly folded scaffold with two
distinct loops, namely, the trypsin binding loop (loop 1) and the
secondary loop (loop 2) (26). Loop 1 contains the active site resi-
due for trypsin inhibitory activity, and loop 2 contains the site for
backbone cyclization in the natural biosynthetic process. The an-
uran peptides studied have additional conserved residues in the
binding loop (W and P) and additional residues in the secondary
loop, where only the glycine preceding the first cysteine residue is
conserved. Based on these sequence similarities, we have termed
these anuran peptides with similarity to SFTI-1 the SFTI-1-like
frog (SLF) peptides.
The cyclic nature of SFTI-1 contributes to its stability and its
resistance to degradation by proteases (26), which is a limitation
of linear antimicrobial peptides. Cyclization has been used as one
of the strategies in drug design to improve stability; for example,
cyclization of the antimicrobial peptide pyrrhocoricin improved
its in vivopharmaceutical properties (27). The in vitro stability and
antimalarial activity of the antimicrobial peptide gomesin, from
the Brazilian spider Acanthoscurria gomesiana, were also im-
proved after backbone cyclization (28).
In this study, a series of SLF peptides were evaluated for their in
vivo efficacy in a murine Staphylococcus aureus wound infection
model. Three of the active peptides were cyclized in an attempt to
improve their stability. The structures of the most active peptide
and its cyclic analogue were determined to elucidate the effects of
cyclization on their antimicrobial and trypsin inhibitory activities.
MATERIALS AND METHODS
Peptide synthesis and purification. 9-Fluorenylmethoxycarbonyl
(Fmoc)-based chemistry was used to synthesize linear peptides on an
automated synthesizer (Symphony; Protein Technologies, Inc.). 2-Chlo-
rotrityl resin (Novabiochem) was used to assemble the peptide chain, and
amino acids were Fmoc deprotected using 30% piperidine (Auspep Pty.
Ltd.) in dimethylformamide (DMF). Fmoc-protected amino acids (CS
Bio Co.) were coupled with HCTU [O-(6-chlorobenzotriazol-1-yl)-
N,N,N=,N=-tetramethyluroniumhexafluorophosphate] (Peptide Interna-
tional) and DIPEA (N,N-diisopropylethylamine) (Auspep Pty. Ltd.) in
DMF (RCI Labscan Ltd.) (28). The cyclic peptides were synthesized by
t-butyloxycarbonyl (Boc)-based solid-phase peptide synthesis using stan-
dard protocols (29, 30). A thioester-based linker (!-mercaptopropionic
acid) was used to facilitate cyclization by native chemical ligation (NCL)
(31). Previously described standard protocols for hydrogen fluoride
cleavage were used to cleave the peptides from the resin (32). The cleaved
linear reduced peptides were purified by C18 reverse-phase (RP)-high-
performance liquid chromatography (HPLC) using a gradient of buffer B
(90%acetonitrile in 0.05%aqueous trifluoroacetic acid [TFA]) and buffer
A (0.05% aqueous TFA) of 1% per minute. Peptide cyclization was
achieved by native chemical ligationwith a procedure involving two steps,
i.e., cyclization in the presence of a reducing agent (TCEP [tris(2-carboxy-
ethyl)phosphine]) followed by oxidation, with both steps involving over-
night stirring at room temperature in 0.1 M ammonium bicarbonate
buffer (pH 8.5). Peptides were purified by RP-HPLC at each step. The
molecular weight and purity of the peptides were confirmed by liq-
uid chromatography-electrospray ionization-mass spectrometry (LC-
ESI-MS).
Structure determination by NMR spectroscopy. 1H nuclear mag-
netic resonance (NMR) measurements were carried out with a Bruker
Avance-600 spectrometer for all peptides. Each peptide ("3 mg) was
dissolved in 90% H2O-10% D2O (99.9 and 99.99%, respectively; Cam-
bridge Isotope Laboratories, Woburn, MA) at pH 5, and DSS (4,4-di-
methyl-4-silapentane-1-sulfonic acid) was added as a chemical shift ref-
erence. Two-dimensional NMR data were recorded in phase-sensitive
mode using time-proportional phase incrementation for quadrature de-
tection in the t1 dimension (33). Total correlation spectroscopy (TOCSY)
experiments used an MLEV-17 spin-lock sequence (34) with a mixing
time of 80 ms, and nuclear Overhauser effect spectroscopy (NOESY) ex-
periments used mixing times of 100 to 200 ms (35). Amide proton tem-
perature sensitivity and deuterium exchange experimentswere conducted
to determine hydrogen-bonding constraints. Talos#was used for predic-
tion of the $ and % backbone angles (36). Structural calculations were
carried out with CYANA 3.0, using torsion angle dynamics. The 20 low-
est-energy structures with the bestMolProbity scores were selected for the
final ensemble (37).
Trypsin inhibition. Trypsin inhibition constants (Ki) of the peptides
were measured by a rapid microplate assay using a modification of the
method described by Erlanger et al. (38). Reactions were conducted in a
96-well plate containing 15 &l of 0.45 mg/ml bovine pancreatic trypsin
(Sigma-Aldrich), 5&l of buffer (50mMTris, 20mMCaCl2 [pH 8.2]), 125
&l of 0.435 mg/ml L-BAPNA (N'-benzoyl-L-arginine-4-nitroanilide hy-
drochloride) (Sigma-Aldrich), and peptides at final concentrations rang-
ing from 6.67mM to 0.065mM. The reaction was quenched with 25&l of
TABLE 1 Characteristics of SLF peptides from anuran skin secretions that were highly similar to SFTI-1
Peptide Origin Sequencea
Peptide property
NC aHI pI
Composition (%)
HY BA NE AC
ORB Odorrana grahami 5.9 (0.42 11.0 40 25 35 0
ORB2K Odorrana grahami 4.9 (0.44 10.6 35 24 41 0
pYR Rana sevosa 4.9 (0.87 10.9 39 22 39 0
Rana-Eb Rana esculenta 4.9 (1.22 10.5 29 24 47 0
Rana-Tb Rana temporaria 4.9 (0.88 10.5 35 25 41 0
SFTI-1 Helianthus annuus 0.9 (0.13 8.3 36 14 43 7
a Peptides contain a Bowman-Birk inhibitor (BBI) reactive loop (enclosed in dashed box) and a disulfide bond (black lines). SFTI-1 has a naturally cyclic backbone (gray line). NC,
net charge; aHI, grand average of hydropathicity index; pI, isoelectric point; HY, hydrophobic amino acids; BA, basic amino acids; NE, neutral amino acids; AC, acidic amino acids.
b Ranacyclin peptides are abbreviated as Rana.
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30% acetic acid after 10min of incubation at 25°C. A PowerWave XS plate
reader (Bio-Tek) was used to measure the absorbance of p-nitroanilide
(pNA) at 410 nm.
In vitro antimicrobial assays. The MICs of peptides against S. aureus
were determined using the standardized serial dilutionmethod, according
to North Carolina Science Leadership Association (NCSLA) guidelines
(39). Overnight colonies of Staphylococcus aureus (strain ATCC 29213)
were suspended and standardized at 0.5 units by a turbidity method, fol-
lowed by dilution in Mueller-Hinton (MH) broth. For MIC determina-
tions, peptides were added at 1 to 200 !M concentrations from a stock
solution, and gentamicin was used as a positive control. Each well of the
96-well plate contained 90!l of bacteria (1" 105 cells) inMHagar and 10
!l of peptide solution. Ampicillin (40mg ·ml#1) and phosphate-buffered
saline (PBS) were used as positive and negative controls, respectively.
Each data point wasmeasured in triplicate. The polypropylene plates were
incubated for 24 h at 37°C. Peptide MICs were determined as the lowest
tested concentration that resulted in 100% development inhibition, in
comparison to the negative control. The MIC is defined as the lowest
concentration of an antimicrobial compound that completely inhibits the
growth of the organism, as detected by the unaided eye (40).
Hemolytic assays. All peptides were tested for their abilities to hemo-
lyze red blood cells (RBCs). Using a previously described method (41),
serially diluted peptides (final concentrations of 0.4 to 50!M)were incu-
bated with human RBCs in 96-well plates for 1 h at 37°C and then were
centrifuged at 150 relative centrifugal force (RCF) for 5 min. The absor-
bance of the supernatant, containing plasma and lysed RBCs, was mea-
sured at 415 nm with a PowerWave XS plate reader (Bio-Tek). Triton
X-100 (0.1%) andPBSwere used as positive andnegative controls, respec-
tively. Melittin, a cationic hemolytic peptide, was used as a positive con-
trol and was tested at initial concentrations ranging from 0.4 to 50 !M.
Percent hemolysis was calculated using the absorbance of maximum lysis
in the positive-control samples (Triton X-100).
Cell cytotoxicity. The cytotoxic effects of anuran peptides on human
foreskin fibroblast (HFF-1) cells andmelanoma (MM96L) cells were eval-
uated using an MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tet-
razolium bromide] assay. Cells were seeded in 96-well plates at 3 " 103
cells/well (100!l) with 15% fetal bovine serum (FBS) inDulbecco’smod-
ified Eagle’s medium (DMEM) for HFF-1 cells (Gibco) or 10% FBS in
RPMI 1640 medium for MM96L cells, supplemented with 2 mM L-glu-
tamine and 1 mM sodium pyruvate (Gibco). All cells were incubated at
37°C in 5% CO2 for 24 h. The medium was removed and replaced with
fresh serum-free medium (90 !l/well), and then peptides were added. All
peptides were tested in triplicate, with final peptide concentrations rang-
ing from 1 to 200 !M, and were incubated with cells for 2 h. A negative
vehicle control (water) and a positive control (1% Triton X-100) were
included in the assay. After 2 h of incubation, 10 !l of MTT (5 mg/ml in
PBS) was added to each well, and the cells were further incubated for 3 h
before the removal of supernatant. The formazan crystals formed in each
well were dissolved in 100!l dimethylsulfoxide (DMSO), and absorbance
was measured at 600 nm using a BioTek PowerWave XS spectrophotom-
eter. Data were analyzed using the GraphPad Prism program, and 50%
inhibitory concentration (IC50) values were obtained from the sigmoidal
dose-response curves.
Acute toxicity. Acute toxicity assays were based on the method de-
scribed by Navon-Venezia and coworkers (42), with intraperitoneal (i.p.)
administration of the tested peptides to groups of 10 C57BL/6 mice. Each
mouse was injected with 0.5 ml of a solution of freshly prepared pyR or
cpYR in PBS. The doses of peptides administered per mouse were 0, 5, 10,
25, 50, and 100 mg · kg of body weight#1. Animals were inspected for
adverse effects for 30 min, and survival was monitored for 6 h thereafter.
In vivo antimicrobial activity. Female C57BL6 mice (6 to 8 weeks of
age) were obtained from CEMIB-Unicamp (Brazil). The study was ap-
proved by the Animal Use Committee at the Institute of Biological Sci-
ences, University of Brasilia. Briefly, groups of mice (n$ 4/group in each
experiment) were anesthetized with a combination of ketamine and xyla-
zine, their backs were shaved, and the surgical area was disinfected with
70% ethanol. A 1-cm incision was made, and 25 !l with 2" 109 CFU S.
aureus was pipetted into the incision. The mice were euthanized at 7 days
after surgery, and the wound tissue was excised, weighed, and homoge-
nized in 1 ml of PBS. Serial dilutions of the homogenates were plated in
triplicate onmannitol salt agar plates, and results were expressed as CFU/
gramof tissue. Peptides were administered to animals daily. Peptides were
solubilized in water for injection at two different concentrations, 1.5 mg ·
kg#1 and 3.0 mg · kg#1, and were injected into the wound in a 25-!l
volume; PBS was used as a negative control and 10 mg · kg#1 neomycin
sulfate as a positive control.
Serum stability. The linear and cyclic forms of pYR and SFTI-1 pep-
tides were evaluated in serum stability assays using an establishedmethod
(30). Human AB serum (Sigma) was used in this assay. Lipids were re-
moved by centrifugation at 13,000 rpm for 15 min prior to the assay.
Peptides (initial concentration, 2 mg/ml) diluted 10-fold in serum (test)
or PBS (negative control) were incubated at 37°C. At each time point (0, 3,
6, 10, and 24 h), triplicate aliquots were taken from each peptide sample in
serum or PBS and denatured with equal volumes of 6M urea, followed by
10 min of incubation at 4°C. The serum proteins were then precipitated
with an equal volume of 20% trichloroacetic acid, with a 10-min incuba-
tion at 4°C followed by centrifugation at 13,000 rpm for 15 min. The
supernatant was stored at 4°C until analysis. The relative concentration of
the intact peptide, in comparison with the level at the start of the experi-
ment, was measured by ultra-high performance liquid chromatography
(uHPLC) for each peptide sample, using the integrated area of the peak
corresponding to the intact peptide (with UV absorbance at 214 nm) on
the HPLC trace. The mean and standard deviation were calculated for
each peptide.
RESULTS
Synthesis of antimicrobial peptides. The SLF peptides (Table 1)
were synthesized to study their structures, biological characteris-
tics, and in vivo antimicrobial efficacy against S. aureus in an ani-
mal wound infection model. The cyclic versions of the SLF pep-
tides are prefixed with c, and the open or acyclic form of SFTI-1 is
prefixed with o. The native open-chain peptides were synthesized
using Fmoc-based chemistry and were oxidized in ammonium
bicarbonate buffer (pH 8.5). SFTI and the cyclic versions of the
anuran peptides were synthesized using Boc-based chemistry with
a C-terminal thioester to facilitate cyclization. Cyclization (in the
presence of reducing agent) and oxidation were carried out in two
separate steps. These conditions led to efficient cyclization of pep-
tides without the requirement for additional linker residues.
Structure determinationbyNMRspectroscopy.Thepeptides
were analyzed byNMR spectroscopy. The secondaryH% chemical
shifts (Fig. 1) were calculated using the measured chemical shifts
and the random coil values reported by Wishart et al. (43). Sec-
ondary H% chemical shifts are highly sensitive to structural mod-
ifications, and thus they offer an excellent platform to observe
structural differences due to amino acid variations (44). The linear
and cyclic constructs had comparable chemical shifts, suggesting
that the cyclization of the backbone did not have a significant
influence on structure. The first proline in the binding loop (CX
TKSIPPK/IP) is in a cis conformation, consistent with SFTI-1
(32). The other proline residues are in a trans conformation in all
peptides.
The three-dimensional structures of open and cyclic pYR (Fig.
2) were elucidated using the programCYANA, and the ensembles
chosen to represent the final structureswere based on the 20 struc-
tures from a set of 100 structures with the lowest MolProbity
scores (37, 45). Statistics showing the precision and stereochemi-
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cal qualities of the pYR structures are presented in Table 2. In the
cyclic form, the loop with the disulfide bond (loop 2) showed less
structural variation than the loop with the free termini (loop 1).
In vitro biological activity. The SLF peptides contain a BBI
loop similar to SFTI-1. For this reason, the trypsin inhibitory ac-
tivities of the SLF peptides were assessed and compared with that
of SFTI-1 (Fig. 3), which has been reported to have an inhibition
constant of 1.7 pM (29). cpYR was found to have trypsin inhibi-
tory activity similar to that of SFTI-1. The other peptides had
significantly reduced inhibitory activity, ranging between 13 and
50%, relative to SFTI-1. Cyclization improved the inhibitory ac-
tivities of all peptides, but opening of the SFTI-1 chain resulted in
decreased inhibitory activity, compared to wild-type SFTI-1, con-
sistent with previous studies (26).
The antimicrobial activities of the peptides were measured in
an in vitro assay with the widely used sensitive S. aureus strain
ATCC 29213, onMH agar, using a dilutionmethod. Table 3 pres-
ents the MIC data for open and cyclic forms of the peptides. pYR
was the most potent peptide, with an MIC of 50 !M against S.
aureus. Rana-E and Rana-T showedMICs of 100!M,whereas the
other open peptides had MICs greater than 100 !M. Backbone
cyclization resulted in decreased potency of pYR, while MIC val-
ues for cORB and cORB2K were "100 !M. Cyclic and open
SFTI-1 forms had no antimicrobial activity at concentrations up
to 100 !M.
The hemolytic activities of all peptides were determined in hu-
man blood. Melittin, a well-studied and highly hemolytic peptide
from honeybee venom (46), and Triton X-100 were used as a
positive controls and PBS was used as a negative control in the
assay. All peptides were found to be nonhemolytic at up to 50!M
concentrations (data not shown). To further evaluate the toxicity
and effects of cyclization of these peptides, the cytotoxicities of
open and cyclic pYR andORBwere determined with human fore-
skin fibroblast (HFF-1) and melanoma (MM96L) cell lines. The
peptides were noncytotoxic at up to 200 !M, except for cpYR,
whichwas found to kill 20%of the cells in both cell lines at 200!M
(Fig. 4).
Acute toxicity.Toxicity was assessed in vivo for pYR and cpYR.
FIG 1 H#NMR secondary shift analysis of SLF peptides and SFTI-1. Second-
ary shifts were obtained by subtracting experimental 1H NMR H# chemical
shifts from random coil shifts for the corresponding residue (43). The ORB/
ORB2k open and cyclic peptides have similar shifts in loop 1, whereas the
Rana-E/T and pYR peptides have similar secondary shifts in loop 1. Loop 1
contains a highly conserved BBI reactive loop (dotted gray box).
FIG 2 NMR solution structures of open and cyclic pYR. (A and B) Structural
ensembles of open (A) and cyclic (B) pYR. Disulfide bonds are highlighted in
gray. (C) Three-dimensional structural comparison of pYR peptides with
truncatedORB2K (PDB accession number 2O9Q) and SFTI-1 (PDB accession
number 1JBL).
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First, acute toxicity was examined after i.p. administration of a
single dose of each peptide to groups of C57BL/6 mice (n ! 5
mice/group). No immediate adverse events were noted for the
peptides at doses of up to 25 mg · kg"1 (Table 4). Toxicity level I,
involving narrowing of the eyes, was notedminutes after injection
in mice injected with doses of peptides above 50 mg · kg"1, except
for one animal with pYR at 50 mg · kg"1. Toxicity level II, involv-
ing crouching and cuddling, was observed in a few mice injected
with doses of pYR or neomycin sulfate above 50 mg · kg"1. No
deaths were observed for any of the treated mice, and most mice
recovered 2 h after treatment.
In vivo antimicrobial activity. The therapeutic efficacy of the
anuran defense peptides against S. aureuswas studied in a murine
wound infectionmodel (Fig. 5). The woundwas infected with 2#
109 CFU of S. aureus ATCC 29213 at the start of therapy, and
changes in bacterial loads were evaluated after 7 days of daily an-
timicrobial therapy with antimicrobial peptides. The negative-
control group of mice (untreated group) was given PBS instead of
antimicrobial agent, whereas the positive-control group was
treated with neomycin sulfate antibiotic at 10 mg · kg"1 (antibi-
otic-treated group). Neomycin sulfate is an antibiotic from the
aminogylcoside family that is used in topical ointments, and this
has been used to study S. aureus infections (47, 48). The bacterial
recoveries for the antibiotic-treated group and the untreated
group were found to be 4.1 $ 1.0 and 10.9 $ 0.3 log10CFU/g of
tissue, respectively.
The antimicrobial peptides were administered daily at the site
of infection at doses of 1 or 3 mg · kg"1. The bacterial recovery for
TABLE 2 Structural statistics for NMR solution structures of pYR and cpYR
Parameter pYR cpYR
Experimental restraintsa
No. of interproton distance restraints 170 202
No. of intraresidue restraints 39 51
No. of sequential restraints 72 80
No. of medium-range (i" j of%5) restraints 27 27
No. of long-range (i" j of!5) restraints 32 44
No. of hydrogen bond restraintsb 4 4
No. of disulfide bond restraints 2 2
No. of dihedral angle restraints (& and') 20 22
RMS deviation from mean (mean$ SD)c
Backbone atoms (residues 22-45) 1.27$ 0.53 0.72$ 0.33
Heavy atoms (residues 22-45) 2.53$ 0.83 2.13$ 0.65
Stereochemical quality (mean$ SD)d
Residues in most favored Ramachandran region (%) 96.47$ 4.83 87.50$ 2.99
Ramachandran outliers (%) 0.29$ 1.31 0.31$ 1.40
Unfavorable side chain rotamers (%) 8.82$ 7.27 11.00$ 8.72
Clash score, all atoms (no. of overlaps/1,000 atoms)e 13.55$ 2.30 8.97$ 3.16
Overall MolProbity score 2.41$ 0.50 2.74$ 0.34
a Only structurally relevant restraints, as defined by CYANA, are included.
b Two restraints were used per hydrogen bond.
c RMS, root mean square; SD, standard deviation.
d Stereochemical properties were obtained by MolProbity (http://molprobity.biochem.duke.edu).
e The clash score is defined as the number of steric overlaps of(0.4 Å per 1,000 atoms.
FIG 3 Relative trypsin inhibitory activities of SLF peptides, compared with
SFTI-1. SFTI-1 has an equilibrium dissociation constantKi of 17 pM (29). The
statistical significance was calculated with respect to SFTI-1 by one-way anal-
ysis of variance (ANOVA) and the post hoc Bonferroni test. !!!!, P% 0.0001.
TABLE 3 In vitro efficacy of SLF peptides against Staphylococcus aureus
strain ATCC 29213
Peptide MIC ()M)
ORB (100
cORB (100
ORB2k (100
cORB2k (100
pYR 50
cpYR 75
Rana-E 100
Rana-T 100
oSFTI-1 (100
SFTI-1 (100
Gentamicin 48
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pYR at 3mg · kg!1 was found to be 4.3" 0.7 log10CFU/g of tissue,
which was equivalent to the antibiotic control (20 mg · kg!1).
Lowering the dose of pYR by one-third increased the bacterial
recovery 1.5-fold. The other open-form anuran peptides signif-
icantly reduced the numbers of log10CFU/g of tissue, compared
to the untreated group of mice; however, they were less efficient
than pYR.
Backbone cyclization of the peptides resulted in a decrease or
loss of antimicrobial activity. The cyclic analogue (cpYR) of the
most active open peptide (pYR) completely lost therapeutic effi-
cacy even at 3 mg · kg!1. cORB and cORB2K showed reduced
bacterial clearance in wounds by 1 to 1.5 log10 CFU/g of tissue,
compared to their respective open forms.
Serum stability.The open and cyclic forms of pYR and SFTI-1
were incubated in human serum (Fig. 6), and the cyclic peptides
were found to have improved stability over the open forms over 24
h. SFTI-1 did not degrade at all, whereas 57.2 " 0.9% of cpYR
degraded after 24 h. oSFTI-1 was more stable than pYR.
DISCUSSION
Antimicrobial peptides are found in both animal and plant species
and are used in host defense mechanisms. There is growing inter-
est in exploring the potential of antimicrobial peptides as antibi-
otics to combat the decreased efficacy of conventional small-mol-
ecule antibiotics (49, 50). Some antimicrobial peptides kill
microbes directly, while others are effective by modulating the
innate immune system (51). The ability of antimicrobial peptides
to neutralize endotoxemia/sepsis and to stimulate host innate re-
sponses while dampening potentially deleterious inflammatory
responses offers an added advantage over small-molecule antibi-
otics (17). In this study, five antimicrobial peptides of anuran
origin, containing a reactive site loop of BBIs, were evaluated for
their therapeutic efficacy to treat S. aureus-infected wounds in
mice. Three active peptides were backbone cyclized in an attempt
to improve their biological properties.
Several SLF peptides have been reported to have in vitro anti-
microbial activity against a range of microbes, but only ORB and
ORB2K have been tested against S. aureus ATCC 25923 (21–23).
In light of these observations, we evaluated the in vitro antimicro-
bial activities of five SLF peptides against S. aureus strain ATCC
29213, a strain isolated from wounds (Table 3). ORB and ORB2K
were found to have much greater inhibitory activities than re-
ported (21). Variations in the antimicrobial susceptibility testing
methods have been found to have significant effects on the MICs
of compounds, as demonstrated using the cysteine-rich antimi-
crobial peptide protegrin-1, for example (52). Differences are also
dependent on the characteristics of the antimicrobial agents, in-
cluding hydrophobicmoments, exposed charges, amphipathicity,
and peptide flexibility (53, 54). pYR was found to be the most
active SLFpeptide, while others hadmoderate-to-poor antimicro-
bial activity. Loop 2 of these SLF peptides has significant sequence
diversity, compared to loop 1, and this diversity in the length and
number of hydrophobic and cationic residues might be responsi-
ble for the observed variations in antimicrobial activity.
The high sequence similarity of the anuran peptides to SFTI-1,
a stable and naturally cyclic peptide, guided this study toward the
development of cyclic antimicrobial peptides that could poten-
tially have improved stability and biological activities. Therefore,
TABLE 4 Evaluation of acute toxicity in mice treated with pYR, cpYR,
or neomycin sulfate (positive control)
Dose (mg · kg!1) and
effecta
No. of mice (n# 5/group)
Neomycin sulfate pYR cpYR
0
No effect 5 5 5
Toxicity level I 0 0 0
Toxicity level II 0 0 0
5
No effect 5 5 5
Toxicity level I 0 0 0
Toxicity level II 0 0 0
10
No effect 5 5 5
Toxicity level I 0 0 0
Toxicity level II 0 0 0
25
No effect 3 4 5
Toxicity level I 2 1 0
Toxicity level II 0 0 0
50
No effect 2 2 4
Toxicity level I 0 2 1
Toxicity level II 3 1 0
100
No effect 2 1 3
Toxicity level I 0 2 2
Toxicity level II 3 2 0
a Toxicity grading was as follows: level I, narrowing of eyes; level II, crouching and
cuddling.
FIG 4 Cytotoxic activity of selected ORB and pYR peptides against noncan-
cerous (HFF-1) (A) and cancerous (MM96L) (B) cells. Both open and cyclic
forms of the peptides were tested, and melittin was used as a positive control
(0% viability corresponds to 100% cell death).
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pYR, ORB, and ORB2K were cyclized using a method previously
used for SFTI-1 (29, 32). Cyclization of a peptide backbone has
been used previously to effectively improve in vitro stability, but
the proximity between the N and C termini has a significant influ-
ence on the ease of cyclization (55, 56). Apart from contributing to
structural stability, head-to-tail cyclization provides useful in-
sights into the significance of the C and N termini of peptides in
biological activity and folding (57). The structures of pYR, ORB,
and ORB2K were found to be well suited for cyclization, as the
overall folding was maintained following cyclization. Cyclization
of pYR decreased the in vitro antimicrobial activity but improved
the stability of the peptide in serum. The decrease in antimicrobial
activity might be related to the loss of flexibility in residues near
the termini and the positive charge at the N terminus. Since the
antimicrobial activities of ORB, ORB2K, and SFTI-1 were above
the upper limit of the in vitro assay, the impact of cyclization on
the stability of these peptides was not examined.
The specificity of the peptides for bacterial cells was examined
by analysis of their hemolytic activities and their cytotoxicities for
mammalian cells. None of the peptides was found to exhibit he-
molytic activity. Open and cyclic forms of pYR and ORB were not
cytotoxic to human foreskin fibroblast or melanoma cells. The
lack of hemolytic and cytotoxicity activity with human cells indi-
cated that the SLF peptides are selective for bacterial cells. pYR,
cpYR, and neomycin sulfate did not cause acute toxicity at clini-
cally used doses (10 mg · kg!1), while mild toxicity at doses of 25,
50, or 100 mg · kg!1 was seen in a few animals from each group.
Toxic effects were resolved after 2 h in most cases.
We evaluated the in vivo efficacy of the SLF peptides for the
treatment of S. aureus skin infections in the widely used C57BL
mouse model. The relationship between the in vitro efficacy and
the in vivo efficacy of antimicrobial agents remains unclear, and
FIG 5 In vivo efficacy of SLF peptides against S. aureus in the murine thigh infection model. Both open (A) and cyclic (B) forms were tested at 1 and 3mg · kg!1
(5 animals tested per compound). PBS and neomycin sulfate (3 mg · kg!1) were used as negative (C!) and positive (C") controls, respectively. The statistical
significance was calculated with respect to the untreated group (C!) by one-way ANOVA and the post hoc Bonferroni test. !!, P# 0.01; !!!, P# 0.001; !!!!,
P# 0.0001.
FIG 6 Serum stability of open and cyclic forms of pYR and SFTI-1. Backbone-
cyclized pYR and SFTI-1 had better stability in human serum than did their
open forms.
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prediction of in vivo activity is very challenging, due to variations
in potency that can occur due tomany uncontrolled parameters in
the host systems (58, 59). Despite the challenges of using in vitro
potency to predict in vivo potency, we found that the most potent
peptide in the in vitro study, pYR,was also themost potent peptide
in treating S. aureus skin infections in mice. pYR (at 3 mg · kg!1)
reduced bacterial loads in the wounds similarly to the positive-
control compound neomycin sulfate (at 10 mg · kg!1), a broad-
spectrum antibiotic that is used in topical ointments and is most
effective against S. aureus (48).
In conclusion, this study has investigated a class of "-sheet
multifunctional antimicrobial peptides that are effective in treat-
ing S. aureus skin infections in a murine model. Although cycliza-
tionwas shownpreviously to enhance stability and bioactivity (28,
60), in this case an improvement in stability was observed but
bioactivity was reduced. Structural or charge distribution changes
upon cyclization might be responsible for the decreased antimi-
crobial activity. The choice of peptide for further development
(open versus cyclic) reflects a balance between stability and
bioactivity. Further studies are needed to investigate the mech-
anisms of action of these peptides, to fully explore their poten-
tial for clinical use.
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CHAPTER 4 
 
 
4 SFTI-1 LIKE FROG PEPTIDES AS 
MELANOCORTIN SUBTYPE SELECTIVE 
ANTAGONISTS 
 
 
 
 
 
 
 
 
 
“Innovation distinguishes between a leader and a follower.” 
Steve Jobs, Entrepreneur and Inventor (1955 – 2011) 
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4.1 RELEVANCE TO THESIS AND SIGNIFICANCE OF WORK 
 
Kalata B1, a cyclic peptide from the plant Oldenlandia affinis, has been used as a 
scaffold for grafting the melanocortin receptor-activating sequence and has led to the 
development of a novel selective melanocortin agonist (Eliasen et. al., 2012). In 
another study (unpublished work) SFTI-1 was tested for activity and affinity towards 
MCR. It was found to have relatively low activity, but had some selective binding 
affinity towards MCRs. Due to the high sequence and structural similarity of SLF 
peptides to SFTI-1, they were screened for their binding and functional activity 
towards melanocortin receptors, with the objective of discovering novel selective 
scaffolds or ligands for one of the MCRs. Figure 4.1 shows the context of Chapter 4 
in the thesis and its contribution to the drug development and commercialisation 
process. This chapter is prepared as a manuscript for submission to the journal - 
‘Peptides’. 
 
Melanocortin receptors are pharmaceutically important receptors that are involved in 
complex physiological functions (Hruby et. al., 2011a). They have been associated 
with various diseases, including obesity, erectile dysfunction and skin cancer. It has 
been challenging to transform non-selective endogenous agonist and antagonist 
ligands into selective and potent ligands. In this study I investigated SLF peptides for 
selectivity and activity towards melanocortin receptors. Two peptides (pYR and 
HVBBI) had selectivity towards the melanocortin receptor 5 (MC5R). Minor 
sequence variations had a significant influence on selectivity, as did backbone 
cyclization. The selectivity observed for these frog-skin peptides indicates that they 
might be useful for developing potent and selective antagonists for MCRs, which are 
linked to the treatment of a range of conditions, such as obesity.  
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Figure 4.1 Schematic representation of the layout of the thesis showing its 
progression across chapters.  
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4.2 INTRODUCTION 
 
The melanocortin system consists of the melanocortin peptides α and β melanocyte 
stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH), as well as 
melanocortin receptors (MCR) and the endogenous melanocortin antagonist agouti 
and agouti-related proteins (Hruby et. al., 2011a; Yang, 2011). A primordial gene 
proopiomelanocortin (POMC) encodes the POMC peptide that is processed into MSH 
and ACTH (Getting, 2006). These peptides interact with the human MCRs (hMCR) to 
induce various biological effects, depending upon the MCR subtype. Five MCRs have 
been characterised - MC1R to MC5R, which are seven-transmembrane G protein-
coupled receptors. The five cloned hMCRs are positively coupled to adenylyl cyclase 
that leads to accumulation of cAMP and this is used to evaluate activation in assays 
(Getting, 2006). MCRs are well distributed throughout the body and present in 
various cell types, including melanocytes, adrenal cortex, adipocytes and many others 
(Haskell-Luevano et. al., 1999). Characteristics of the MCRs are summarized in Table 
4.1. 
 
Since the cloning of MCRs in the early 1990s, these receptors have been studied for 
their involvement in various physiological functions (Cai et. al., 2005). MCRs are 
critically involved with several processes and disease states, including feeding 
behaviour, pigmentation, immune response, sexual motivation, learning, pain and 
sebaceous gland secretion (Cain et. al., 2006; Ducrest et. al., 2008; Fan et. al., 1997; 
Hruby et. al., 2011b).  MC1R plays a central role in skin pigmentation (Kennedy et. 
al., 2001), MC2R is involved with regulation of steroid production in the adrenal 
gland (Zimanyi et. al., 2003), MC3R plays a potential role in energy metabolism and 
inflammation, MC4R has been found to be associated with obesity and sexual 
functions (Farooqi et. al., 2003; Van der Ploeg et. al., 2002) and MC5R is involved 
with exocrine gland function, especially sebaceous gland secretions (Abdel-Malek, 
2001). The physiological roles of the MCRs suggests they might be useful therapeutic 
targets for various diseases/conditions ranging from skin cancer to obesity and acne 
(Adan et. al., 1996; Adan et. al., 2001; Wikberg, 2001). 
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Table 4.1 Overview of melanocortin receptors – expression, functions, associated 
diseases and ligands. 
 
Properties MC1R MC2R MC3R MC4R MC5R 
Sites of 
expression 
Melanocytes, 
macrophages 
Adrenal 
cortex, 
adipocytes 
Central 
nervous 
system 
(CNS), 
gastrointestin
al (GI) tract, 
kidney 
CNS, spinal 
cord 
Lymphocytes, 
exocrine 
glands, 
adrenal 
glands, lymph 
nodes and 
many more 
Physiological 
functions 
Skin 
pigmentation
, pelage 
colouration, 
inflammation 
Steroidogene
-sis 
Energy 
balance, 
inflammation,  
Ingestive 
behaviour, 
energy 
balance, 
erectile 
function 
Exocrine 
gland 
function, 
regulation of 
sebaceous 
glands 
Associated 
diseases 
Skin cancer Familial 
glucocortic 
-oid 
deficiency 
Obesity Obesity Decreased 
production of 
sebaceous 
lipids in mice 
Agonist α,β MSH, 
ACTH 
ACTH α,β,γ MSH, 
ACTH 
βMSH, 
ACTH 
αMSH 
Antagonist Agouti Agouti AgRp Agouti, 
AgRp 
Agouti 
 
 
The endogenous MCR ligands, MSH and ACTH share a highly conserved 
tetrapeptide pharmacophore, His-Phe-Arg-Trp. Based on this pharmacophore, Hruby 
and co-workers developed melanotan I (MTI) and II (MTII), which are synthetic 
cyclic lactam analogs of α-MSH (Al-Obeidi et. al., 1989). MTI and MTII are 
currently being clinically tested for tanning of the skin and for diagnosis and 
treatment of male erectile dysfunction, respectively (Dorr et. al., 1996; Langan et. al., 
2010). Another analog of α-MSH without the C-terminal amide, called bremelanotide 
(PT-141) is an agonist of MC3R and MC4R, and underwent a phase II clinical trial 
for sexual arousal disorder and erectile dysfunction, however due to side effects the 
development was discontinued (Hruby et. al., 2011a; Hruby et. al., 2011b). The lack 
of receptor subtype selectivity and structural stability of melanocortin ligands are 
major hurdles in the development of MCR based therapeutics (Hruby et. al., 2011b). 
Therefore, a primary goal in this field is to obtain melanocortin analogues that have 
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selective affinity towards receptor subtypes as either agonists or antagonists and are 
bioavailable (Hruby, 2002; Hruby et. al., 2011a).  
 
Cyclization of peptides is an approach that has been used to overcome the lack of 
stability in peptide based drug leads (Clark et. al., 2012; Clark et. al., 2005; Lovelace 
et. al., 2006). Naturally occurring cyclic peptides from plants (cyclotides) have been 
used as scaffolds to stabilize bioactive sequences with antiangiogenic (Gunasekera et. 
al., 2008), angiogenic (Chan et. al., 2011) and bradykinin antagonistic activity (Wong 
et. al., 2012) with potential applications in treating cancer, wound healing and 
inflammatory pain, respectively. A cyclotide has also recently been used as a scaffold 
to develop agonists against MC4R, which is a target for obesity therapies. The 
tetrapeptide His-Phe-Arg-Trp was “grafted’ into the inter-cysteine loops of kalata B1 
and an analogue was developed that had higher affinity but lower potency than α-
MSH for the hMC4R (Eliasen et. al., 2012). Although this peptide requires further 
optimization to improve its agonist activity towards hMC4R, it validated the approach 
of using cyclic peptides as scaffolds for developing selective MCR ligands. 
 
In the current study I have shown that SFTI-1, a naturally occurring cyclic peptide 
from plants, has potent inhibitory activity against the MC3R receptor.  SFTI-1 is a 14 
amino acid backbone cyclic peptide discovered from Helianthus annuus (sunflower) 
seeds that is a potent serine protease inhibitor (Luckett et. al., 1999). Protease 
inhibitors from frogs with similar inhibitory loop sequences to SFTI-1 were also 
tested for their activity against MCRs. These peptides have been previously termed as 
SFTI-1 Like Frog (SLF) peptides (Malik et. al., 2015) and the structure is known for 
ORB2K (truncated ORB, discovered from Odorrana grahami). The sequences of the 
peptides are given in Figure 4.2. This analysis indicates that relatively minor sequence 
variations have a significant influence on MCR potency and selectivity, and provides 
a basis for further studies aimed at developing highly selective ligands for MCRs.  
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Figure 4.2 The sequence and structure of SFTI-1 and SLF peptides.  
A) Peptides have highly conserved trypsin inhibitory sequence, TKSIPPK/I, where 
the first Lys is crucial for its activity. ‘#’ corresponds to the naturally occurring cyclic 
peptide. B) Structures of SFTI-1 (grey) and ORB2K (black) (PDB codes 2O9Q and 
1JBL, respectively), drawn using MolMol, show high similarity in the loop enclosed 
by the disulfide bond.  
 
 
4.3 MATERIALS AND METHODS  
4.3.1 Peptide synthesis and purification 
 
The open and cyclic (prefix – ‘c’) peptides were synthesized by solid phase peptide 
synthesis using Fmoc (9-fluorenylmethoxycarbonyl) and Boc (tert-
butyloxycarbonyl) based chemistry, respectively as per methods described previously 
(Chan et. al., 2013; Malik et. al., 2015). The peptides were oxidized in ammonium 
bicarbonate buffer (0.1 M, pH 8.5) overnight. The cyclic peptides were cyclized 
overnight prior to oxidation in ammonium bicarbonate buffer (0.1 M, pH 8.5) and 
TCEP (2 µM). The peptides were purified after each step by reverse phase C18 HPLC 
(1% minute gradient of 90% acetonitrile in 0.05% aqueous TFA). Mass and purity of 
the peptides were confirmed by liquid chromatography electrospray ionization mass 
spectrometry (LC-ESI-MS).  
 
4.3.2 NMR sample analysis 
 
1H-NMR measurements of the peptides (~3 mgs) in 90% (v/v) H20, 10% (v/v)D2O 
(99.9 and 99.99%, Cambridge Isotope Laboratories, Woburn, MA) at pH 5 were 
performed using Bruker Avance-600 spectrometer at 290 K. The recorded spectra 
were analysed using CcpNmr (CCPN Software) (Vranken et. al., 2005). The 
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sequential assignment procedure developed by Wüthrich was used to specifically 
assign the amino acids using TOCSY and NOESY spectra (Wüthrich, 1986). The αH-
secondary shifts of the residues were calculated using random coil 1H chemical shifts 
provided by Wishart et al (Wishart et. al., 1995) and these shifts were used for 
structural comparisons.  
 
4.3.3 Melanocortin receptor activity assay 
 
Melanocortin competitive receptor binding assays were carried out by collaborators at 
the University of Arizona using HEK293 cells stably expressing the human 
melanocortin receptors (hMCR) 1, 3, 4 and 5 using methods described previously, 
where each assay was performed in triplicate (Hruby et. al., 2007; Mayorov et. al., 
2011; Ying et. al., 2006). In the competitive binding assay, cells were incubated with 
different concentrations of unlabelled peptides to be analysed and labelled [125I]-
[Nle4, D-Phe7]-α-MSH (Perkin–Elmer Life Science, 20,000 cpm/well, 33.06 pM). 
MTII (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 ) was used as a control. The data 
was analysed using the program GraphPad Prism (GraphPad Software, San Diego, 
CA). IC50 values were determined by analysing the data using a nonlinear least square 
analysis for each melanocortin receptor. 
 
4.4 RESULTS  
4.4.1 Peptide Synthesis 
 
Six open and three cyclic 14 - 20 residue peptides were synthesized using solid phase 
peptide synthesis (SPPS) to study their interactions with melanocortin receptors. The 
open-chain and cyclic peptides were synthesized by Fmoc and Boc based chemistry, 
respectively. The open chain peptides were oxidised in 0.1 M ammonium bicarbonate. 
The cyclic peptides were synthesized using native chemical ligation (Daly et. al., 
1999; Tam et. al., 1999) with a two-step approach; the cyclization step was carried 
out in the presence to TCEP to facilitate cyclization and the purified cyclic peptides 
were oxidised in 0.1 M ammonium bicarbonate. Both the open and cyclic peptides 
resulted in one major isomer following oxidation of the cysteine residues. Peptides 
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were purified and characterised by RP-HPLC (reverse phase HPLC) and mass 
spectrometry.  
 
4.4.2 NMR analysis 
 
The structures of the purified peptides were analysed using NMR spectroscopy. 
Despite the small size of the peptides they generally displayed a single set of spin 
systems in the TOCSY spectra, consistent with a single conformation. The secondary 
αH chemical shifts were calculated by subtracting the random coil values determined 
by Wishart et al (Wishart et. al., 1995) from the αH chemical shifts (Figure 4.3).  
 
 
 
Figure 4.3 A comparison of the secondary shifts of chemically synthesised SFTI-
1 and SLF peptides.  
The secondary shifts were generated by subtracting 1H NMR chemical from random 
coil shifts (Wishart et. al., 1995). Variations observed between SFTI-1 and the SLF 
peptides are at the two Cys residues due to two extra residues in the disulfide enclosed 
loop and the first Pro of trypsin inhibitory loop TKSIPPK/I. Numbers 1 – 20 
correspond to the position of residues as per Figure 4.2 and the grey dotted box 
encloses the trypsin inhibitory sequence, TKSIPPK/I.  
 
 
The secondary αH chemical shifts are similar for all of the SLF peptides, indicating 
that they have a similar structure. More significant differences were observed between 
SFTI-1 and the SLF peptides but there are similarities in the protease inhibitory 
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binding loop, suggesting that the overall fold in that region of the molecule is similar 
for all of the peptides.    
 
4.4.3 Melanocortin receptor activity assay 
 
The peptides were evaluated for their binding affinity to the recombinant human 
melanocortin receptors hMC1R, hMC3R, hMC4R and hMC5R, expressed on 
HEK293 cells. MTII was used as a control for the assays. The competitive binding 
assay results for the peptides are shown in Table 4.2. Two peptides, pYR and HVBBI, 
had selectivity towards the melanocortin receptor 5 (MC5R), ,with IC50’s of 11.6 and 
1.65 nM, respectively. The binding efficiencies were 29% and 20%, respectively.  
ORB and ORB2K bound to hMC5R at sub-nanomolar concentrations of 0.5 nM and 
0.4 nM and 33 and 45% binding efficiency (BE), respectively. However, they were 
not as selective as the pYR and HVBBI peptides. ORB2K has a significantly lower 
IC50 at the MC3R compared to ORB. Cyclization of ORB and ORB2K changed the 
selectivity compared to the open forms, with cORB2K having partial antagonistic 
activity (IC50 275 nM, 29% binding efficiency) and both cORB and cORB2K having 
weak, full antagonist activity (7-9 µM, 100% binding efficiency). Ranacyclin-T has 
partial antagonistic activity at the hMC5R (IC50 1.6 µM, 57% binding efficiency) 
whereas pYR had low binding affinity towards hMC5R, and no affinity towards other 
receptors. Interestingly, only the cyclic peptides cORB, cORB2K and SFTI-1 had 
binding affinity towards hMC4R; albeit with weak binding.  
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Table 4.2 Binding affinities of SFTI and SLF peptides at human melanocortin 
receptors.a 
 
Peptide MC1R MC3R MC4R MC5R 
IC50 (nM) %BE IC50 (nM) %BE IC50 (nM) %BE IC50 (nM) %BE 
ORB NB NB 166 32 NB NB 0.505 33 
ORB2K >10,000 NB 0.552 20 NB NB 0.397 45 
ranacyclin-E 1.92 8 NB NB NB NB 1140 33 
ranacyclin-T NB NB 8.55 4 NB NB 1630 57 
pYR NB NB NB NB NB NB 11.6 29 
HVBBI NB NB NB NB NB NB 1.65 20 
cORB 2.18 17 NB NB 8930 100 8.31 39 
cORB2K 275 29 NB NB 7020 100 0.16 24 
SFTI-1 488  39 20.9  25 5640 69 244 26 
MTII 20.1 100 44 100 537 100 337 100 
(NB indicates IC50 > 10,000 nM producing no significant binding) 
a Experiments carried out by Minying Cai (University of Arizona) 
 
 
4.5 DISCUSSION  
 
The melanocortin receptors are involved in multiple biological processes and studies 
have indicated that agonists and antagonists are useful in understanding the 
physiological functions of the receptors and might also have potential as novel 
therapeutics (Wikberg, 1999; Yang, 2011). However, the endogenous melanocortin 
ligands are non-selective as they share a conserved pharmacophore, thus limiting their 
use as drug leads. Indeed, development of analogues based on the endogenous ligands 
has failed to deliver MCR targeting drugs to the market.  
 
In this study, I evaluated the activity of small protease inhibitors towards MCRs. 
The structures of SFTI-1 (Korsinczky et. al., 2001) and pYR (Malik et. al., 2015) 
have been previously analysed using NMR spectroscopy and ORB2K jhas been 
analysedusing X-ray crystallography (Li et. al., 2007). The structures of ranacyclin E 
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and T had not previously been analysed. A comparison of the structures of SFTI-1 
and ORB2K indicates that the trypsin inhibitory binding loop is similar between the 
two peptides (Figure 4.2). Analysis of the secondary shifts of the SLF peptides 
confirms the structures are similar across the family of peptides.  
 
A competitive binding assay of the SLF peptides for MCR antagonistic activity 
suggests complex structure activity relationships are involved. In general the binding 
efficiencies were low, with only cORB and cORB2K showing high binding 
efficiencies. The low percentage of binding efficiency suggests the peptides have 
weak affinity towards particular MCRs. Despite the low binding efficiencies there is a 
significant variation in the selectivities observed. pYR and HVBBI showed no 
binding to hMC1R, hMC3R or hMC4R, but had IC50’s of 11.6 and 1.65 nM, 
respectively at the hMC5R. The binding efficiencies at this subtype for the two 
peptides were 29 and 20%, respectively.   
 
MC5R is the most widely distributed subtype in tissues among the MCRs. It is found 
in both peripheral and central exocrine glands and contributes to exocrine gland 
function and thermoregulation (Chen et. al., 1997), although the functional 
characteristics of MC5R have been studied less extensively than the other MCR 
subtypes. It has been suggested antagonists might be useful in the treatment of acne, 
whereas an agonist would increase glandular secretion that might help in alleviating 
conditions such as dry eyes and mouth (Bednarek et. al., 2007; Hruby et. al., 2011b; 
Wikberg, 2001).  
 
 ORB and ORB2K displayed binding to the hMC5R receptor at nanomolar 
concentrations while at other receptors they showed high IC50 values and low or no 
binding. ORB is a strong trypsin inhibitor with moderate antimicrobial activity and 
ORB2K is a truncated version of ORB (Li et. al., 2007). Although the binding at the 
MC5R was similar for the two peptides, ORB2K had a lower IC50 at MC3R compared 
to ORB, suggesting that the truncations at the N- and C-termini of ORB have an 
influence at the MC3R. Truncation studies have previously been carried out for MCR 
ligands with melanotan II, derived from melanotan I  (MTI), Ac-Nle-c[Asp-DPhe-
Arg-Trp-Lys]-NH2.  MTII is in clinical trials for the diagnosis and treatment of male 
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erectile dysfunction (Hadley et. al., 2006; Ückert et. al., 2014).  
 
ORB and ORB2K were backbone cyclized to study the impact of cyclization on their 
biological properties. Cyclization of ORB and ORB2K resulted in significant changes 
at the hMC1R, hMC3R and hMC4R. The cyclic versions of ORB and ORB2K are full 
antagonists at the hMC4R but have weak IC50s (8.9 and 7.0 µM, respectively).  MCR 
ligands have been cyclized in the past to improve stability and cycliztion has also 
resulted in a change in selectivity (Bednarek et. al., 2001; Prusis et. al., 2001; Schiöth 
et. al., 1998; Ying et. al., 2003). A study on a cyclic lactam of α-MSH found that 
rigidity of the linker arm and ring size affects the antagonist selectivity of MCRs 
(Mayorov et. al., 2011; Mayorov et. al., 2006). Similar to the open-form peptides, 
shortening of cORB to cORB2K had a similar impact on the hMC4R receptor as 
truncation resulted in improved binding affinity and efficiency. The MC4R receptor 
plays an important role in energy homeostasis (MacNeil et. al., 2002) and a MC4R 
antagonist (like AgRP and SHU9119) has been shown to stimulate food intake in 
mice and also, reverses the effect of cancer induced anorexia  (Wisse et. al., 2001). 
 
The design of a MCR ligand with high specificity and selectivity is a complex task 
and to date most of the development has been limited to the modification of 
endogenous ligands. This study offers five novel scaffolds that have limited 
selectivity towards either hMC5R or hMC4R and could potentially offer a unique 
platform for the development of melanocortin based therapeutics. Further elucidation 
of the structure-activity relationships will help in identifying importance of residues 
for each MCR that might be used to develop ligands with improved selectivity and 
specificity. Backbone cyclization of these peptides is known to improve stability; 
however further investigation is required to understand the importance of N and C 
termini as cyclization resulted in a change in selectivity of the peptides. Overall, SLF 
peptides offer an excellent starting point towards the development of selective 
melanocortin antagonists and further optimization could potentially provide 
pharmaceutically relevant peptide based drug leads. 
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CHAPTER 5 
 
5 UNDERSTANDING BIOSYNTHESIS OF 
NATURALLY OCCURING CYCLIC PLANT 
PEPTIDES 
 
 
 
 
 
 
 
“It is not the strongest of the species that survives, nor the most intelligent, but the 
one most responsive to change.” Charles Darwin, Naturalist (1809 - 1882) 
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5.1 RELEVANCE TO THESIS AND SIGNIFICANCE OF WORK 
 
Understanding the biosynthesis of naturally occurring macrocyclic peptides might 
provide alternative methods for their production and facilitate their development as 
therapeutic or agricultural agents. The biosynthesis of cyclotides, one of the largest 
families of macrocyclic peptides, appears to involve an asparaginyl endopeptidase but 
there are many unanswered questions regarding the mechanisms involved. A review 
paper on cyclotide biosynthesis, co-authored by the candidate was published in 
Current Opinion in Chemical Biology (2013) that provides further background to the 
work presented in this chapter. This review summarizes recent studies on the 
mechanism of cyclotide biosynthesis and it is presented in Appendix II as an adjunct 
to the chapter. Figure 5.1 shows the context of Chapter 5 in the thesis and its 
contribution in the drug development and commercialisation process. This chapter is 
presented as manuscript for submission to the journal - ‘Journal of Biological 
Chemistry’. 
 
Using truncated precursor fragments of the trypsin inhibitor cyclotide, MCoTI-II, I 
have shown that an asparaginyl endopeptidase can carry out both the N and C 
terminal cleavage reactions as well as cyclization. Furthermore, for the first time I 
have shown that full length acyclic versions are present in plant extracts. The 
presence of these acyclic forms implies the efficiency of cyclization for naturally 
occurring cyclic peptides is not as high as previously thought. 
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Figure 5.1 Schematic representation of the layout of the thesis showing its 
progression across chapters.  
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5.2 INTRODUCTION 
 
Cyclotides are plant-derived peptides composed of 28-37 residues and a characteristic 
head-to-tail cyclic backbone and cystine knot arrangement of the three-disulfide 
bonds (Craik et. al., 1999; Craik et. al., 2002). The structural motif in cyclotides is 
termed the cyclic cystine knot (CCK), and provides exceptional chemical and 
biological stability to the peptides (Ireland et. al., 2010). As a result of this stability 
the cyclotide framework is being pursued as a scaffold in drug design (Jagadish et. al., 
2010; Wong et. al., 2012).    
 
More than 250 cyclotides have been discovered from various plant families, including 
the Rubiaceae, Violaceae, Cucurbitaceae, Fabaceae and Solanaceae and this 
distribution indicates that head-to-tail cyclization of proteins may be a widespread 
event (Chiche et. al., 2004; Kaas et. al., 2010). The processes involved in the 
cyclization are beginning to be elucidated, with initial insights gained from 
determining the gene sequences of kalata B1 and kalata B2 from Oldenlandia affinis 
(Jennings et. al., 2001). Following this initial discovery, genes from Violaceae plant 
families were discovered (Dutton et. al., 2004; Jennings et. al., 2001; Zhang et. al., 
2009) and the gene encoding the cyclotide MCoTI-II has recently been discovered 
(Mylne et. al., 2012). A typical cyclotide pro-peptide has an endoplasmic reticulum 
(ER) signal sequence that is followed by a N-terminal region (Ntr) of the cyclotide 
sequence, and finally a C-terminal region (Ctr) Several of the cyclotide precursors, 
including those for kalata B2 and MCoTI-II have repeating N and C termini units, 
which could be a result of extensive internal expansion (Craik et. al., 2013b; Mylne et. 
al., 2011; Mylne et. al., 2012).  
 
Cyclotide precursor proteins are thought to undergo oxidative folding (Daly et. al., 
2011; Gruber et. al., 2007; Jennings et. al., 2001; Mylne et. al., 2011) prior to 
processing to form the mature cyclic peptide. All cyclotide precursors known so far 
contain a conserved Asx (Asp/Asn) residue at a site corresponding to the C-terminus 
of the mature peptide sequence.  By contrast, cyclotide-like peptides without the 
conserved Asx residue have been found in several species, but they lack a cyclic 
backbone and these acyclic peptides have recently been termed acyclotides (Poth et. 
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al., 2012). Based on the conservation of the C-terminal Asx residue it was proposed 
an asparaginyl endopeptidase (AEP) is one of the key elements in the maturation and 
cyclization of cyclotides (Gillon et. al., 2008; Saska et. al., 2008b; Saska et. al., 2007). 
Evidence for the role of an AEP in the biosynthesis initially involved in vivo 
transfection of cyclotide genes in both AEP containing and AEP-null transgenic 
plants (Conlan et. al., 2012; Gillon et. al., 2008; Mylne et. al., 2012; Saska et. al., 
2007). Recently, a study has shown that an enzyme isolated from Clitoria ternatea, a 
plant that naturally contains cyclotides, can efficiently cyclize kalata B1 sequences 
(Nguyen et. al., 2014). This enzyme, termed butelase 1, has much greater specificity 
for asparagine residues compared to aspartic acid residues and appears to function as 
a ligase rather than a protease. There are numerous cyclotides that appear to be 
cyclized via an aspartic acid rather than an asparagine, which poses the question of 
whether there are specific enzymes involved in cyclizing different cyclotides.  
 
One cyclotide subfamily that exclusively contains cyclotides cyclized via an aspartic 
acid are the trypsin inhibitor cyclotides from Momordica cochinchinensis. MCoTI-II 
is one of the most well studied members of this subfamily and in the current study I 
used in vitro studies to probe the role of AEP in the maturation of MCoTI-II. Unlike 
the majority of cyclotides, an Asn residue precedes the N-terminal residue of the 
cyclic MCoTIs, thus suggesting a potential role of AEP in cleaving the cyclotide and 
ligating the termini (Mylne et. al., 2012). Truncated MCoTI-II precursors were 
designed with N and C terminal extensions as shown in Figure 5.2A and showed that 
an AEP can carry out two cleavage reactions as well as cyclization to form the mature 
cyclic peptide. I also report for the first time the presence of naturally occurring full-
length acyclotides of MCoTI-like peptides. These peptides contain the conserved C-
terminal Asp residue but do not have a cyclic backbone, providing insight into the 
efficiency of the cyclization reaction for MCoTI peptides.  
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Figure 5.2 MCoTI-II and its synthesized precursor variants.  
A) Aligned sequences includes the MCoTI-II region (black font), N and C terminal 
extensions (red font; name contains number of residues in superscript) and three-
disulfide bonds (lines at top) while [MCoTI] indicates cyclic peptide. B) MCoTI-II 
was discovered Momordica cochinchinensis seeds. C) MCoTI-II structure (PDP ID: 
1IB9) comprises of three disulfide bonds (yellow) forming loops 1 - 6 and two anti-
parallel β-sheets (red). AEP is proposed to ligate at Gly1 and Asp34 to form a cyclic 
backbone. 
 
 
5.3 MATERIALS AND METHODS 
5.3.1 Peptide synthesis  
 
Fmoc (9-fluorenylmethoxycarbonyl) based chemistry was used to synthesize acyclic 
(acy) peptides on an automated synthesizer (Symphony Multiplex Synthesiser; 
Protein Technologies, Inc.). In brief, Rink Amide MBHA resin (100-200 mesh) 
(Merck Millipore International) was used as the solid support to assemble the peptide 
chain. Fmoc groups were deprotected using 30% piperidine (Auspep Pty. Ltd.) in 
DMF (RCI Labscan Ltd.), followed by coupling of Fmoc-protected amino acids using 
HCTU (Peptide International) and DIPEA (Merck Millipore International) in DMF. 
Assembled peptides were cleaved from resin using a standard Fmoc cleavage cocktail 
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(TFA:milli-Q-H2O:TIPSI = 95:2.5:2.5, 2.5 h at room temperature). Cleaved peptide 
was subsequently precipitated using diethyl ether, re-dissolved in 45% acetonitrile 
containing 0.05% TFA, and lyophilised. Oxidations of the peptides were carried out 
in ammonium bicarbonate buffer (0.1 M, pH 8.5) by incubating overnight. Peptides 
were purified and purity was examined by standard protocol as described earlier 
(Quimbar et. al., 2013).   
 
Cyclic (cyc) peptides were synthesized through Boc-based solid phase peptide 
synthesis using standard protocols previously described (Chan et. al., 2011). Peptides 
were assembled on a thio-ester based linker that could subsequently allow cyclization 
by means of a thiazip mechanism of native chemical ligation (NCL). Previously 
described standard protocols of hydrogen fluoride cleavage were carried out to cleave 
the peptides from the resin (Daly et. al., 2006). The cleaved linear-reduced peptides 
were purified by reverse phase C18 HPLC (1 %/min gradient of 90% acetonitrile in 
0.05% aqueous TFA). Oxidation and cyclization of cyclic peptide was done in single 
step reaction in ammonium bicarbonate buffer (0.1M, pH 8.5) by incubating 
overnight, and purified as above. Mass and purity of the peptides was confirmed by 
liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS) on 
Shimadzu HPLC with LCMS-2020. 
 
5.3.2 NMR spectroscopy  
 
NMR spectra of the peptides were recorded on a Bruker Avance 600 spectrometer 
equipped with shielded gradient unit and chemical shifts were referenced using 
sodium 2,2-dimethyl-2silapentane-5-sulfonate. 2-3 mg/ml of peptide samples were 
made in 90% H2O, 10% D2O (Cambridge Isotope Laboratories) at pH 5. The spectra 
were recorded as described previously (Chen et. al., 2005) and analysed using 
CCPNMR followed by automated Nuclear Overhauser Effect assignment and other 
calculations in CYANA (Guntert, 2009; Vranken et. al., 2005). Two-dimensional 
spectra consisted of TOCSY using MLEV-17 spin lock with a mixing time of 80ms 
and NOESY with 100 and 200 ms, 1H-13C HSQC spectra, 1H-15N HSQC spectra and 
DQF-COSY.  Φ and ψ backbone angles were generated using TALOS+ chemical 
shift analysis (Shen et. al., 2009). Structural statistics were calculated using 
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MolProbity and structures with top 20 score were selected for study (Davis et. al., 
2007). αH secondary shift were calculated by subtracting the random coil of 1H NMR 
shifts of Wishart et al. (Wishart et. al., 1995) from experimental αH chemical shifts. 
 
5.3.3 Assay for asparaginyl bond hydrolysis and ligation  
 
Jackbean (Canavalia ensiformis) and recombinant human AEP were purchased from 
Clontech Laboratories, Inc. and R&D Systems Inc., respectively. Optimum buffer and 
pH condition were determined by testing recommended buffers from the two AEP 
suppliers and Johansen’s buffer (1acy) (Johansen et. al., 1999) for both the AEP. 
R&D Systems, Inc.’s recommended buffer was chosen for the assay and buffer pH 
conditions were optimized. Incubation time was optimized by incubating samples for 
0, 1, 2, 4, 8, 16 and 22 h; following this 0.5, 1, 1.5, 3 and 6 h were chosen for the 
assay. Both Jackbean and human AEP were activated in activation buffer (50 mM 
Sodium Acetate, 100 mM NaCl, pH 4.0) for 2 h at 37°C followed by dilution in assay 
buffer (50 mM MES (sodium salt 2-(n-Morpholino)-ethanesulfonic acid), 250 mM 
NaCl, pH 5.0). The peptide was added enzyme-buffer mix and incubated for 6 h. The 
reaction was stopped by adding 0.1 % formic acid and 0.25 µg of kalata B2 as internal 
standard (IS). The product of the enzyme reaction was detected and quantified using 
liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS). 
 
5.3.4 Detection and quantification of peptide  
 
Enzyme catalysed peptide reactions and peptides extracted from seeds were 
monitored by LC-ESI-MS using a HP 1100 Series HPLC (Agilent Technologies) and 
Applied Biosystems (ABI) Q-Star Pulsar mass spectrometer equipped with an 
electrospray ionisation (ESI) source.  95 µL of reaction mixture was injected onto a 
Phenomenex C18 column (150 mm X 2.1 mm I.D., 5 µm particle size) protected with 
Phenomenex precolumn 0.5 µm filter at 200 µL/min flow rate while maintaining 40°C 
column temperature. A 2% gradient from 2 to 80% solvent B (90% acetonitrile, 0.1% 
formic acid) was utilized to elute peptides, which were examined by online 
electrospray mass spectrometry. Spectra were recorded under same LC-TOF-MS 
parameters (after optimization) capillary voltage, nitrogen flow, drying temperature 
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and fragmentor voltage across a range from 600 to 1800 m/z. Data acquisition and 
analysis were conducted using Applied Biosystems/MDS-SCIEX Analyst QS v1.1 
software. All the spectra were processed for baseline correction and Gaussian 
smoothing.  
 
5.3.5 Characterization of enzymatically obtained MCoTI-II  
 
Co-elution studies were performed on cyclic MCoTI-II produced by AEP processing 
of the pro-peptide. The synthesized native MCoTI-II (MCoTI-IINAT) and AEP 
produced MCoTI-II (MCoTI-IIAEP) were mixed in 1:1 and 2:1 ratio and subjected to 
isocratic conditions. Isocratic condition used were 9% buffer B (90% CH3 CN, 0.05% 
trifluoroacetic acid) in buffer A (0.05% trifluoroacetic acid) on C18 Phenomenex 
column (150 mm X 2.1 mm I.D., 5 µm). MS fragmentation of the 3450.54 Da 
(monoisotopic mass) of MCoTI-II precursor ion was performed on the Applied 
Biosystems (ABI) Q-Star Pulsar mass spectrometer. Ratio of 3+, 4+ and 5+ ions of 
MCoTI-II were compared with synthesized MCoTI-II and across samples for 
equivalent proportion. Also, retention time of MCoTI-II was monitored for no 
variation across HPLC runs. Using same instrument MS/MS fragmentation pattern 
was obtained in a positive ion reflector mode for both synthesized MCoTI-IINAT and 
MCoTI-IIAEP.  
 
5.3.6 Extraction and isolation of peptide  
 
Momordica cochinchinensis seeds (Vietnam) were homogenized with liquid nitrogen 
and suspended in two separate buffers – 1) 0.2 M sodium phosphate (pH 6.0) (Chem 
Supply) and 2) 60% aqueous acetonitrile (RCI Labscan Limited) in 1% formic acid 
(ACN/water/FA) for 30 mins at 4 °C, followed by centrifuging at 17,000 X g for 30 
mins. The resulting extract was filtered and freeze-dried. The crude extract was 
characterized using LC-ESI-MS. The peptide with mass corresponding to acy[MCoTI-
II] and acy[MCoTI-IV] was purified and purity was checked using methods described 
previously (Quimbar et. al., 2013). Structural analysis of the purified peptides was 
carried out by NMR spectrometry using methods described above. 
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5.4 RESULTS 
 
5.4.1 Peptide synthesis and structure elucidation  
 
A range of truncated MCoTI-II precursors was synthesized Fmoc chemistry on a 
Symphony synthesizer using HCTU on Rink Amide MBHA resin.  The MCoTI-II 
precursors were oxidized in 0.1 M ammonium bicarbonate at pH 8. Cyclic MCoTI-II 
was synthesized using Boc chemistry on phenylacetamidomethyl - Gly-Boc resin 
along with a S–tritylmercaptopropionic acid linker to facilitate cyclization. As 
described previously, MCoTI-II was cyclized and oxidized using a one-pot method in 
ammonium bicarbonate buffer via a thia-zip mechanism (Cĕmažar et. al., 2008a; Daly 
et. al., 2006).  After cleavage, peptides were purified by RP-HPLC followed by 
analysis with mass spectrometry.  
 
NMR spectroscopy was used to analyse the structures of the truncated MCoTI-II 
precursors. A comparison of the αH secondary chemical shifts with native MCoTI-II 
is shown in Figure 5.3A. The MCoTI-II domain in all the truncated precursors had 
similar secondary shifts to the native peptide, indicating that the native-fold was 
maintained. The N-terminal regions of N16[MCoTI]C4  and N16[MCoTI]C0 appear to 
be highly flexible based on the secondary shifts being close to zero. The three-
dimensional structure of N16[MCoTI]C0  (Figure 5.3 B and C) was determined and 
confirmed disorder in the N-terminal region, and that the native fold was maintained 
in the MCoTI-II domain. The structural statistics for the NMR solution structure of 
N16[MCoTI]C0 are presented in Table 5.1. 
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Figure 5.3 Structure details on MCoTI-II precursor variants using NMR 
spectroscopy.  
A) Secondary αH shift of MCoTI-II precursors in comparison with MCoTI-II. B) The 
lowest energy ribbon structure and a superposition of the 20 lowest energy line 
structures of N16[MCoTI]C0, respectively. Structures comprise of MCoTI-II region 
(green), N-terminal precursor region (red), three disulfide bonds (yellow; ball and 
stick format), α-helix (red) and two antiparallel β-sheets (light blue).  
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Table 5.1 Structural statistics for the NMR solution structure of N16[MCoTI]C0 
 
Experimental restraints2 
 Interproton distance restraints 416 
Intraresidue 138 
Sequential 159 
Medium range (i–j < 5) 46 
Long range (i–j >= 5) 73 
Hydrogen-bond restraints3 4 
Disulfide-bond restraints  18 
Dihedral-angle restraints (Ψ,Φ ) 22 
R.m.s. deviation from mean 
 Backbone atoms 0.53 ± 0.21 
Heavy atoms 1.47 ± 0.32 
Stereochemical quality4 
 Residues in most favoured Ramachandran region (%) 73.19  ± 0.07 
Ramachandran outliers (%) 3.89 ± 0.03 
Unfavourable sidechain rotamers (%)  8.05 ± 2.43 
Clashscore, all atoms5 2.77 ± 1.88 
Overall MolProbity score 2.8 ± 0.28 
1 Statistics are presented as mean ±  S.D. 
2 Only structurally relevant restraints, as defined by CYANA, are included. 
3 Two restraints were used per hydrogen bond. 
4 According to MolProbity (http://molprobity.biochem.duke.edu) (Davis et. al., 2007). 
5 Defined as the number of steric overlaps >0.4 A˚ per thousand atoms. 
 
 
5.4.2 Incubation of the truncated precursor constructs with AEP 
 
MCoTI-II precursors were incubated with commercially available Jackbean AEP and 
the formation of MCoTI-II monitored with mass spectrometry. The activity of AEP 
was found to decrease after 6 h based on incubation time optimization experiments 
over 24 h (data not shown). Therefore, analysis of enzymatic products was evaluated 
between 0.5-6 h. The precursor peptides (95-97% pure) were converted to various 
products, depending upon the amino acid composition at the pro-peptide regions 
(Figure 5.4). Kalata B2 (a 29 amino acid cyclotide) was chosen as an internal standard 
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(IS) because of its similar size to MCoTI-II and its elution time, which was 
approximately 10 min after any peptide fragment associated with the experiment. The 
products from the enzymatic reaction were quantified by comparing the peak area to 
the peak area of the IS as previously described (Colgrave et. al., 2005; Saska et. al., 
2008a).  
 
 
 
 
Figure 5.4 In vitro enzymatic processing of MCoTI-II from its precursor peptides.  
A) Chromatogram showing the production of MCoTI-II from N0[MCoTI]C8 after 6 h 
incubation with Jackbean AEP. B) Comparison of the amount of MCoTI-II processed 
by AEP from six different precursor peptides (n=3). (The statistical significance was 
determined in comparison to N0[MCoTI]C0 by one-way ANOVA and post-hoc 
Bonferroni test with p<0.05, considered statistically significant illustrated by an 
asterisk (*), where ‘*’ - p<0.01, ‘***’ - p<0.001, ‘***’ - p<0.0001). C) Similar MS 
fragments profile obtained for 3+, 4+ and 5+ ions for both [MCoTI]AEP and 
[MCoTI]NAT from LC-ESI-MS analysis. D) Co-elution of the 3450.54 Da peptide 
produced by Jackbean AEP from N0[MCoTI]C8 with [MCoTI]NAT under isocratic 
condition. Peptides were mixed in two ratios and analysed by RP-HPLC.  
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Figure 5.4A shows an example of the enzymatic conversion of precursors 
(N0[MCoTI]C8) to MCoTI-II after 6 h incubation with AEP. The peak observed with 
a mass of 3450.54 Da was confirmed to correspond to MCoTI-II (MCoTI-IIAEP) based 
on analysis using a combination of chromatography and mass spectrometry 
techniques. The 3+, 4+ and 5+ ions of MCoTI-IIAEP were found to be equivalent to 
native MCoTI-II (Figure 5.4C) and the peptide co-eluted with native MCoTI-II at 
ratios of 1:1 and 1:2 under isocratic conditions, as shown in Figure 5.4D. 
N0[MCoTI]C4 produced the largest amount of MCoTI-II, whereas no cyclic product 
was observed upon incubation of either N16[MCoTI]C0 and N0[MCoTI]C0 with AEP. 
  
 
5.4.3 Discovery and characterization of acyclic MCoTIs from seeds  
 
Acyclic counterparts of several cyclic MCoTI peptides were observed in the M. 
cochinchinensis seed extracts. The cyclic forms were more abundant than the acyclic 
forms (acyMCoTIs) as highlighted in Figure 5.5 for the cyclic and acyclic versions of 
MCoTI-II. Peptide extraction methods used in previous studies (Chan et. al., 2009; 
Mylne et. al., 2012) did not reveal the presence of acyMCoTIs. However using either 
sodium phosphate buffer (w/v, pH 6) or a water:acetonitrile mixture (1:1 v/v) resulted 
in successful extraction of acyMCoTIs. acyMCoTI-II and acyMCoTI-IV were isolated 
for sequencing and structural determination. Sequencing of the reduced, alkylated and 
acetylated peptides with mass spectrometry confirmed that the peptides were acyclic 
and that their sequences matched the cyclic counterparts. Analysis of the αH 
secondary shifts of acyMCoTI-II and acyMCoTI-IV confirmed the peptides extracted 
from seeds were identical to the chemically synthesized acyclic versions (Figure 5.6). 
acyMCoTI-II and acyMCoTI-IV had similar secondary shifts to MCoTI-II, indicating 
the presence of the cystine knot conformation. 
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Figure 5.5 LC-MS trace of a crude peptide extract from M. cochinchinensis seeds 
showing the retention time and relative intensities of the different peptides. A) Crude 
extract containing cyclic MCoTI-I – III, IV, VII and VIII, previously known MCoTI-
V, VI and newly discovered acyclic variants of MCoTI-I – III, IV, VII and VIII. B & 
C) Extracted ion chromatogram of cyclic MCoTI-II (c) and acyclic MCoTI-II (a), 
respectively. The acyclic MCoTI-II is 24.7 % of cyclic MCoTI-II. 
 
 
Figure 5.6 αH NMR shift comparison of M. cochinchinensis seed extracted 
acyclic  
MCoTI-II (blue) and MCoTI-IV (red) with synthesized acyclic MCoTI-II (pink) and 
cyclic McoTI-II (green).  
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5.5 DISCUSSION 
 
Backbone cyclized peptides such as the cyclotides have potential in the design of 
peptide-based drugs because they are generally stable against enzymatic or thermal 
degradation. However, there is limited information available on the processing and 
maturation of cyclotides from their precursors within plant cells. Understanding the 
biosynthesis might provide alternative methods for the production of cyclotides and 
therefore facilitate their development as drug leads. In this study I have characterized 
the role of AEP in the post-translational processing of cyclic peptides in an in vitro 
system. 
 
Analysis of the structures of the MCoTI-II precursors using NMR spectroscopy 
suggested that the native three-dimensional fold of the mature peptide was retained. 
However, the Ntr and Ctr precursor residues present in the truncated precursors 
appear to be flexible based on αH chemical shifts, which are close to random coil 
(Figure 5.3). Determination of the three-dimensional structure of N16[MCoTI]C0 
confirmed the presence of two antiparallel β-strands and a short helix in the MCoTI-II 
region, consistent with the structure of the native peptide. Furthermore, the 16-residue 
Ntr region was disordered and this arrangement renders the Asn-1 and Asp34 exposed 
to the solvent and enzyme attack.  
 
The susceptibility of the truncated precursors to AEP (legumain/vacuolar processing 
enzyme), a cysteine endopeptidase with high specificity for Asn and Asp (Hara-
Hishimura et. al., 1993; Hara-Nishimura et. al., 1991; Kinoshita et. al., 1995; 
Kinoshita et. al., 1999), was determined using the commercially available plant AEP 
from Jackbean (Canavalia ensiformis). Incubating N0[MCoTI]C0 or N16[MCoTI]C0 
with AEP did not yield any cyclic peptide. However, native MCoTI-II was produced 
as a result of incubation of AEP with precursor variants that contained some part of 
the Ctr region. Co-elution studies between MCoTI-IIAEP with MCoTI-IINat were used 
to confirm that MCoTI-IIAEP had the native-like three-dimensional fold and Gly1-
Asp34 ligation. The number of residues in the Ctr region influenced the amount of 
MCoTI-II observed with N0[MCoTI]C4 found to yield significantly more MCoTI-II 
than the longer peptide N0[MCoTI]C8. The number of residues in the Ntr region also 
influenced the amount of MCoTI-II produced, with N16[MCoTI]C4 (native) and 
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N0[MCoTI]C4 (truncated) both resulting in less MCoTI-II than N0[MCoTI]C4. The 
influence of the number of residues in the Ctr region is consistent with a recent study 
that showed increasing the number of Ctr residues of a kalata B1 precursor construct 
decreased the production of cyclic product when incubated with butelase 1 (Nguyen 
et. al., 2014). The extra residues at the C-terminus might interfere with the binding of 
the active site residues.  
 
One of the main by-products in the in vitro reactions of AEP with the precursor 
constructs was acyclic MCoTI-II (acyMCoTI-II). The presence of acyMCoTI-II in the 
in vitro reactions led us to question the efficiency of AEP in planta. Peptides with 
masses corresponding to acyclic equivalents of cyclic MCoTIs were observed in M. 
cochinchinensis seed extracts using two different extraction methods (sodium 
phosphate and ACN/water/FA). This is the first time full-length acyclic peptides, 
equivalent to naturally occurring cyclotides, have been discovered. Although it is 
possible that full length acyclic cyclotides are present in other plants, it is interesting 
to speculate that the presence of these acyclic forms in M. cochinchinensis is related 
to the inefficiency of AEP enzymes in processing Asp rather than Asn containing 
peptides.  
 
Butelase 1, the ligase from Clitoria ternatea, was significantly more efficient at 
cyclizing Asn containing peptides compared to peptides that were cyclized via an Asp 
residue (Nguyen et. al., 2014). Kalata B1 and SFTI constructs with Asp residues 
resulted in less than 10% of the cyclic product formed compared to >95% when the 
Asp was mutated to an Asn (Nguyen et. al., 2014). However, despite the apparent 
inefficiency of the cyclization reaction for the M. cochinchinensis cyclotides, the 
cyclic forms are still significantly more abundant than the acyclic forms in contrast to 
the studies with butelase 1. A range of sequence specific enzymes might be involved 
in the processing of cyclotides.  
 
Overall this study indicates that AEP can cleave MCoTI-II from its precursor and 
ligate its N and C termini to form the cyclic backbone under in vitro conditions. The 
C-terminal region is essential for cyclization in contrast to the N-terminal region. The 
presence of full-length acyclic variants of known MCoTIs suggests that not all 
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cyclotides are cyclized efficiently in plants and has implications for the specificity of 
cyclotide processing enzymes. 
 
 
  82 
CHAPTER 6 
6 UNDERSTANDING THE BUSINESS MODEL 
CONCEPT: FROM ITS GENESIS AND 
DEVELOPMENT TO CONTINUED 
REINTERPRETATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: http://wallpoper.com/wallpaper/mind-machine 
 
 
 
 
 
 
“The greatest enemy of knowledge is not ignorance, it is the illusion of knowledge.” 
Stephen Hawking, Theoretical physicist, (1942 - ) 
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6.1 RELEVANCE TO THESIS AND SIGNIFICANCE OF WORK 
 
A bio-entrepreneur has to navigate through various challenges in the 
commercialisation process, ranging from seeking and attracting large amounts of 
financial capital, scaling up production to overcoming regulatory hurdles. 
Commercial development of a drug, besides being highly capital intensive, is fraught 
with risks and uncertainties of both science and commercialisation such as clinical 
trials and volatile market. Figure 6.1 shows the context of Chapter 6 in the thesis and 
its contribution in the drug development and commercialisation process. 
  
To minimize risk and to maximize the chances of successful commercialisation, a bio-
entrepreneur must expend upfront effort in understanding and adopting an appropriate 
business model (BM) to achieve growth. An appropriate business model can guide 
commercialisation strategy and equip the bio-entrepreneur with the essential 
operational decision-making capability. 
 
 As an integral part of the drug development cycle, in this thesis, I explore the role 
and significance of BMs in the drug commercialisation process. In this chapter, I 
delve deeper into BM as a research area in general and its application in the 
biotechnology sector in particular. In Chapter 7, I continue the investigation of BMs 
by illuminating successful businesses models for periods in the evolution of the 
biotechnology industry by presenting the results in statistical and graphical formats.  
  
While business models in other sectors have been well studied over decades, the 
biotechnology industry has been relatively slow in understanding the role of BMs and 
their implications on a biotechnology firm’s success and performance. To date 
researchers have been unable to clearly understand the factors that contribute to 
success or failure for biotechnology firms, especially over time. 
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Figure 6.1 Schematic representation of the layout of the thesis showing its 
progression across chapters.  
 
This chapter presents a systematic review of existing literature over the last two 
decades in the BM area. The purpose of the review is to not only establish a baseline 
for the contributions of this thesis in this area, but to develop a deeper appreciation of 
the issues involved in tailoring BM models to the biotechnology industry.  The review 
process involved a systematic screening (David et. al., 2004; Newbert, 2007; Zott et. 
al., 2011) of contributions from 22,000 articles on ‘BM’, which were subsequently 
filtered down to 170 contributions pertaining to the inception and progression of BM 
concept. The filtered articles were then analysed in detail. 
This review provides a foundation for developing a BM framework that best 
illustrates the dynamic characteristics of the biotechnology industry to survive harsh 
market and financial conditions. 
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6.2 INTRODUCTION 
 
Contemporary organisational studies have moved their focus from the consideration 
of static and equilibrated organisational environments to the consideration of dynamic 
organisational models in which the organisation is constantly changing its strategy 
and business processes to survive internal and external environmental changes (Baum 
et. al., 1996; Kelly et. al., 1991). A central objective of organisational studies has 
been to understand these changes and their implications for firm performance. The 
concept of the ‘BM’ originated in organisational studies as a tool to represent 
organisational structure and explain where value is created.   
 
Broadly, BM defines the workings of an organisation, however it has potential to be 
used as a strategic and decision-making tool (Zott et. al., 2008). To date, BM has been 
described in a static context using terms such as ‘architecture’ (Dubosson-Torbay et. 
al., 2002; Slywotzky, 1999; Timmers, 1998), ‘description’ (Chesbrough et. al., 2002), 
‘design’ (Mayo et. al., 1999), ‘tool’ (Osterwalder et. al., 2005), ‘method’ (Afuah et. 
al., 2001), ‘representation’ (Shafer et. al., 2005), ‘framework’ (Chesbrough et. al., 
2002), ‘statement’ (Stewart et. al., 2000) or ‘depiction’ (Amit et. al., 2001), without 
incorporating the concepts of dynamism, change or momentum in definitions. 
 
A BM’s power, integrity and efficacy are limited if it lacks empirical support and is 
constrained by the typical two-dimensional framework, thereby making organisation 
change monitoring difficult if not impossible. Additionally, the discrepancies over the 
BM’s definition, framework, structure and components has led to a diversity in the 
conceptualisation and use of the term (Morris et. al., 2005; Osterwalder et. al., 2005).  
 
The focus of this literature review is to provide a comprehensive overview of the 
recent advances in BM research, emphasising the evolution of the BM concept. Given 
that a systematic literature review is an accepted inductive, longitudinal and 
methodical approach, this method will be used to evaluate the developments in the 
field of the BMs (Mulrow, 1994; White et. al., 2005). This literature review highlights 
the contribution of different schools of thought towards the emergence of the BM 
concept that is widely accepted and applied in business today. The relevant literature 
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will be reviewed in a sequential longitudinal manner, observing connections with 
closely related disciplines. 
 
6.3 ANTECEDENTS TO THE BUSINESS-MODEL CONCEPT 
 
Chesbrough and Rosenbloom first discussed the antecedents of the BM concept, 
proposing that Chandler was the first researcher to discuss a comparative account of 
growth and change. Chandler’s strategy and structure formed the underpinning 
platform of business model development (i.e. structure follows strategy) (Chandler, 
1962; Chesbrough et. al., 2002). Later, Ansoff applied the concept of structural 
change to corporate strategy and suggested that strategy can be used to align the 
organisation with the opportunities and threats posed by its environment (Ansoff, 
1965). Andrews proposed that business strategy is a part of corporate strategy and 
pattern (strategy) is the relational foundation of corporate activities (Andrews, 1971). 
Another building block for the BM concept was offered by Prahalad and Bettis, who 
explained the pattern of diversification and performance, referred as ‘dominant logic’. 
According to dominant logic, management logic evolves due to characteristics of core 
business, critical tasks for success and top management’s mindset. They also stated 
the importance of understanding an organisation’s performance, portfolio 
management and diversification also indirectly contributed towards the evolution of 
the BM concept – this could be seen to be the first glimpse of a dynamic view of the 
business model (Prahalad et. al., 1986). Bettis and Haspeslagh in 1978, described how 
managers used concepts such as portfolio management, as a tool or dogma by which 
to manage their businesses (Bettis et. al., 1978; Haspeslagh, 2003). 
 
Few key authors have acknowledged the influence of Porter’s work on BM concept. 
Morris (Morris et. al., 2005) and (Hedman et. al., 2003) proposed that the BM 
concept builds on the successful reconfiguration of the value-chain concept (Porter et. 
al., 1985) and Porter’s advanced work on value-system strategic positioning (Porter, 
1996). Porter’s work on the dynamic theory of strategy (Porter, 1991) is also of great 
importance in its coverage of the critical nature of the environment that affects the 
nature of the firm. Dynamic processes of the market can result in superior 
performance if a company develops and implements an internally consistent set of 
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goals and policies that aligns its strengths and weakness with external opportunities 
and threats to define its position in market. In addition to these schools of thought the 
origin of the BM concept can also be found in evolutionary economics. The need for 
constant redefinition of BM to keep pace with the changing external environment and 
competition reflects Darwin’s notion of the ‘survival of the fittest’.  
 
To understand the theories of evolutionary economics, it is important to turn to 
evolutionary biology. One way of understanding the evolutionary economics is via 
comparison with the Darwinian evolution. Amalgamating the two schools of thought 
– evolutionary biology and evolutionary economics could contribute towards better 
understanding of the dynamism and evolution in the BMs of organisations. The 
transfer of knowledge between economics and biology has a long history.  Darwin 
and Wallace’s evolutionary theories were influenced by the work of economist 
Thomas Malthus. Malthus’s work on population economics had a great effect on the 
Darwin’s acclaimed work On the Origin of Species, both at the theoretical and 
empirical level. It compelled Darwin to look beyond the species level, where 
knowledge is limited. At the species level, the variations between individuals in the 
species makes the theories of evolution less close to reality and leads to 
misinterpretation of observations, however observing changes at population would 
provide additional information on dynamic changes (Jones, 1989). From Darwin and 
Wallace’s perspective, evolution denotes the change inherited in a population by 
natural selection over successive generations. This change gives rise to diversity at 
each level of the biological organisations (Hall, 2011). Several examples of analogies 
between biology and business ecosystems are provided below: 
 
 Survival of the fittest or natural selection: Henderson strongly supports that the idea 
competition among organisations existed before concept of strategy was incorporated 
in organisational studies, and competitors have always employed a combination of 
resources to survive (Henderson, 1989). Researchers have always emphasised the 
need for reviving existing BMs; this need is a result of strategic manoeuvring 
triggered by external events that determine a course of action (Cavalcante et. al., 
2011; Johnson et. al., 2008; Sosna et. al., 2010). Some firms that have used great 
technology, failed due to application of inappropriate BMs or through a lack of BM 
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innovation, for example, Kodak, IBM and Ericsson (Probst et. al., 2005; Sull, 2005), 
suggesting the firms that best adapt to changing markets continue making profit, 
while others proceed on the path of deterioration. 
 
Variation under domestication: The incubator firm, a financially and technologically 
protected firm is maintained in a secure environment such as the environment of a 
university. While this reduces the probability of firm failure, it also delays timely 
entry to market (Cooper, 1986; Rothaermel et. al., 2005). A study has demonstrated 
that such firms have lower research and development (R&D) expenses with a higher 
level of innovative output. The incubator stage induces changes in the organisation 
that makes the organisation different from other organisations that do not have 
opportunities to be in a financially secured environment that allows them to improve 
organisational knowledge and competence (George et. al., 2002). 
 
More offspring are produced than survive: A ‘boom and bust cycle’ is a typical 
example of this law. The entry of large number of firms into market due to a huge 
influx capital due to over-expectation of profits or a bandwagon effect leaves a large 
number of such newly set-up firms struggling for limited resources; this is followed 
by a ‘bust’ situation because of which strong organisations survive while weaker ones 
disappear (Greve et. al., 2006; Pontarotti, 2011; Ruef, 2006). 
 
Overall, the knowledge gained in the biological sciences over the centuries could be 
adapted with or without adjustment to study processes and events in the economic 
world. However, the usefulness of biological analogies to the world of economics has 
been demonstrated by various evolutionary economists since Malthus, for including, 
Alfred Marshall, Herbert Spencer, Thorstein Velben, Edith Penrose, Joseph 
Schumpeter and the neo-Shumpeterian economists (Becker et. al., 2012; Fagerberg, 
2003; Hodgson, 1997; Kelm, 1997). Alfred Marshall said that the “Mecca of 
economics lies in economic biology rather than economic dynamics’ (Lecaillon, 
1963). Veblen believed that only evolutionary thought is capable of explaining the 
technological development process in a capitalist economy, describing economic 
organisation as a process of ongoing evolution (Veblen, 1898). Figure 6.2 summarises 
the contribution of various schools of thought towards the evolution of BM concept 
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that have been explained above and the key areas of BM that have been studied by 
researchers over last few decades. Additionally a new concept is emerging, ‘BM 
innovation’, that refers to the reinvention or creation of the business itself. 
 
 
 
Figure 6.2 Theoretical foundation of the BM concept.  
Schematic representation of the evolution of the BM concept, shows the schools of 
thought (left) that contributed towards evolution of BM concept and various key areas 
of BM (right) that have been studied.  
 
6.4 METHODOLOGY 
 
A combination of two level of analysis – quantitative and qualitative, was used to 
conduct multi-level systematic literature review on ‘business model’. David and Han 
(2004)  and Newbert (Newbert, 2007) adopted a quantitative method for evaluation of 
articles on resource based view (RBV) while Zott et al  (Zott et. al., 2011) employed 
more qualitative approach for identifying recent advances in the field of BMs. Since 
the term ‘BM’ is widely used, therefore solely using one of the above methods would 
not have isolated the most relevant publications as both these method have their 
advantages and disadvantages. Therefore the systematic literature review 
methodology is designed after extensive standardization with the objective of 
retaining relevant articles while removing substantively irrelevant articles through 
various filtration steps as shown in Table 6.1. 
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Quantitative analysis includes data collection, followed by a series of steps to filter 
out insubstantial articles and this is influenced by previous works (David et. al., 2004; 
Newbert, 2007). Thomson Reuter’s Web of Knowledge (Wok) and EBSCO’s (EB) 
EconLit and Business source complete (BSC) databases were selected to search for 
journal articles as these provided the broadest and deepest coverage of articles in 
related fields. An inverted pyramid approach was taken to filter the articles on the 
basis of keywords. Since this study aimed at consolidating the state of academic 
research on BM, the phrase ‘business model*’ was searched in title and abstract in EB 
database while in topic for WoK database due to lack of the previous option in this 
database. A set of ‘ ’ was used to search a phrase and * was used at the end of word 
‘model’ as a wild card in order to retrieve variation of the word stem or root. The 
search was then restricted to scholarly journals including academic articles and review, 
research area of business economics (as oppose to sciences and other discipline) and 
articles in English language only. The articles from both the database were then 
combined and duplicates were removed. 
Table 6.1. Summary of selection criteria to consolidate the state of academic 
research on BM with special emphasis on the biotechnology industry 
 
Filter Type Database Description Result 
Quantitative    
Substantive WoK WoK database searched for ‘business model’ searched in 
‘topic’ option 
11009 
EB EB database searched for ‘business model’ searched in 
‘title and abstract’  
19283 
Substantive  WoK Filtered: Article & Review, in business economics area 
and English language  
1596 
EB 1030 
Methodologic
al & 
duplicates 
WoK At least the phrase ‘business model’ must appear in title 
or abstract and duplicates within database are removed 
1546 
EB 852 
Substantive & 
methodologic
al 
WoK Remaining abstracts were read for substantive relevance 
and statistical relevance 
124 
EB 42 
Duplicates Both/ 
merged 
Articles from both databases are merged and duplicates 
removed 
151 
 
Substantive Both/ 
merged + 
external 
Articles added that were discussed in prominent articles 
that did not appear in the databases were added 
170 
 
Qualitative analysis included eliminating substantively irrelevant articles that did not 
contain the phrase ‘business model’ in the title or abstract or they were published in 
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solo journals (journals containing only one article). The articles obtained 
independently from WoK and EB were imported to Thomson Reuters’ referencing 
tool, EndNote X5 starting with WoK and followed by EB in the same file and during 
this process duplicates were removed. The advantage of this method was WoK 
provided the citation count of the articles while EB does not. Thereafter, the list of 
articles was exported to Microsoft Excel in a customized template containing - 
authors, article title, journal title, times cited (citation count) and abstract; this 
information was then used for further analysis. The missing information like citation 
count (not available for all EB unique articles) was manually entered after searching 
on EB again or Google Scholar (GS). In case of WoK, EB and GS, citation count 
refers to the number of times the article of interest has been cited within respective 
database’s product range. The final step was to read the articles thoroughly to analyse 
them substantively for relevance of to our context and those articles were removed 
that insignificantly used the phrase ‘business model. For the first time these many 
articles even marginally or trivially focused on the application or understanding of the 
BM have been studied. During this process I discovered that these articles could be 
divided into following areas – i) articles that discussed the BM as a conceptual tool, 
ii) articles in which BM was used as a metonym, iii) articles that led to diversification 
in the concept of BMs and iv) the reviews.   
 
6.5 RESULTS AND DISCUSSION 
6.5.1 Business model — yesterday and today 
A search of electronic media reveals that the term ‘business model’ was first used in 
1937 in the title of a newspaper article ‘Labor legislation—railroad business model’ 
that discussed the plan to tackle the labour problem in the railroad business (Beatty, 
1937). It was then used in an agricultural economics article (titles: what are business 
models and how should they be used?) in 1957 (Six, 1958) and then used in 
computer-science journals throughout the 1970s (Durrhammer, 1969; Forringt, 1973; 
Jones, 1960; Kugel, 1972; Noble, 1968; Stanford, 1972). It was not until the mid-
1990s that it was used in the context of the e-business, information technology (IT) 
and mobile businesses that coincided with the ‘dot-com bubble’ and this is reflected 
in the research on the BMs that are mainly focused on these businesses (Alt et. al., 
2001; Chesbrough, 2003; Timmers, 1998; Zott et. al., 2010). Since then, the semantic 
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drift in the term ‘BM’ has led to its current extensive use by entrepreneurs and 
academics to discuss businesses and more often, business strategy, organisational 
structure and innovation. Despite the number of publications and practical 
applications of this term in industry, researchers and entrepreneurs have not been able 
to come to a universally accepted definition, typology or ontology of the term. 
Systematic analysis of the literature provided a better idea on the research into BMs, 
and the gaps in research that need to be addressed so that this concept can be 
employed to its full potential. The BM concept has diversified to such a degree that a 
major part of this concept now refers to innovation and business processes. As such, I 
will be studying publications longitudinally to understand the evolution of thoughts in 
this area. 
 
Table 6.1 presents articles obtained through our methodology. After undergoing 
filtering, 170 articles were read in detail, 106 of which focused on BM as their core 
concept. This sample size is larger than other reviews of BMs (Dubosson-Torbay et. 
al., 2002; Morris et. al., 2005; Zott et. al., 2011). It was observed that the BM concept 
was engrained in business research during the mid-1990s, and since then, its 
popularity has increased among researchers. Analysing the vast pool of literature in 
the past two decades, I observed that the concept of BMs has not matured; conversely, 
it has diverged and been increasingly misinterpreted. It has been used to explain the 
principal activities of a firm (Muller, 2002; Nosella et. al., 2005, 2006) or demand-
chain management (Juttner et. al., 2007). It has been interchangeably used for strategy 
(Hamel, 1999; Rucci et. al., 1998; Sahlman, 1999) and business processes (Rothman 
et. al., 2006; Willemstein et. al., 2007), and this has led to the confusion in 
terminology and diversity in the views on the BM concept (Magretta, 2002; Morris et. 
al., 2005).  
 
I divided the literature on BM into four categories based on the nature of contribution 
made in the research area (Figure 6.3): first, articles that have contributed towards the 
advancement of the concept of BM, and discussed it as a conceptual tool; second, 
articles that have used the term BM metonymically (i.e. a substitute for a closely 
associated concept); third, articles in which the BM concept has diversified and the 
core logic is missing; and fourth, reviews on BM that have summarised and evaluated 
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the literature from various lenses. Importantly, I have used longitudinal analysis of the 
literature to understand the evolution of the BM concept. Figure 6.3 illustrates the 
interpretation of data on publications obtained from the SLR conducted on the BM 
concept. Figure 6.3A shows that BM research area is relatively new concept and the 
widespread usage of the BM concept has been increasing ever since the introduction 
of the term ‘BM’ in business field of research.  
 
Figure 6.3 State of articles published in BM area.  
A) Number of articles published on BM and in the field of business. B) Number of 
articles in four categories and entire BM research area. C) Journals that have accepted 
articles on BM.  
6.5.2 Business model—tracing evolutionary footprints in business economics 
6.5.2.1 Business model—a conceptual tool  
The BM concept has changed over time, becoming more applicable to real world and 
system based. Broadly, scholars from the past two decades have worked around five 
major aspects of BMs: the definitional (Timmers, 1998), categorical (Mahadevan, 
2000; Morris et. al., 2005; Osterwalder, 2004b), functional (Alt et. al., 2001; Gordijn 
et. al., 2001b), processual (Desai et. al., 2005; Koo et. al., 2004; Osterwalder et. al., 
2002) and evaluative (Desai et. al., 2005). These aspects have been defined in the 
context of various characteristics of a firm, for example, the firm’s business function, 
value chain, network and systems approach. The various studies contributing to these 
different aspects are presented in Figure 6.4.  
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Timmers offered the earliest work to propose a definition for and the types of BM. 
Timmers laid the foundation of contemporary research and initiated the process of 
defining, classifying and empirically evaluating the BMs. Since inception of BMs, 
value chain remained at the centre of the BM research. Timmers viewed e-commerce 
BMs as a description of product, services, information flows, revenues and business 
actors, and classified businesses on the basis of their value chain. Timmers’s eleven 
proposed BMs were classified based on a two-dimensional distribution consisting of 
degree of innovation and functional integration (Timmers, 1998). On the basis of 
value chain, Mahadevan divided internet-based e-commerce companies into three 
groups: portals (AOL.com, Cnet.com), market (ebay.com, ChemConnect) and 
product/service providers (Amazon.com, Dell). The major factors contributing 
towards the choice of a BM were identified by Mahadevan; these are the external 
environment, the physical attributes of the goods traded and the supply chain 
(Mahadevan, 2000). Rappa proposed eight different types of web-based BMs based 
on value chain. However, he noted that these BMs could be implemented in a variety 
of ways and a firm may amalgamate several different models as a part of their 
business strategy. 
 
According to Linder and Cantrell, BM components vary in accordance with revenue 
models, value proposition, organisational structure and arrangements for trading 
relationships. In addition, they emphasized that BMs are crucial for the survival of a 
firm against ever-increasing competition, innovations in technology, market shifts, 
and changes in consumer tastes (Linder et. al., 2000). Another publication clarified 
the myths surrounding BM, highlighting that a BM can be used in different industries, 
that executives often do not completely understand their BM, and that BMs must be 
transformed over time to survive in accordance with the pace of organisational 
changes (Linder et. al., 2001). Kraemer et al. discussed the changing business strategy 
and operational system of Dell Corp using the BM concept, and found that Dell 
Corp’s BM concept is over-simplified than required for its execution. Dynamism in 
BMs has been widely discussed and it has been proposed that the development of an 
efficient and flexible BM is equally as important as the BM’s execution, Dell Corp 
succeeded in both aspects (Kraemer et. al., 2000).  
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Table 6.2. Selected definitions of the term ‘BM’ 
 
Author    Year                                      Definition                                               Type 
Linder 1996 Organization’s core logic for creating value V 
Timmers 1998 Architecture for the product, service and information flows, including a description of 
the various business actors and their roles, the potential benefits for the various 
business actors and the sources of revenues. 
V 
Tapscott 1998 It is the entire system for delivering utility to customers and earning a profit from that 
activity. 
V 
Stewart 2000 A statement of how a firm will make money and sustain its profit stream over time V 
Mahadeva
n 
2000 A unique blend of three streams that are critical for business success: the value stream 
for business partners and buyers, the revenue stream, and the logistical stream. 
B 
Linder 2000 An operating business model is the organization's core logic for creating value. V 
Rappa 2000 Business model describe the revenue generation presective and positioning in the value 
chain 
V 
Amit 2001 A depiction of the content, structure, and governance of transactions designed so as to 
create value through the exploitation of business opportunities. 
V 
Weill 2001 A description of the roles and relationships among a firm's consumers, customers, 
allies, and suppliers that identifies the major flows of product, information, and money, 
and the major benefits to participants. 
B 
Petrovic 2001 A mental representation of certain aspects of the real work that are relevant for the 
business 
B 
Afuah 2001 The method by which a firm builds and uses its resources to offer its customer better 
value than its competitors and to make money doing so. 
V 
Magretta 2002 Business models are “stories that explain how enterprises work.  B 
Dubosson
-Torbay 
2002 The architecture of a firm and its network of partners for creating, marketing and 
delivering value and relationship capital to one or several segments of customers in 
order to generate profitable and sustainable revenue streams. 
B
 
V 
Chesbrou
gh 
2002 The heuristic logic that connects technical potential with the realization of economic 
values 
V 
Seddon 2004 A business model outlines the essential details of a firm’s value proposition for its 
various stakeholders and the activity system the firm uses to create and deliver value to 
its customers. 
V 
Morris 2005 A concise representation of how an interrelated set of decision variables in the areas of 
venture strategy, architecture, and economics are addressed to create sustainable 
competitive advantage in defined markets 
B 
Osterwald
er 
2005 A business model is a conceptual tool that contains a set of elements and their 
relationships and allows expressing the business logic of a specific firm.  
B
 
V 
Shafer 2005 A representation of a firm's underlying core logic and strategic choices for creating and 
capturing value within a value network 
V 
Van Der 
Meer 
2007 ‘Cognitive device to convert technical aspects of a product or service into economic 
value’ 
V 
Johnson 2008 Business models “consist of four interlocking elements, that, taken together, create and 
deliver value. 
V 
Bjorkdahl 2009 The logic and the activities that create and appropriate economic value, and the link 
between them 
B 
Teece 2010 It articulates the logic, the data and other evidence that support a value proposition for 
the customer, and a viable structure of revenues and costs for the enterprise delivering 
that value. 
B 
Sabatier 2010 A portfolio of business models as the range of different ways a firm delivers value to 
its customers to ensure both its medium term viability and future development. 
V 
The definitions were divided into two categories: ‘V’ where the term ‘BM’ has been used in 
context to value chain and ‘B’ the definitions that have used BM concept to define business 
development. 
 
It was not until Gordijn and Akkerman’s work that BMs were graphically presented to 
gain better understanding and application of the concept (Gordijn et. al., 2001a; 
Gordijn et. al., 2001b). Gordijn and Akkerman named this representation ‘e3-value’, 
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which was a conceptual-modelling approach to e-business in which they employed 
the ontology-based diagramming approach inspired by Borst and Akkerman’s work in 
computer science (Borst et. al., 1997). Their work was built on defining, developing 
and executing innovative BMs for a news service combined with IT. In their work, 
they achieved two different BMs by reversing revenue causality: terminating and 
originating. They proposed that the e3-value methodology could be used as a 
framework to represent and analyse complex business ideas and could prove 
advantageous in understanding innovative e-business’s BMs (Gordijn et. al., 2001a; 
Gordijn et. al., 2001b). 
 
In 2001, Alt and Zimmermann proposed six basic elements of BM: mission (goal and 
value proposition); structure (actors and focus); processes (customer orientation and 
coordination mechanism); revenue (sources and business logic); legal issues; and 
technology (Alt et. al., 2001). These authors recommended that designing BMs 
should be driven by all six of these generic elements as well as the dynamics of these 
elements. Petrovic et al.’s work was greatly influenced by Alt and Zimmermann’s six-
element BMs, and they used the system-dynamics approach to consider the BM as a 
dynamically complex system. As with such a system, BMs can neither be understood 
by focusing on internal components, nor by thinking of them as a black box that could 
resolve every business structure problem. A BM is combinatorial and dynamically 
complex system and supports the structure and sharing of knowledge by clearly 
identifying key components of an organisation (Petrovic et. al., 2001). Hedman and 
Kalling also proposed a BM consisting of six casually related cross-sectional 
components. To include dynamism in the BM, they included a longitudinal dimension, 
comprising constraints on actors, and cognitive and social limitations (Hedman et. al., 
2003). Chesbrough and Rosenbloom supported the idea that a BM can provide a 
coherent framework that converts the inputs (i.e. the technological characteristics and 
potential) into economic outputs (i.e. customers and markets). It is proposed that a 
BM is a mediating construct between technology and economic value (Chesbrough et. 
al., 2002; Chesbrough et. al., 2003).  
 
Several authors have attempted to underline clearly the differences between a BM and 
strategy and provided a framework that integrates strategy, BM and tactics. This 
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difference can by defined by considering that a BM is built on knowledge that is 
cognitively limited and biased, and is about value creation for customers and business 
rather than for the shareholders (Magretta, 2002; Seddon et. al., 2004a). Strategy 
involves more stringent choices that are based on more reliable information. Adapting 
BMs is triggered by challenges to understand complex organisational structures and a 
search for alternative models that could be more advantageous to a particular 
organisation than simply using a successful well-established BM (Chesbrough et. al., 
2002).  
 
Magretta supported the idea that BMs are often used interchangeably with other 
organisational studies concepts such as strategy and business processes. BMs are 
described ‘as a system, explaining how the pieces of a business fit together’, while 
strategy explains logic that will lead to a business performing better than its 
competitors (Magretta, 2002). Seddon et al. differentiated strategy and BMs in a real-
world firm. A BM was considered an abstract representation of some part of the 
firm’s strategy, and unlike strategy, it did not consider the firm’s competitive 
positioning (Seddon et. al., 2004b). Seddon et al.’s conceptualisation of strategy was 
based on work from Porter and the Harvard Business School. Given that BMs are a 
more recent concept than strategy, Seddon et al. suggested that the BM concept is 
underdeveloped, therefore fails to capture the totality of different attributes of an 
organisation. Casadesus-Masanell and Ricart view BMs as a reflection of the firm’s 
realised strategy, whereas a strategy is a contingency plan on which the BM should be 
constructed.  
 
Osterwalder and Pigneur (2002) realised one of the principal problems in the field of 
BMs is the absence of a virtual tool to understand the construction and ontology 
followed by BMs; this limits the application of BMs in the real world. The idea and 
definition of BMs are built on idea that BMs describe the logic of a ‘business system’ 
for creating value (Chesbrough et. al., 2002; Gordijn et. al., 2001a; Petrovic et. al., 
2001). Osterwalder and Pigneur’s e-business ontology had four key components: 
product innovation, customer relationships, infrastructure management and financial 
aspects. Product innovation is based on the firm’s capabilities that in turn build the 
target customer and value proposition. Infrastructure management maintains the 
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relationship between the resources/assets of a firm, its partner networks and activity 
configuration. The concept of customer relationships is comprised of information 
strategies, channels and trust. The final component is comprised of the financial 
aspects that determine the ability of a firm to survive against competition. Based on 
Linder and Cantrell’s work the BMs can be of three main types: the revenue model, 
profit model and cost structure (Linder et. al., 2000; Linder et. al., 2001). Osterwalder 
and Pigneur discussed the roadmap of the BM concept, beginning from the ontology 
level (i.e. definition and foundation), moving to the measures level (i.e. indicators of 
BMs) and finally to the dynamic-equation level (i.e. the development of equations for 
indicators followed by simulations to predict the future). 
 
Auer and Follack studied the effect of the dynamism of the internet on e-business 
BMs. Their work and their definition of BMs were greatly influenced by the work of 
Timmers and Petrovic et al. (Petrovic et. al., 2001; Timmers, 1998). According to 
Auer and Follack, the business plan is the predecessor of the BM, and only when a 
business plan is updated as per the market, can it be seen as a BM. Auer and Follack 
also suggested the steps and observations involved in the development of a BM (from 
the identification of the core business logic to the development of the action plan), 
which is referred to as ‘evolaris methodology’ (Auer et. al., 2002). Brink and Holmén 
analysed the relationship between evolved capabilities and changes in BMs of 
bioscience firms. They found that most of the firms radically changed their BMs at 
the same time changes in capabilities were observed. In addition, firms successfully 
adapted BMs that initially lacked critical technological capabilities and only partially 
leveraged their accumulated capabilities (Birkin et. al., 2009).  
 
Desai and Currie used BMs as a tool to study the market, business, managerial and 
technical challenges faced by application service providers and web services (Desai et. 
al., 2005). Bonaccorsi et al. conducted an empirical study of 146 Italian software 
firms on the evolution of hybrid BMs and determinants of strategic choices firms 
made. They operationalised the notion of hybrid models and supported the idea that 
hybrid nature of businesses is not a transient stage but a permanent feature 
(Bonaccorsi et. al., 2006). Björkdahl studied the changes in BMs to analyse 
interdependency between product knowledge and technological opportunities in 
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gaining economic value from firm’s technological potential. Björkdahl found that 
firms researched and changed their BMs substantially at different stages of growth to 
overcome difficulties. Some firms established autonomous venture organisations to 
provide freedom to make changes. Overall, firms found it inevitable to change their 
BMs to sustain along with changing markets and to gain economic value from 
investment in technology (Bjorkdahl, 2009). 
 
Miles et al. studied the co-evolution of business and organisational models and 
believe that the sustainability of new BMs depends on managerial philosophies and 
organisational processes (Miles et. al., 2006). In previous work, they proposed three 
kinds of BMs based on firm’s period of market penetration, market segmentation and 
market exploration (Miles et. al., 2000). They proposed a new organisational form 
called ‘innovation form’ (late 1980s era) in which firms learn to interact with 
networks and communities, mostly in developed nations where continuous 
knowledge-driven innovation is the primary means of value creation. This innovation 
form is largely affected by effective collaborations both within and across the firms 
(Miles et. al., 2009). 
 
Johnson et al. demonstrated the relationship between four elements of a BM 
framework: customer value proposition (CVP), profit formula, key resources, and key 
processes (Johnson et. al., 2008). Kiani et al. attempted to provide better 
understanding of causal BMs for e-businesses using a causal loop diagram (Kiani et. 
al., 2009). However, their model closely resembles previous ontological models and 
does not provide any added advantage (Afuah et. al., 2001; Osterwalder, 2004b; 
Petrovic et. al., 2001). Similarly, Yuwei and Manning proposed a BM with four self-
explanatory components: financial, resource, exchange and organisation, which in 
themselves were considered a model that drives the strategic logic of a firm (Yuwei et. 
al., 2009). 
 
Sánchez and Richart explored the factors that influence BM innovation. They believe 
that to analyse BMs, they must be represented in form of causal loop diagrams (Baum 
et. al., 1994; Sánchez et. al., 2010). McGrath’s research was influenced by 
Chesbrough and Rosenbloom (Chesbrough et. al., 2002) and used Xerox Corporation 
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as a case study (McGrath, 2010). McGrath supported the idea that the BM concept is 
a powerful tool for strategic purposes, and BM innovation occurs at both the firm and 
industry level. Gambardella and Anita also suggested that BM innovation occurs at 
both these levels (Jacobides et. al., 2006) and intellectual assets play an important role 
in new knowledge-exchange industries (Gambardella et. al., 2010). 
 
Sabatier et al. suggested that the notion of recipes for different dishes could be used as 
an analogy for a BM portfolio, seeing the BM as serving a combination of contrasting 
dishes for guests. The BM concept was used as a tool by Sabatier et.al. to ‘position 
the value proposition in the value chain’, and emphasis has been placed on balancing 
the BM portfolio, which can be deconstructed and reorganised to fit a firm’s strategy 
and the changing external environment (Sabatier et. al., 2010). Cavalcante et al. also 
supported the idea of dynamism, and on the basis of process changes proposed four 
types of BM: creation, extension, revision and termination. They believe a dynamic 
BM has both static (i.e. existing firm activities) and flexible (i.e. changes to 
environment) characteristics (Cavalcante et. al., 2011). Figure 6.4 summarises the 
sections of business area in which BM has been studied such as value chain, network 
and business function. It has been observed that empirical analysis of proposed BM 
and their association with business networks lack the attention of researchers and in-
depth analysis. 
 
Huelsbeck et al. empirically tested the BMs’ framework for a causal relationship 
between components. Although their statistical results were weak, they provided a 
basis for the development of a framework for testing BMs. These authors were 
concerned about the indifference of the researched company’s management towards 
the lack of validation of their BMs, and they suggested that more research is required 
to develop tools for the empirical testing of BMs (Huelsbeck et. al., 2011). Aspara et 
al. placed strong emphasis on the system-dynamics nature of BM evolution. They 
suggested that the components of the BM are dynamically interlinked over time and 
this linkage occurs due to the inheritance and development of these components both 
within and across the various level of businesses (Aspara et. al., 2011). However, 
George and Bock suggested that the BM is a static configuration of organisational 
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elements and activity characteristics, while strategy is a dynamic set of activities and 
processes (George et. al., 2011).  
 
 
 
Figure 6.4 Segregation of key literature based on relationship between various 
elements of BM research that have been studied in context to the specific 
segment of an organisation. 
6.5.2.2 Business model—a metonym 
Terms such as ‘BM’, ‘strategy’, ‘business concept’, ‘revenue model’ and ‘economic 
model’ are often used interchangeably in the literature (Morris et. al., 2005; Morris et. 
al., 2006). Figure 6.5 presents the evolutionary lineage of the BM concept, 
demonstrating the contribution and co-dependency of the areas of strategy and 
innovation within the BM concept. Research scholars represents BMs using static 
frameworks until the year 2000; in the time since then, the rapidly changing e-
business environment has driven the need for understanding dynamism in BMs. 
However, the biotechnology area has not fully utilised the potential of BM concept. 
 
Several articles published in the Harvard Business Review in the late 1990s that used 
the term ‘BM’. However, BMs were not the true subject of analysis in these articles. 
Nonetheless, this term was used to provide a description or conceptualisation of the 
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businesses. For example, Ghosh discussed the dynamism required in e-businesses to 
capture capabilities. However, it appears that the term ‘BM’ was used interchangeably 
with the term ‘strategy’ in several articles (Ghosh, 1998; Hamel, 1999; Lovins et. al., 
1999; Prahalad et. al., 1998; Rucci et. al., 1998; Sahlman, 1999). Hamel used the term 
‘BM’ to discuss the innovation and strategy of new start-ups and existing dying 
businesses; however, BMs were not the main topic of discussion. Hemel stated that 
the lifespan of today’s businesses are longer than a butterfly’s but shorter than a dog’s, 
suggesting that businesses must regularly consider making changes in their processes 
according to the external market. Such changes include resource allocation, resource 
attraction and innovation (Hamel, 1999). Shalman supported the idea of seeking and 
adapting new BMs due to the changing economy. He provided various examples of 
companies with innovative value chains, ranging from products, services to 
distribution systems, which decreased prices of products and increased the volume of 
new start-ups (Sahlman, 1999).  
 
Hargadon et al. also discussed BMs as a means by which to explain business structure, 
and created the idea of the ‘knowledge-brokering cycle’ around the concept of 
business strategy to capture a good idea among existing ideas, keeping good ideas 
alive in the organisation, and imagining new uses of such ideas and testing them. 
Hargadon et al. stated that the BM was the final step of the knowledge-brokering 
cycle and a final segment of business strategy (Hargadon et. al., 2000). 
 
Amit and Zott (2001) have contributed significantly to BM research, although in the 
work, BM was used as a unit of analysis to identify sources of value creation in e-
business. They stated that a ‘BM depicts the design of transaction content, structure 
and governance so as to create value through the exploitation of business 
opportunities’. These researchers conducted an inductive study on 59 e-business firms, 
using a questionnaire to identify the source of value creation for this industry. Four 
sources of value creation were reported: efficiency, novelty, lock-in and 
complementarities. The BM concept was not used to define the logic of a firm, but 
was used to isolate various sources of value chain (Amit et. al., 2001).  
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Figure 6.5 Evolutionary lineage of business model concept 
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As many other researchers, Sashi and O’Leary used BM to define the value chain and 
the strategy of a firm (Sashi et. al., 2002). Ittner et al. studied strategic-performance 
measures in financial-services firms and used causal business modelling as one of the 
measurement techniques and more significance was given to non-financial value 
drivers (Ittner et. al., 2003). Some researchers have stated that financial measures are 
‘backward looking’ and lack predictive ability in explaining a firm’s performance 
(Brancato, 1995; Fisher, 1995). It has been indicated that the importance of having a 
combination of financial and non-performance measures to achieve a better indication 
of firm performance (Hoque et. al., 2000; Kaplan et. al., 1993; Scott et. al., 1999). 
Kaplan and Norton argued that BMs have become an integral part of a balanced-
scorecard concept; however, 76.9 per cent of the firms they studied did not respond to 
BM changes and managers are not confident towards this approach.  
 
Koo et al. (2004) focused on understanding the implications of BMs on competitive 
strategies that affect business performance. Their research suggested that market 
focus is strongly related to firm performance; however, they observed that a mismatch 
between strategy and performance could also be due to market forces and 
organisational behaviours that could be captured using Porter’s model (Koo et. al., 
2004).  
 
BM-based knowledge was established by early 2000, and since then, the term ‘BM’ 
has been loosely used by entrepreneurs and in the literature to describe businesses 
processes (Govindarajan et. al., 2005; Hart et. al., 2004; Markides et. al., 2004; Wells, 
2004). During this period, Sanders and Boivie conducted a quantitative analysis to 
study the relationship between a firm’s market valuation and corporate-governance 
characteristics. Their study was well designed, and discussed firm size, sales growth, 
net income, firm age and stock-related variables to study firm market valuation at 
initial public offering (IPO) (Sanders et. al., 2004). Breznitz studied the Taiwanese IT 
industry, and used the concept of BMs to define the strategies and processes of 
businesses but provided no clear explanation of the term ‘BM’ (Breznitz, 2005). 
Athreye (2005) studied dynamic capabilities among firms and the role of 
management’s experimentation with BMs. In this study, the term ‘BM’ was 
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appropriately used to its real meaning, but was used to define business processes in 
the Indian software industry (Athreye, 2005).  
6.5.2.3 Business model —concept diversification 
 
In approximately the mid-2000s, it appears that the BM concept was well established 
and researchers did not feel it necessary to introduce the concept in their work. Garvin 
and Levesque discussed management issues faced in a company during the 
establishment of new businesses and discussed the issues on the BM front (Garvin et. 
al., 2006). Van der Meer discussed the application of open innovation in Dutch firms 
and the challenges these firms face in handling BMs (i.e. the structure of their 
businesses). Author described BM as tool to obtain economic value from 
products/services. Additionally, BM defined a firm’s core competences and 
innovative potential, and it should create value for both consumers and providers (van 
der Meer, 2007).  
Brousseau and Penard proposed a three-dimensional framework of digital BMs, using 
the three dimensions - the economics of matching, the economics of assembling and 
the economics of knowledge management (Brousseau et. al., 2007). Juttner et al. used 
‘BM’ as a term to define demand-chain management as a new strategy for creating 
value (Juttner et. al., 2007). Walters discussed the developments in BMs in the 
changing market environment, using Dell Corp as an example case (Walters, 2008). 
Mets explored the knowledge-market development trajectories and used BMs as one 
of the variables in the study to characterise enterprises. Agreeing with Chesbrough 
and Rosenbloon (Chesbrough et. al., 2002), Mets accepted BMs as a mediator 
between technical inputs and economic outputs (Mets, 2009). Onetti and Capobianco 
(2009) discussed the open source innovation while understanding how open-source 
firms develop successful BMs (Onetti et. al., 2009).  
Thoma attempted to understand strategic behaviour, BMs and the performance of 
firms. Thoma’s research focused on technological and industrial convergence and as 
with other research developed during late 2000s, BM was used as a platform to 
explain the business operations of a technological firm (Thoma, 2009). Heavily 
influenced by previous research (Afuah et. al., 2001; Magretta, 2002), Doganova and 
Eyquem-Renault presented the role of BMs as that of an innovation process and 
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market device, and described their view as a schematic description of business 
(Doganova et. al., 2009). Balocco et al. studied BMs in e-business to identify critical 
success factors and value chain was used a medium for their analysis (Balocco et. al., 
2010).   
Research on BMs of biotechnology and biopharmaceutical firms has conducted 
empirical studies to analyse such businesses. However, such research has generally 
vaguely used BM as tool for their research and organisation’s activities as constituting 
a product, service or hybrid firm were referred as type of BM. Similar to this, Persidis 
and De Rubertis discussed the business processes of spin-off versus start-up 
biotechnology firms (Persidis et. al., 2000). Nilsson analysed the establishment, 
position, finance and structure of the Swedish biotechnology industry using BMs as 
the tool of analysis. Nilsson researched the effect of the age, size, activities and 
accessibility to financial resources of firms in the industry (Nilsson, 2001). Bower 
also discussed the evolution of BMs in the biotechnology industry, researching the 
strategy of Genentech Inc. and the changes that have occurred in BM since its 
inception in 1976 (Bower, 2003). Mangematin et al. discussed the evolution of 
biotechnology in depth and proposed the use of different types of BMs in this industry. 
They stated that BM was a category of ‘firm in relation to the market it targets, its 
expected growth, its modes of governance, and the organisation of its activity’ 
(Mangematin et. al., 2003).   
 
6.5.2.4 Business model —reviews 
Dubosson-Torbay et al. (2002) examined the complete picture of BMs, with the aim 
of defining critical performance indicators used by e-business firms. The authors were 
the first to outline clearly the components of a BM. Their BM for e-businesses has 
four components and the respective indicators of these components: product 
innovation (target customer, value proposition, capabilities); customer relationships 
(get a feel, serving, branding); infrastructure management (resources/assets, 
activities/processes, partner network); and financial aspects (revenue, profit, cost). 
They then classified BMs based on a set of measures using a balanced-scorecard 
approach; these are product measures, customer measures, infrastructure measures 
and financial measures. They proposed that using these components and indicators, 
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the performance of a firm could be monitored. However, further empirical work is 
required in this area to validate the significance of the components and application of 
BMs in real world. 
Osterwalder, Pigneur and Tucci (2005), the developers of the most popular BM 
visualisation tool, BM canvas, reviewed BMs, describing various segments of the BM 
concept: definition, meta model, taxonomy sub-meta model, view of company, 
modelled instances, and real-world company (Osterwalder et. al., 2005). In this 
review, it was concluded that BM is a sole concept and it was proposed that BM is the 
core of an organisation that is guided by business strategy, organisation and 
information and communications technology (ICT). Osterwalder, Pigneur and Tucci 
underlined the nine basic building blocks of BMs; these are value proposition, target 
customer, distribution channel, relationship, value configuration, core competency, 
partner network, cost structure and revenue model. They concluded that a firm must 
constantly evolve its BM to remain profitable in a dynamic environment. The 
shortcoming of this study is that it was tailored for IT and e-businesses and it cannot 
be directly applied to other closely related industries such as biotechnology industry 
(Osterwalder et. al., 2005).  
 
Morris et al. in 2005 stated that the BM concept is built on strategy and its associated 
theoretical traditions, mostly the value-chain concept, value systems, resource-based 
view and strategic positioning (Morris et. al., 2005). On the basis of previous studies, 
Shafer et al. summarised the components of BMs into four categories: strategic 
choices, value networks, created value and captured value. These authors stated that a 
BM is not a strategy, and that in fact, BMs facilitate the ‘analysis, testing and 
validation of the cause-and-effect relationships that flow from strategic choices’ 
(Shafer et. al., 2005). While stating that a good BM can serve as an essential strategic 
tool, they discussed the problems associated with the application of BMs that are 
based on flawed assumptions underlying core logic and value networks, limitations in 
strategic choices and the misunderstanding value creation and value capture (Shafer et. 
al., 2005).  
 
Baden-Fuller and Morgan reviewed the literature on BMs in the fields of biology and 
economics. They summarised the means that are used to describe and classify BMs 
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(Baden-Fuller et. al., 2010). These authors concluded that BMs have a multivalent 
character and that is challenging to come to a consensus of a single, fixed definition, 
taxonomy or typology (Baden-Fuller et. al., 2010). George and Bock conducted a 
systematic literature review to reconstruct the concept of BMs and identify their 
elements from the perspective of entrepreneurship (George et. al., 2011). These 
findings provided a new direction to the development of BM concept by linking 
opportunity co-creation, entrepreneurial cognition and organisational outcomes.  
 
6.6 Conclusions 
 
The biotechnology industry is the result of the efforts of a generation of molecular 
biologists and risk-taking venture capitalists. Some of these people successfully 
triumphed over obstacles in academia and industry to deliver their first recombinant 
products to the market as reviewed by Bud (Bud 1991). Determining the success and 
evolution of this science-driven industry has remained a hot topic among scholars and 
venture capitalist. The usual accounting measures to study the BM of the firms cannot 
be used because this industry does not earn revenues during its first few years. To 
understand the evolution of the biotechnology industry, I needed a tool that could 
empirically evaluate change and business model (BM) offered a promising platform 
to observe the structure of the industry and its dynamism.  
 
The highly dynamic e-business environment of the 1990s created a void for the 
development of a tool to summarise working of an organisation so that ideas and 
business processes could be shared within the market using well-known platform. It 
has been widely used in the electronic and web – based industry. This led to the 
establishment of the BM concept. However, application of BM has been limited in the 
biotechnology industry. Since 1990s, various researchers have attempted to define, 
characterise, identify and understand the elements of a BM and the relationship 
between these elements. BMs can be an excellent decision-making tool used to 
identify the areas of a business that need to be modified to create growth and help the 
managers to improve communication among the stakeholders. However, research on 
BMs lack common consensus on its ontology, empirical proof of the concept for their 
application in real world and a means to incorporate dynamism within the BM 
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framework. The variation in the conceptualisations of BMs is exemplified by the 
diverse definitions of the form, structure, variables and elements of a BM. Such 
variation has resulted in a need for a generally accepted definition of a BM. Given 
that the understanding of the BM derives from a multitude of theoretical perspectives, 
there is great complication in delimiting the nature and components of a BM and 
determining what constitutes an efficient and effective model (Morris et. al., 2005; 
Weinhardt et. al., 2011). Therefore, more research is required to address the gaps in 
the understanding of this concept and to avoid the disintegration of the term ‘BM’ due 
to its diversification and misuse.  
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CHAPTER 7 
 
7 IMPACT OF CHANGES IN THE BUSINESS 
MODEL OF THE BIOTECHNOLOGY 
INDUSTRY ON PERFORMANCE  
 
 
 
 
 
 
 
 
“Situations emerge in the process of creative destruction in which many firms may 
have to perish that nevertheless would be able to live on vigorously and usefully if 
they could weather a particular storm.” 
Joseph Alois Schumpeter, Economist and Political Scientist (1883 – 1950) 
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7.1 RELEVANCE TO THESIS AND SIGNIFICANCE OF WORK  
 
The systematic literature review presented in Chapter 6 indicated the existence of a 
diversity of views over BM themes, structure, variables and elements have sustained 
debate over its conceptualization, application and usage. This resulted in a largely 
static and over simplistic application of BM research to real world business problems 
(Morris et. al., 2005; Osterwalder et. al., 2005). A generic BM is made up of various 
components, which have been studied and applied to develop and manage supply 
networks, which reduce operating costs and maximize their effectiveness in the 
marketplace and for this purpose firms are increasingly adopting dynamic BMs (Burn 
et. al., 2005; Hedman et. al., 2003; Morris et. al., 2005). In the last decade, 
contemporary organisational studies have started to change their perspective from 
static, equilibrated organisational environment to dynamic models according to which 
an organisation is constantly changes its strategies and processes in response to the 
changes in external environment. Dynamic BMs represent continuous change that 
makes firms learn constantly new and better ways to run their business (Mason et. al., 
2008).  
 
The BM research area and biotechnology industry are young fields. Therefore 
research in these areas has not matured sufficiently to clearly define the dynamism 
and evolutionary changes in them. A better understanding and adequate incorporation 
of the BM concept in the biotechnology industry could potentially improve the 
performance and survival rate of the biotechnology firms. Therefore it becomes even 
more important to fill the gaps between them and study the evolution of BMs in 
biotechnology industry, which could eventually help bioentrepreneurs and research 
scholars to understand the working of this industry better. 
 
This study is aimed to create a platform for researchers and entrepreneurs to help 
them understand the functioning of a firm and use the knowledge generated to make 
important strategic decisions. After extensive literature research, to create the tool to 
understand biotechnology businesses, I predominantly combined the organisation 
structure visualisation tool, BM canvas with the analytical technique, structural 
equation modelling, to observe quantitatively the dynamics of this industry. A reliable 
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BM model was generated for the biotechnology industry, after empirically testing its 
viability on a population of publicly listed/delisted biotechnology firms in the United 
States of American (USA). This helped us in tracing the evolution of BMs in 
biotechnology industry and changes that have occurred as a result of external and 
internal environmental factors. Figure 7.1 shows the context of Chapter 7 in the thesis 
and its contribution in the drug development and commercialisation process. 
 
 
 
Figure 7.1 Schematic representation of the layout of the thesis showing its 
progression across chapters. 
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7.2 INTRODUCTION  
 
Despite the extensive work by researchers on BM as highlighted in Chapter 6, the 
main limitations in this area are its application in limited type of industries, static 
organisational approach and lack of empirical studies. Most of the BM visualization 
tools such as BM canvas and road-mapping have been primarily developed to meet 
the need of few highly innovative industries like e-businesses and web-based 
businesses. Their two-dimensional framework lacks the capacity for capturing 
dynamism in internal and external organisation’s environment. In today’s world, 
change is unquestionably required to survive the rapidly changing markets. Failure to 
observe, evaluate and respond to these changes, limits the effectiveness of business 
monitoring tools. Also, there have not been many empirical studies to test validity and 
impact of BMs used in real world. Additionally, the diversity in the case study 
analysis has been limited to individual firms like big businesses like Xerox and Apple 
corporations or e-businesses, rather than industry-level (Amit et. al., 2012; 
Chesbrough et. al., 2002; Timmers, 1998). 
 
In order to understand the profile of a successful BM, it is important to define its 
ontology and framework first. This can then be used to study the evolution system. 
From the past two decades research scholars have tried to understand different aspects 
of the term ‘BM’ such as its definition, classification, components, and its application 
in real world. Additionally, BM concept has been studied in combination to various 
other concepts like innovation, strategy, organisation networks. Yet, lack of adequate 
empirical proof for the theoretical models has led to a semantic drift, alongside 
advancement of its usage as powerful organisational tool.  
 
In this study, individual firm BMs are aggregated to the level of the biotechnology 
industry to develop an appropriate dynamic framework for the biotechnology industry 
and quantitative methods would be employed to provide empirical support for the 
frame, followed by using it to understand the dynamics of industry. A major objective 
of this research is to observe the changes in the profile of a successful BM over time, 
using a range of performance indicators for the firms within the industry as 
performance criteria change with environmental influences and shocks. The 
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biotechnology industry has been selected as the research setting for this study, as it is 
a dynamically changing industry, with rapid technological trajectories. It has been in 
existence as an industry for forty years, sufficient to track change in individual BMs 
(Mangematin et. al., 2003) and to map these changes to the population of firms in the 
US biotechnology sector to gauge the evolutionary path industry has taken. This is 
also a major industry for the US and global economy. Given its origin in the US, size 
and comparative success of the industry in the US compared to all others around the 
world, the US industry provides the strongest foundation for an evolutionary study 
(Bae et. al., 2011; Zucker et. al., 1999). This study will gauge how, how much and in 
which ways BMs have changed over the life of the industry.  
 
7.3 THEORETICAL BACKGROUND 
 
BM concept 
 
The term BM has been in use for over 20 years. Researchers have attempted to define 
it by expressing it using terms like architecture, description, tool, method, 
representation, statement, design, representation, framework or depiction (Afuah et. 
al., 2001; Amit et. al., 2001; Chesbrough et. al., 2002; Dubosson-Torbay et. al., 2002; 
Mayo et. al., 1999; Osterwalder et. al., 2005; Shafer et. al., 2005; Slywotzky, 1999; 
Stewart et. al., 2000; Timmers, 1998). However no common consensus on BM 
definition has been achieved. On the contrary its core concept to understand 
organisation structure better has been diluted and it is being interchangeably used for 
business strategy (Hamel, 1999; Rucci et. al., 1998; Sahlman, 1999) and business 
processes (Rothman et. al., 2006; Willemstein et. al., 2007).  
 
The definitions available (Table 6.2) have remained static with limited consideration 
of change and development over time as discussed in Chapter 6. I define BM as a 
dynamic analytical tool to create and capture value from business functions, where its 
components together define the firm performance and it as a whole underlines the 
objectives and state of an organisation, thus making the components specific to an 
organisation’s nature. 
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One of the early attempts to develop BM visualization tool was by Gordijn and 
Akkermans, who created ‘the e3-value model’. The e3-value model was designed to 
understand how economic value is created and exchanged within a network of actors. 
Similar to BM canvas, it is also made up on constructs tailored for e-businesses 
revolving around actors and value related constructs (Gordijn et. al., 2001b). This 
value model to understand business transactions and it lacks the complete description 
of an organisation. However, it is useful in understanding the tangible exchanges 
within business.  
 
A BM tool that is rapidly gaining popularity in real world is ‘business model canvas’, 
a two-dimensional visualization framework developed to understand value 
proposition and value creation of a firm. It rapidly gained popularity due to its 
simplicity and ease of representing a business plan (Osterwalder, 2004a). This 
simplicity limits its ability to capture the complexity of the individual firm’s internal 
BM, let alone rather than its partner network. Also, due to the static nature of BM 
canvas it fails to seize the constant temporal changes in a firm. Components of BM 
canvas ranging from value chain, value proposition to cost structure (Osterwalder et. 
al., 2005), are relatively under-developed as they primarily represent the organisation 
structure, but fail to capture the significance of each component towards organisation 
growth and it does not track the changes in each component with changing 
environment. These limitations restrict the application of BM canvas in the 
developmental stages of e-businesses or web-based businesses (De Reuver et. al., 
2013). 
 
Another approach to visualize BM is STOF (Bouwman et. al., 2008). STOF also 
describes value capturing and creation using four domains – service, technology, 
organisation and finance. It uses the relationship between these domains to deliver 
value for customer and service provider. This is a broad and more structured approach 
than BM canvas that could be employed in business-to-business (B2B) or business-to-
customer (B2C).   
 
Along with the creation of BM visualization tool, only a handful of studies (Table 
8.1) have provided empirical support for proposed BM frameworks or application of 
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BMs as quantitative tools to assess the performance of firms (Hall et. al., 2012; 
Huelsbeck et. al., 2011; Zott et. al., 2008). Broadly speaking, researchers have used 
two types analytical techniques to provide empirical proofs for BMs - 1) early studies 
revolved around case studies (Amit et. al., 2001; Chesbrough et. al., 2002; Dubosson-
Torbay et. al., 2002; Timmers, 1998) and 2) recently structural equation modeling 
(SEM) (Hall et. al., 2012; Huelsbeck et. al., 2011; Zott et. al., 2008) has been used to 
provide more data driven analysis.  
Table 7.1 Comparison of empirical studies conducted around testing of BMs or 
its associations with other organisational factors 
 
 Zott et. al. (2008) Huelsbeck et. al. (2011) Hall et. al. (2012) 
Purpose Examine fit between firm’s 
product market strategy 
and BM 
Testing of BM and 
interpretations and uses of 
those test 
Relationship between 
innovation and BM with 
sustainable management. 
Sample Public listed Europe and 
US companies between 
1996- 2000 
Single-product 
biotechnology firm 
German and Netherlands 
firms 
Data 
collection  
IPO prospectuses, annual 
reports, analysts report and 
web sites. Measurement 
scales; firm evaluation by 
trained students 
Proprietary data and 
publicly available data 
from Compustat and CRSP 
Survey on five - point 
Liker scale 
Method Hierarchical ordinary least 
squares regression 
Linear regression Structural equation 
modeling 
Independent 
variables 
 
Novelty, differentiation, 
cost leadership, timing of 
entry 
R&D expenditure Internal, regulator, value 
chain, public 
Dependent 
variables 
 
Market value. Control 
variables - competition, 
market size, age of firm, 
entry mode, product scope, 
market scope 
Instrument placements, 
reagents released, reagent 
sales, revenues, gross 
margin/sales, financial 
performance 
Integration, inputs, 
emission, markets, risk, 
image, efficiency 
Results BM and product market 
strategy are complements, 
not substitute 
Poor model fit 
hypothesised BM. High 
confidence in company’s 
BM by top management. 
Innovation is panacea for 
sustainable development 
on if BM are radical to 
enable strong 
performance effects 
 
Zott and Amit created a model to investigate combinations of BM themes and product 
market strategies. They found that the BM and product market strategy are different 
and they could not be employed as substitutes for each other (Zott et. al., 2008). 
Huelsbeck et al developed a BM framework for a medical test equipment 
manufacturer and empirically tested the model for causal relationship between the 
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components. The objective was to develop a BM framework tool that could be used as 
a strategy tool to assess outcomes in various circumstances (Huelsbeck et. al., 2011). 
This approach was limited to single business firm and the statistical results were weak. 
Hall and Wagner, in the same year used SEM to compare the BMs and the role of 
different stakeholders groups in a moderation analysis (Hall et. al., 2012).  
 
BM is still a growing concept and it needs further investigation to address its 
limitations like the inability of entrepreneurs to assess the model quality, analysing 
temporal transitions due to dynamic changes, incorporating the impact of 
environmental conditions and lack of archetypical BM framework for each industry. 
The BM components need to be tailored for each industry or firm, as they would 
differ depending upon the nature of organisation. The generated model needs to be 
systematically assessed for both quantitative and qualitative capability. Empirical 
analysis of BMs is essential for validating the significance of each BM component 
and it also assists in observing the dynamics of organisation structure in response to 
changing external and internal factors. 
 
Based on the extensive literature review presented in the previous chapter, in this 
study, I have developed a theoretical BM framework (Figure 7.2) that best assesses 
the performance of biotechnology industry and empirically tested it. This platform 
could help researchers and entrepreneurs study the dynamic changes in biotechnology 
industry since its inception and understand the evolution resulting from various 
internal and external factors. Studying the dynamic changes over time will shed light 
on the recurring success and failure pattern in the industry and the appropriateness of 
BMs to their current environment, with the purpose of improving strategic decision 
making in firms. On the whole, exploring the past using historical data could 
potentially help us understand the adaptability and survival of firms which can then be 
employed in future strategy design.  
                                                                                    The Science and Business of Novel Therapeutics 
 118 
 
Figure 7.2 Pictorial illustration of the BM framework for biotechnology industry. 
It shows the hypothesised relationship between BM components and firm 
performance. The evolution in the BM framework is tracked by observing the changes 
in the relationship between the constructs from 1985 – 2013. 
 
BM framework for biotechnology industry 
The predominant characteristic of biotechnology industry is its large investment in 
research and development (R&D) and this makes it different from other 
comparatively recent industries like communication and technology based businesses 
and e-businesses on which many BM papers have been based (Del Monte et. al., 
2003; Hall et. al., 2007). Nonetheless as compared to other industries, biotechnology 
is expected to face far more challenges beyond R&D expenditures, including every 
long product development cycles, complex science, high speculative development and 
high cash burn rate (March-Chorda et. al., 2009). Financial skepticism is not the only 
hurdle that a biotechnology firm faces. The industry as a whole is stressed by many 
threats and challenges from its changing environment (Munos, 2009). The 
biotechnology firm’s key internal factors - R&D expenditure, revenue stream, firm 
size and financial status, were identified that drive its performance (measured by net 
profit) and this together contributed towards the development of BM for 
biotechnology industry.  
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R&D expenditure 
Being a technology driven industry, R&D expenditure becomes a crucial indicator of 
a firm’s growth or success. According to the Oliver’s (2000) data, the industrial age 
firms (like automobile makers, energy and steel producers) spend 5% of their revenue 
on R&D, while typically; biotechnology companies spend a minimum thrice of its 
revenues (Oliver, 2000). Biotechnology investment strategy has been categorised as 
high risk-high return making its stocks highly risky and volatile (Tan et. al., 2007). 
There have been studies that analysed the relationship between R&D and growth 
using R&D intensity (R&D expenditure/sales) as a construct. The limitation of this 
was that it did not independently consider the direct contribution of investment on 
R&D but only a factor of sales. R&D expenditure influences the growth of the firms 
(Morbey, 1988), however there could be a significant and uncertain lag from money 
spend in R&D to the profits made (Hall et. al., 2007; Jefferson et. al., 2006; 
MacKenzie, 2005). Parcharidis and Varsakelis have shown that for industrial and 
computer firms R&D expenditure has negative relationship with profitability for the 
year of investment, while strong positive relationship after two years (Parcharidis et. 
al., 2007). The relationship between R&D expenditure and firm performance is 
governed by the nature of firm, portfolio, exclusivity of patents and competition (Jaffe, 
1986). There has been diversity in the opinion and results on the relationship between 
these constructs, especially for the industries like biotechnology that are based on 
high technological demand (Coad et. al., 2010; Del Monte et. al., 2003). Due to the 
R&D intensive nature of biotechnology industry and extended product development 
period I hypothesise that: 
 
Hypothesis 1: The greater the R&D expenditure, the lower is the firm performance. 
 
Revenue stream  
Cash has been regarded as the king of the biotechnology sector. Few larger 
biotechnology firms have access to billion of dollars in capital reserves, while there 
are unnerving numbers of the public biotechnology firms that are unsustainable 
because of financial scarcity (Kessel et. al., 2007). The generation of sufficient 
revenues is crucial for the continuation of operations and finances for adequate 
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growth (Lewis et. al., 1983). The R&D intensive biotechnology firms struggle for 
finances in their early stage. After the early stages of growth the primary objective of 
biotechnology firm is the generation of enough revenues towards the continuation of 
operations and finances for adequate growth (Lewis et. al., 1983). Some firms 
perform better than others on capitalization of their IP, while other have ‘hit and miss’ 
or fail due to absence of enough revenue to survive (Hwang, 2004). Previous studies 
have investigated the relationship between revenues generated by the firm and its 
performance; their results indicated a positive relationship (Cho et. al., 2005; 
Huelsbeck et. al., 2011; Kleinschmidt et. al., 1991). I hypothesise the same for 
biotechnology industry:  
 
Hypothesis 2: The greater the revenue stream, the higher is the firm performance.  
 
Firm size 
Firm size plays a key role in industrial organisation and applied microeconomics. 
Studies have shown that firm size is related to firm’s productivity, profitability and 
survival (Beck et. al., 2005). Although, there is no common consensus on the ideal 
measure of firm size and it depends on the objective behind its use (Shalit et. al., 
1977). According to studies, firm size is negatively associated with firm performance 
(Evans, 1987; Hall, 1988), although ‘Gilbrat’s law’ suggests that there is no 
correlation between them (Almus et. al., 1999; Audretsch, 1995; Wagner, 1992). 
Changes like accretion of technology, knowledge and skills, competence and 
productivity boosts result in the increased size of the firm, but a slow down in growth. 
Slow growth of a firm can result in organisational failure (Hwang, 2004; Kazanjian et. 
al., 1990), that can be a direct outcome of the firm failing to be economically, 
politically and legally effective. Since, biotechnology companies have prolonged 
period of financial stress therefore I hypothesise that increase in firm size results in 
decreased firm performance due to increased demands on limited revenues. 
 
Hypothesis 3: The greater the firm size, the lower is the firm performance. 
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Financial status 
Financial status of a firm is important in management research as it reflects the 
variation in the performance of a firm. Access to finances is the key to growth beyond 
firm’s own immediate resource base, as it is crucial for firm’s survival and convincing 
venture capitalists or alternative growth capital investors of its potential (Oliver, 
2001). Poor financial status of a firm limits its access to resources and adversely 
affects its reputation in the market, therefore it is responsible in carving out a firm’s 
strategic niche positions (Freeman, 2000). Researchers have used financial ratios to 
investigate predictive ability and behavioural impact of the ratios on decision-making. 
The accounting based financial ratios have been used to evaluate financial position of 
the firm (Chen et. al., 1981; Lin et. al., 2011). The financial ratios also reflect the 
quality of management and organisation in terms of their efficiency to use fixed assets, 
working capital and profitability (Parker, 1991). Based on this, I hypothesise that:  
 
Hypothesis 4: The greater the financial status, the higher is the firm performance. 
 
Evolutionary analysis 
Researchers are changing their outlook from static BM canvas tool to 
transformational tool that could be used to address the dynamics and focus of an 
organisation (Demil et. al., 2010; Hedman et. al., 2003). Changes in an organisation's 
internal and external environment creates the need for transformation of a firm either 
by posing a threat to existing practice or by creating an opportunity for new growth, 
diversification, and some transitions occur from intrinsic pressures (Gray et. al., 1985; 
Mintzberg, 1984). Chandler suggested that there are certain patterns and trends that 
organisations experience as they grow (Chandler, 1962). Broadly speaking, there are 
three common scenarios during the growth of an organisation: early failures, stability 
once resource generation is achieved (with possible oscillations) and growth reversal 
following expansion (Garnsey, 1998). Therefore I propose that: 
 
Hypothesis 5: There is temporal change in the relationship of BM framework and firm 
performance. 
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The external environmental conditions under which a firm had been incorporated 
could have a profound effect on its performance. One study has shown that the effects 
of founding years are not permanent and as a firm develops, other factors like firm 
size, human capital, GDP growth and entry rates affect the survival of a firm (Geroski 
et. al., 2010). Particularly strongly the organisational ecologists emphasize the impact 
of external environmental conditions at the time of founding on the survival of firms. 
Others believe that it is the impact of strategic choices that had been made during 
early years affects its performance (Hannan, 1998; Henderson, 1999; Mitchell, 1994). 
Founding years could have long – lasting effects on a firm’s survival, also decisions 
made during that period affects its performance and probabilities of survival (Geroski 
et. al., 2010). I hypothesise that: 
 
Hypothesis 6: The profile of BM framework varies between the eras in which 
biotechnology firm are founded.  
 
7.4 METHODOLOGY 
 
Measures 
In this study, a BM framework is proposed comprising of four key constructs 
(independent variables) - R&D expenditure, revenue stream, firm size and financial 
status, in order to understand the influence of them on firm performance (dependent 
variable) (Figure 7.2). R&D expenditure, revenue stream, firm size and firm 
performance were measured by R&D expenses, total revenues, total number of 
employees and net profit, respectively. Financial status of the firms was calculated as 
an unweighted average of four financial ratios – cost of goods-to-total assets 
(efficiency ratio), current asset-to-current liabilities (liquidity ratio), debt-to-equity 
(solvency ratio) and net profit-to-net sales (profitability ratio). Both independent and 
dependent variable were continuous variable for which the data was collected every 
year since 1985 to 2013. The data for firm size was unavailable till 1995. 
 
Data collection 
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Data was collected for population of the US based publically listed and unlisted 
biotechnology firms. Data on the firm’s characteristics was collected primarily from 
Osiris database (Bureau van Dijk product) and missing information was gathered 
from respective firm’s website. Global industry classification standard (code 
#352010) developed by Morgan Stanley Capital International Inc. (MSCI) and 
Standard & Poor’s (S&P), was used for the segregation of biotechnology firms from 
all major public firms. This classification separates biotechnology firms from closely 
related pharmaceuticals and life sciences tools & services firms. The public listed 
firms were chosen as dataset because of data availability, consistency and accuracy 
due to the mandatory requirement of U.S. Securities and Exchange Commission 
(SEC) polices to submit quarterly and annual reports. This methodology is consistent 
with previous work (Zott et. al., 2008). A dataset of 594 firms was used for the study 
and it consisted 387 listed, 198 delisted and 9 unlisted firms (Figure 7.3). The firms 
were divided into three eras based on their incorporation year – Era-1 (<1985-1995; 
E-1), Era-2 (1996-2003; E-2) and Era-3 (2004-2013; E-3). All the data was collected 
on same date.  
 
Figure 7.3 Changing profile of biotechnology industry.  
A) Number of listed, unlisted, delisted and total number of public listed U.S.A. 
biotechnology firms in each year since 1985. B) Amount of venture capital 
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investment available for biotechnology industry and U.S.A. market every year since 
1985. 
 
Structural equation modelling 
 
IBM SPSS and AMOS were employed to analyse both the industry-level models 
(model IN) and era-level models (model E). Maximum likelihood estimation with 
robust standard errors was used for estimation. The independent variables were 
allowed to co-vary. Data grouping on the basis of the year of a firm’s incorporation 
was employed to study the differences between the firms from three different eras (E-
1, E-2 and E-3), while ungrouped data was employed to study the relationship at 
industry level (IN) between years 1985 - 2013 (labelled as superscript before the 
model name). Overall 86 econometric models were examined under same parameters, 
except models from 1985-1994. Due to unavailability on number of employees, the 
models from 1985-1994 were devoid of one variable: the size of the firm.  
 
7.5 RESULTS  
 
The evaluation of the measurement model as shown in Figure 7.2 was based on the 
statistics presented in Table 7.2 for the industry level and era – level analysis. The 
model 1985 – 2013IN has a very good model fit with chi-square (Χ2) greater than 3.841 
for one degree of freedom (df), (except for the years 1990, 1999, 2003 and 2007). 
Generally speaking, for most of the models the comparative fit index (CFI) was above 
0.90, the root mean square error of approximation (RMSEA) was between (0.05-0.08) 
and Tucker-Lewis index (TLI) was above 0.90. Overall, the coefficient of 
determination (R2) that determines how well the independent variables explain the 
effect on dependent variable was greater than 0.75 for model 1995 – 2013IN. A poor R2 
coefficient was observed for model 1985 – 1994IN that could be due to removal of firm 
size construct from the model due to unavailability of the data. Similar model fit 
observations were made for era – level grouped models (E-1, E-2 and E-3). The 
measurement model has a very good Χ2 fit for respective df. Unlike the model IN, 
model E had improved CFI, however RMSEA values worsened. Three R2 values were 
observed in model E corresponding to each era for every year. Overall, model E-1 and 
E-2 had much higher R2 values than model E-3 and R2 values decreased in model 1985-
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1994E-1 for reasons described previously. Model E-3 showed more variability in R2 
values and this trend was similar to early years for firms from E-1 and E-2. After the 
development of the measurement model and establishing good model quality, the next 
step was to analyse the effects of BM constructs on firm performance.  
 
R&D expenditure has negative relationship with firm performance for all the years 
except 1985-1988 and 1998 in both models IN and E (Appendix Table 7.1). The years 
showing positive unstandardized (b) and standardised (β) estimate values also had 
non-significant p-values. A comparison among eras showed that in recent years, E-1 
firms have less significant impact of R&D expenditure on firm performance as 
compared to E-2 and E-3. A trend is observed where significance of R&D 
expenditure decreases with the increase in the length of operation of firms. 
 
Revenue stream as hypothesised has positive relationship with firm performance 
except for models 1985, 2002IN, 1985, 2002E-1, 1998, 2003E-2 and 2006, 2008, 2010E-3 (Appendix 
Table 7.2). In terms of variability in significance of the constructs, a reverse trend to 
R&D expenditure was observed for relationship between revenue stream and firm 
performance. Revenue stream is not significant in the early years of E-1 and E-2 firms, 
and with the longer length of operations than E-3 firms, this constructs significantly 
contributes towards firm performance. A reflection of early years of older firms in E-
1 and E-2 was observed for more recently established firms of group E-3. b – value 
and p – value for revenue stream à firm performance was found to be more volatile 
for E-3 firms than E-1 and E-2 firms.  
 
An increase in firm size is associated with decrease in firm performance, with only 
exception in model 2013IN (Appendix Table 7.3). Similar to revenue stream, firm size 
has more variability in its impact on firm performance than R&D expenditure. Across 
the eras, E-2 and E-3 has shown frequent cycles of significant and non-significant 
effect of this construct. While, firms from E-1 have significant effect on this construct 
on firm performance. 
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Table 7.2 Model fit of the tested BM framework – A) Ungrouped industry-level 
model (Model IN) and B) grouped firms based on incorporation year (eras), 
Model E-1, E-2 and E-3.  
 
 
Year Χ2 (DF) p RMSEA RMSEA (Lo 90%)
RMSEA 
(Hi 90%) CFI TLI R
2
1985 23.84 (1) 0.000 0.196 0.167 0.385 0.821 -0.785 0.343
1986 11.28  (1) 0.001 0.132 0.000 0.198 0.916 0.158 0.544
1987 34.337 (1) 0.000 0.237 0.186 0.403 0.800 -1.002 0.484
1988 55.533 (1) 0.000 0.303 0.314 0.532 0.773 -1.274 0.355
1989 72.326 (1) 0.000 0.347 0.433 0.651 0.778 -1.217 0.644
1990 0.112 (1) 0.737 0.000 0.000 0.140 1.000 1.025 0.680
1991 14.07 (1) 0.000 0.148 0.126 0.344 0.958 0.584 0.140
1992 70.962 (1) 0.000 0.343 0.417 0.635 0.871 -0.293 0.725
1993 15.756 (1) 0.000 0.158 0.606 0.824 0.969 0.691 0.428
1994 114.837 (1) 0.000 0.438 0.587 0.804 0.857 -0.427 0.820
1995 1.98 (1) 0.159 0.041 0.000 0.160 0.999 0.986 0.850
1996 198.903 (1) 0.000 0.578 0.389 0.502 0.838 -1.424 0.849
1997 109.38 (1) 0.000 0.428 0.301 0.414 0.919 -0.210 0.806
1998 74.695 (1) 0.000 0.353 0.253 0.366 0.948 0.227 0.755
1999 0.855 (1) 0.355 0.000 0.242 0.355 1.000 1.002 0.233
2000 2.484 (1) 0.115 0.050 0.022 0.143 0.999 0.982 0.597
2001 44.62 (1) 0.000 0.271 0.177 0.290 0.968 0.516 0.760
2002 14.738 (1) 0.000 0.152 0.226 0.339 0.988 0.827 0.376
2003 3.072 (1) 0.080 0.059 0.030 0.149 0.999 0.987 0.869
2004 37.216 (1) 0.000 0.247 0.047 0.129 0.988 0.818 0.955
2005 0.733 (1) 0.392 0.000 0.082 0.162 1.000 1.001 0.956
2006 22.482 (1) 0.000 0.190 0.180 0.259 0.993 0.894 0.683
2007 0.134 (1) 0.714 0.000 0.153 0.231 1.000 1.004 0.947
2008 32.151 (1) 0.000 0.229 0.109 0.188 0.988 0.827 0.875
2009 87.643 (1) 0.000 0.382 0.142 0.221 0.966 0.492 0.968
2010 72.298 (1) 0.000 0.347 0.142 0.221 0.971 0.564 0.958
2011 50.379 (1) 0.000 0.289 0.118 0.197 0.985 0.771 0.962
2012 99.753 (1) 0.000 0.408 0.124 0.203 0.968 0.518 0.958
2013 131.695 (1) 0.000 0.469 0.181 0.260 0.954 0.315 0.974
Year Χ2 (DF)
p RMSEA RMSEA 
(Lo 90%)
RMSEA 
(Hi 90%)
CFI TLI R2 Era-1 R2 Era-2 R2 Era-3 AIC RFI
1985 23.84 (1) 0.000 0.196 0.167 0.385 0.821 -0.785 0.343 49.840 -0.728
1986 11.28  (1) 0.001 0.132 0.000 0.198 0.916 0.158 0.544 37.280 0.146
1987 34.337 (1) 0.000 0.237 0.186 0.403 0.800 -1.002 0.484 60.337 -0.945
1988 55.533 (1) 0.000 0.303 0.314 0.532 0.773 -1.274 0.355 81.533 -1.223
1989 72.326 (1) 0.000 0.347 0.433 0.651 0.778 -1.217 0.644 98.326 -1.180
1990 0.112 (1) 0.737 0.000 0.000 0.140 1.000 1.025 0.680 26.112 0.997
1991 14.07 (1) 0.000 0.148 0.126 0.344 0.958 0.584 0.140 40.070 0.566
1992 70.962 (1) 0.000 0.343 0.417 0.635 0.871 -0.293 0.725 96.962 -0.287
1993 15.756 (1) 0.000 0.158 0.606 0.824 0.969 0.691 0.428 41.756 0.676
1994 114.837 (1) 0.000 0.438 0.587 0.804 0.857 -0.427 0.820 140.837 -0.422
1995 1.98 (1) 0.159 0.041 0.000 0.160 0.999 0.986 0.850 39.980 0.973
1996 169.831 (2) 0.000 0.444 0.389 0.502 0.853 -1.203 0.861 0.829 245.831 -1.172
1997 109.813  (2) 0.000 0.356 0.301 0.414 0.914 -0.284 0.858 0.261 185.813 -0.278
1998 82.484 (2) 0.000 0.307 0.253 0.366 0.944 0.164 0.813 0.264 158.484 0.161
1999 76.983 (2) 0.000 0.297 0.242 0.355 0.942 0.127 0.287 0.305 152.983 0.124
2000 7.138 (2) 0.028 0.078 0.022 0.143 0.996 0.937 0.702 0.279 83.138 0.915
2001 47.577 (2) 0.000 0.231 0.177 0.290 0.970 0.553 0.885 0.617 123.577 0.543
2002 69.137 (2) 0.000 0.281 0.226 0.339 0.948 0.219 0.395 0.672 145.137 0.214
2003 8.126 (2) 0.017 0.085 0.030 0.149 0.997 0.962 0.960 0.731 84.126 0.950
2004 15.967 (3) 0.001 0.086 0.047 0.129 0.996 0.937 0.972 0.630 0.816 129.967 0.924
2005 28.454 (3) 0.000 0.120 0.082 0.162 0.992 0.876 0.965 0.709 0.885 142.454 0.863
2006 87.286 (3) 0.000 0.218 0.180 0.259 0.970 0.549 0.733 0.298 0.981 201.286 0.541
2007 67.465 (3) 0.000 0.191 0.153 0.231 0.979 0.689 0.955 0.891 0.884 181.465 0.679
2008 41.314 (3) 0.000 0.147 0.109 0.188 0.985 0.774 0.911 0.750 0.801 155.314 0.761
2009 60.5 (3) 0.000 0.180 0.142 0.221 0.979 0.688 0.977 0.969 0.621 174.500 0.677
2010 60.348 (3) 0.000 0.180 0.142 0.221 0.979 0.684 0.969 0.923 0.856 174.348 0.673
2011 45.972 (3) 0.000 0.156 0.118 0.197 0.983 0.751 0.976 0.967 0.770 159.972 0.738
2012 49.721 (3) 0.000 0.162 0.124 0.203 0.980 0.704 0.967 0.976 0.747 163.721 0.690
2013 88.138 (3) 0.000 0.219 0.181 0.260 0.960 0.407 0.981 0.969 0.699 202.138 0.398
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An industry level and era level analysis was conducted to observe the temporal 
change in the relationship between each BM construct and firm performance (Figure 
7.4 and 7.5, respectively). This analysis highlighted the order of impact of each 
construct for every year since 1985. Overall, revenue stream was found to be the most 
important driving factor of firm performance, except for early years where R&D 
expenditure had overpowered revenue stream. Financial status of the industry was 
generally least contributing factor to firm performance, among the constructs studied.  
Since 1995, R&D expenditure and firm size demonstrated an alternating effect in 
form of cycles at the second and third most contributing factor to firm performance. 
The year 2002 stands out, as it has not followed the trend of the industry and probably 
due to radical changes in the U.S.A. market post the Internet bubble event.  
 
The impact of constructs on the BM profile of industry and three ears were compared 
to each other to understand the variations as a result of incorporation years and 
observe industry phenomenon (Appendix Table 7.4). In early years 1985 - 1994, the 
industry was comprised E-1 firms therefore their profile resembles. The first few 
years of each era have high volatility among the constructs. For E-1 firms, revenue 
streams and R&D expenditure were still the most causative constructs. Over the span 
of two decades, E-1 firms attained stability in their BM and revenue streams were 
found to be the most contributing construct. Firm size and R&D expenditure, largely 
followed an alternating cycle similar to model IN. Model E-2 and E-3 had more 
volatility among constructs as compared to E-1, although E-2 had a stable BM since 
2006 and E-3 has not indicated of signs of stabilization till 2013. In 2012-2013 
financial status of the firms has more profound impact on firm performance than 
previous years for in model IN and E-1.  
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Figure 7.4 Representation of relationship between BM constructs and firm 
performance in the industry from 1985-2013.  
BM constructs are arranged in decreasing order (1 à 4) of their influence on firm 
performance in respective years. The four BM constructs are R&D expenditure 
(purple), revenue stream (green), firm size (orange) and financial status (blue). 
Respective standardized regression weights (b-value) are provided inside the bubbles, 
while p-value are superscripted on them where <0.05 (***) are significant and 
insignificant values are mentioned.
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Figure 7.5 Comparison of relationship between BM constructs and firm performance in the industry and different eras from 1985-2013.  
BM constructs are arranged in decreasing order (1 à 4) of their influence on firm performance in respective years. The four BM constructs are 
R&D expenditure (purple), revenue stream (green), firm size (orange) and financial status (blue). 
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7.6 DISCUSSION  
 
The biotechnology industry is driven by research and innovation, while at the same 
time being dependent on its market sector for commercialisation. These 
characteristics of biotechnology industry like high investment in R&D and 
importance of innovation closely resemble some of the high-tech industries such as e-
businesses and web-based businesses. However, the BMs to date are tailored for high-
tech firms like e-businesses or web-based businesses that could not be directly applied 
to biotechnology industry due to its stretched R&D pipelines, risks associated with 
drug-development and high cash burn rate. Due to these industry characteristics, 
conventional methods could be employed in determining the growth and success of 
the biotechnology industry (Zahra, 1996). According to Maurer and Ebers, the 
success of a biotechnology firm can be related to its survival that is itself dependent 
on the firm’s revenue growth and employment growth as well as on its patenting rate 
(Maurer et. al., 2006). Four important BM components were identified based on the 
nature of this industry: R&D expenditure, revenues generated, firm size and financial 
position that drives its performance. In this chapter I have seen the changing trends in 
the BM of biotechnology industry since 1985 and also the nature of firms based on 
the era in which they went public.  
 
Issuing an initial public offering (IPO) brings significant amount of investment to a 
firm that improves its access to debt financing, increases business’s legitimacy and a 
means of exit strategy. For biotechnology firms, going public raises large amount of 
capital required to pursue extensive R&D projects and clinical trials in their early 
stages of growth (Deeds et. al., 1997). Clearly, R&D and innovation remains the 
focus of biotechnology firms in their first few years of incorporation and to sustain 
the large expenses becomes their biggest challenge. A trend is observed in this study 
for the older E-1 firms where R&D expenditure had been the most contributing factor 
governing firm performance, before switched to revenue stream within first few years. 
I believe that this fluctuation is a result of alternating clinical trials expenditure and 
milestone payments, which are more prominent in the firm’s early years. The data 
collected from OSIRIS does not provide the fine details of R&D expenses and sources 
of revenues therefore reasons for these changes could not be analysed in detail. R&D 
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expenditure significantly influences the BM of young biotechnology firms as they 
have to decide whether to increase vertical integration by exclusively developing and 
marketing its products or licensing them out while concentrating on their research 
(March-Chorda et. al., 2009). Tremendous amounts of funds are required to finance 
the drug development process; therefore revenues or access to development capital 
become the major driving force of biotechnology industry performance and its 
sustainability in later stages of growth.  
 
A structural shift in the BM of the biotechnology firms has been observed as they 
successfully mature and gain stability with time (see Figure 7.4). In the first years 
after incorporation, biotechnology firms gain technological competency and expertise 
by focusing on drug development, gaining FDA approvals and establishing product 
pipeline. As such, R&D expenditure is the driving force of biotechnology firms. For 
newly listed firms, the revenue stream is not as vital as enhancing their R&D because 
during the initial stage of drug development, firms would have already established 
funding from a formal source (generally a public offering and venture capital). Thus, 
the firms must be R&D intensive at this stage. The average time taken for 
biotechnology firms to create positive cash flow is approximately eleven years 
(Pisano, 2006a). In addition, R&D costs in biotechnology firms are matched by the 
generation of capital from sales, royalty payments, mergers and acquisitions (M&A), 
and milestone payments. While R&D performance is the key long-term driver of firm 
performance in this industry, the ability of firms to convert drugs into financial 
resources is essential for their sustainability. This phenomenon is observed in the 
BMs of the biotechnology sector, which reflect the firms’ transition from being R&D-
centred to asset-based as the revenue stream becomes a more dominating construct 
than R&D expenditure within the firm. This phenomenon is more obvious in industry 
and older firms from E-1 and E-2, where firms eventually move from being R&D 
intensive to being asset based.  
 
A BM freely evolves, and changes occur in the core components that affect a firm’s 
sustainability. A firm’s success is based on it being able to anticipate and respond to 
these changes. Such emerging change and the ability of a firm to build its capacity 
and sustain performance by changing its BM has been termed ‘dynamic consistency’ 
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(Demil et. al., 2010). A great deal of variability is seen in the early stages of firm 
growth and in each era of incorporation year, this variability stabilises over time. In 
addition, this variability is consistent at corresponding stages of growth across eras, 
suggesting it is a phenomenon of biotechnology industry. Thus, the rationale behind 
the segregation of firms into eras based on incorporation years proved successful as it 
highlighted the differences and similarities among the firms that were established 
across different periods. Changes in industry BMs are predominantly governed by the 
E-1 and E-2 firms, as they are older and larger, and therefore contribute more towards 
the industry than younger and relatively smaller E-3 firms (see Figure 7.4). While the 
firms undergo a long period of a volatile BM, stability increases over time due to 
organisational learning over a span of time. In recent years, E-3 firms present greater 
variability, which demonstrates that they are adjusting their BM more consistently 
and therefore have a more volatile BM. DeCarolis et. al. (1999) suggested that 
‘organisations not only use different knowledge bases and capabilities in developing 
knowledge but also have differential access to externally generated knowledge’. 
Studies have also demonstrated that leaning orientation of a firm is positively 
moderated by its age, as it becomes more efficient and effective in utilising market 
information that then influences its competitive advantage (Calantone et. al., 2002; 
Sinkula et. al., 1997). This is reflected in the learning ability of the biotechnology 
industry as a whole as it moves towards more stable state.   
 
A great deal more variability is seen in the effect of a firm’s size (measured by total 
number of employees) on its performance; this is indicative of the firm’s flexible 
work forces as employees are hired and retained for a short period of time. The 
variability in firm size is consistent across different eras, suggesting that firms in each 
era vary their work force to meet the specific challenges at different stages of their 
developmental cycle. Generally, the R&D work force is contract based; therefore, 
firms do not have to retain these employees during a crisis or in the absence of in-
house R&D work. During events such as M&A or periods when drugs are in clinical 
trials, developmental work is at a minimum, which triggers a drastic reduction in the 
number of employees. The volatility in firm size is even observed in the older firms 
from E-1, suggesting that such volatility is an industry-wide phenomenon that is not 
necessarily confined to a particular era or stage of growth.  
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In this dynamic and temporal observation of BM profiles of the biotechnology 
industry over 28 years, responses to the major shocks in the external environment 
were also observed. According to evolutionary economic and industrial economic 
theories, a firm is largely affected by the structure of, and constant variations in, 
external industrial factors (Vega-Jurado et. al., 2008) such as market opportunities 
(Dougherty, 1990; Levin, 1981; Souitaris, 2002), technological changes (Geroski, 
1990; Levin et. al., 1985) and the conditions of appropriability (Levin, 1981; 
Mansfield, 1981, 1986). These external industrial factors stimulate changes in the 
internal workings of a firm that are required for its survival. Therefore, when 
developing a successful BM (which in turn reflects the workings of an organisation), 
it is of the utmost importance to understand and evaluate the factors that affect the 
performance of a firm. The response to the influx of capital during the internet bubble 
is reflected in the years 2000–2001, with the year 2000 showing the highest number 
of listed firms since 1985. In these years E-2 firms’ revenue stream had stronger 
impact on firm performance than previous years, which was followed by increase in 
R&D expenditure in 2002. The increase in R&D expenditure could have included 
both starting of clinical trials and investment in drug development process. Impact of 
global financial crisis (GFC) during 2007-08 is also observed in E-1 firms during 
which the firm size dropped by two places and regained in following years. 
Surprisingly, E-2 firms showed stability during this period and E-3 firms remained 
volatile. This difference in response of firms from different eras to the GFC could be 
a result of large size of E-1 firms, and therefore it became more important to 
consolidate the finances. Generally speaking, younger and growing firms are 
dependent upon milestone payments from investors that have been promised before 
and this could be the other reason why E-2 and E-3 and industry as a whole had 
comparatively less impact from GFC.  
 
7.7 CONCLUSION 
 
Overall, this study was designed to create a BM framework for biotechnology firms 
and to understand the causative relationship between BM components and firm 
performance. I wanted to utilise the power of BM concept to develop a tool for 
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researchers and entrepreneurs that could be used to improve firm performance by 
understanding the key driving factors. This study is one of the few that have 
attempted to empirically test the hypothetical BM framework for their practicability 
and use it to observe changes in the business units over the years. Studying the 
changes in the BM profile since 1985 showed the transition of the industry from R&D 
intensive to asset based. Also, industry evolved from a volatile to stable state over the 
years. The analysis of firms by categorizing them into era based on their incorporation 
years shed light on the industry phenomenon and era dependent phenomenon of 
changes in BM profile, for example, the younger firms were unstable as their older 
associates in their early stages and shared similar BM profile during respective stages 
of growth.  
 
Although, firm performance was well defined by the four key components of the BM, 
further research is necessary to understand other components contributing to the 
changes in different firm’s life-cycle stages. A cause-and-effect relationship could be 
designed between the BM components that are ubiquitous in the organisations. A 
more comprehensive BM for biotechnology industry when developed has potential to 
be a power decision-making tool. A good BM framework could also help in reducing 
failures in the industry, as market currently lacks a platform where firms can learn 
from each other’s mistakes and successes.  
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Appendix Table 7.1 Results of R&D expenditure à firm performance relationship in the industry and three era models tested from 1985 – 2013. 
β – value: unstandardized regression weight, b – value: standardized regression weight and corresponding p-value are mentioned where <0.05 
(***) are significant and insignificant values are mentioned. 
 
 
β - value b - value S.E. t - value p - value β - value b - value S.E. t - value p - value β - value b - value S.E. t - value p - value β - value b - value S.E. t - value p - value
1985 0.181 0.960 0.045 4.023 *** 0.181 0.960 0.045 4.023 ***
1986 0.116 0.239 0.061 1.905 0.057 0.116 0.239 0.061 1.905 0.057
1987 0.052 0.138 0.047 1.117 0.264 0.052 0.138 0.047 1.117 0.264
1988 0.004 0.019 0.037 0.121 0.904 0.004 0.019 0.037 0.121 0.904
1989 -0.356 -0.943 0.085 -4.190 *** -0.356 -0.943 0.085 -4.190 ***
1990 -0.559 -1.042 0.103 -5.419 *** -0.559 -1.042 0.103 -5.419 ***
1991 -1.207 -0.696 0.321 -3.755 *** -1.207 -0.696 0.321 -3.755 ***
1992 -0.880 -0.761 0.099 -8.909 *** -0.880 -0.761 0.099 -8.909 ***
1993 -0.840 -0.604 0.182 -4.609 *** -0.840 -0.604 0.182 -4.609 ***
1994 -0.303 -0.385 0.062 -4.931 *** -0.303 -0.385 0.062 -4.931 ***
1995 -0.180 -0.156 0.167 -1.073 0.283 -0.180 -0.156 0.167 -1.073 0.283
1996 -0.225 -0.236 0.072 -3.133 *** -0.182 -0.189 0.081 -2.253 *** -1.414 -2.427 0.324 -4.363 ***
1997 -0.231 -0.268 0.064 -3.597 *** -0.334 -0.384 0.071 -4.696 *** -0.063 -0.117 0.073 -0.857 0.391
1998 0.264 0.209 0.100 2.633 *** 0.069 0.054 0.120 0.573 0.567 -0.124 -0.225 0.085 -1.453 0.146
1999 -0.532 -0.321 0.248 -2.143 *** -0.650 -0.387 0.340 -1.910 0.056 -0.188 -0.200 0.145 -1.297 0.195
2000 -0.940 -0.698 0.133 -7.081 *** -1.023 -0.770 0.159 -6.431 *** -0.729 -0.379 0.275 -2.655 ***
2001 -0.569 -0.532 0.075 -7.571 *** -0.240 -0.227 0.075 -3.213 *** -0.689 -0.601 0.122 -5.655 ***
2002 -0.554 -0.424 0.140 -3.948 *** -0.458 -0.354 0.210 -2.184 *** -1.319 -0.838 0.110 -11.946 ***
2003 -0.748 -0.563 0.092 -8.130 *** -0.776 -0.608 0.077 -10.070 *** -0.645 -0.262 0.173 -3.733 *** -0.364 -0.242 0.232 -1.569 0.117
2004 -0.871 -0.809 0.054 -16.221 *** -0.871 -0.775 0.072 -12.126 *** -0.562 -1.234 0.109 -5.164 *** -0.871 -0.775 0.072 -12.126 ***
2005 -1.071 -0.750 0.075 -14.191 *** -1.073 -0.720 0.130 -8.233 *** -0.727 -1.552 0.098 -7.421 *** -0.767 -0.702 0.056 -13.783 ***
2006 0.506 0.501 0.137 3.705 *** 0.550 0.546 0.223 2.462 *** -0.759 -0.834 0.228 -3.334 *** -0.952 -0.343 0.072 -13.184 ***
2007 -0.468 -0.439 0.064 -7.297 *** -0.427 -0.395 0.101 -4.235 *** -0.838 -1.037 0.096 -8.737 *** -0.924 -0.785 0.059 -15.733 ***
2008 -1.162 -0.884 0.121 -9.587 *** -1.768 -1.312 0.193 -9.138 *** -0.561 -0.628 0.150 -3.755 *** -1.025 -0.694 0.097 -10.600 ***
2009 -0.433 -0.274 0.063 -6.850 *** -0.398 -0.236 0.105 -3.780 *** -0.781 -0.975 0.079 -9.852 *** -0.805 -0.627 0.109 -7.401 ***
2010 -0.342 -0.217 0.069 -4.925 *** -0.266 -0.159 0.114 -2.329 *** -0.777 -0.909 0.136 -5.719 *** -1.014 -0.609 0.081 -12.548 ***
2011 -0.364 -0.288 0.056 -6.467 *** -0.244 -0.188 0.083 -2.940 *** -0.573 -0.550 0.090 -6.377 *** -1.089 -1.039 0.074 -14.646 ***
2012 -0.106 -0.085 0.067 -1.568 0.117 0.026 0.020 0.115 0.223 0.824 -0.813 -0.763 0.079 -10.253 *** -1.051 -0.854 0.087 -12.064 ***
2013 -0.527 -0.438 0.052 -10.048 *** -0.465 -0.387 0.081 -5.726 *** -1.073 -0.817 0.119 -9.025 *** -1.020 -0.806 0.079 -12.980 ***
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Appendix Table 7.2 Results of revenue stream à firm performance relationship in the industry and three era models tested from 1985 – 2013. β 
– value: unstandardized regression weight, b – value: standardized regression weight and corresponding p-value are mentioned where <0.05 
(***) are significant and insignificant values are mentioned. 
 
 
β - value b - value S.E. t - value p - value β - value b - value S.E. t - value p - value β - value b - value S.E. t - value p - value β - value b - value S.E. t - value p - value
1985 -0.047 -0.349 0.032 -1.462 0.144 -0.047 -0.349 0.032 -1.462 0.144
1986 0.234 0.540 0.054 4.315 *** 0.234 0.540 0.054 4.315 ***
1987 0.169 0.644 0.032 5.221 *** 0.169 0.644 0.032 5.221 ***
1988 0.051 0.437 0.019 2.764 *** 0.051 0.437 0.019 2.764 ***
1989 0.226 1.469 0.035 6.528 *** 0.226 1.469 0.035 6.528 ***
1990 0.033 0.182 0.035 0.947 0.344 0.033 0.182 0.035 0.947 0.344
1991 0.349 0.652 0.099 3.528 *** 0.349 0.652 0.099 3.528 ***
1992 0.419 1.248 0.029 14.620 *** 0.419 1.248 0.029 14.620 ***
1993 0.383 1.018 0.049 7.767 *** 0.383 1.018 0.049 7.767 ***
1994 0.224 1.093 0.016 14.069 *** 0.224 1.093 0.016 14.069 ***
1995 0.565 1.709 0.044 12.844 *** 0.565 1.709 0.044 12.844 ***
1996 0.340 1.174 0.021 16.424 *** 0.331 1.147 0.023 14.290 *** 0.228 0.672 0.100 2.278 ***
1997 0.339 1.262 0.022 15.777 *** 0.368 1.363 0.023 16.082 *** 0.073 0.424 0.141 0.520 0.603
1998 0.265 0.775 0.033 8.002 *** 0.309 0.881 0.040 7.695 *** -0.022 -0.207 0.024 -0.902 0.367
1999 0.442 1.043 0.075 5.933 *** 0.625 1.429 0.103 6.051 *** 0.026 0.164 0.027 0.975 0.330
2000 0.545 1.545 0.037 14.539 *** 0.732 2.120 0.049 15.061 *** 0.276 0.588 0.067 4.086 ***
2001 0.407 1.505 0.020 20.733 *** 0.562 2.130 0.022 26.147 *** 0.289 0.937 0.033 8.892 ***
2002 -0.090 -0.296 0.037 -2.430 *** -0.222 -0.743 0.063 -3.507 *** 0.562 0.689 0.058 9.731 ***
2003 0.625 2.219 0.022 28.142 *** 0.623 2.343 0.019 32.647 *** -1.045 -0.856 0.186 -5.617 *** 1.278 3.557 0.391 3.267 ***
2004 0.517 2.344 0.013 41.024 *** 0.513 2.302 0.016 33.077 *** 0.419 2.855 0.039 10.783 *** 0.513 2.302 0.016 33.077 ***
2005 0.573 2.060 0.017 32.817 *** 0.585 2.073 0.026 22.510 *** 0.392 2.621 0.030 13.245 *** 0.170 0.639 0.101 1.677 0.094
2006 0.207 0.915 0.035 5.926 *** 0.154 0.689 0.051 2.998 *** 0.492 1.916 0.089 5.539 *** -0.391 -0.631 0.045 -8.714 ***
2007 0.411 1.772 0.016 26.408 *** 0.415 1.788 0.023 17.831 *** 0.568 2.320 0.035 16.161 *** 0.222 0.975 0.040 5.537 ***
2008 0.506 1.812 0.024 20.879 *** 0.570 2.017 0.034 16.960 *** 0.465 1.897 0.062 7.523 *** -0.404 -1.694 0.066 -6.130 ***
2009 0.481 1.514 0.013 36.031 *** 0.477 1.472 0.019 25.689 *** 0.594 2.496 0.027 21.817 *** 0.086 0.460 0.072 1.186 0.236
2010 0.445 1.437 0.014 32.045 *** 0.450 1.416 0.019 23.883 *** 0.395 1.725 0.040 9.895 *** -0.085 -0.560 0.035 -2.456 ***
2011 0.515 1.932 0.022 23.210 *** 0.595 2.214 0.034 17.535 *** 0.533 2.051 0.024 21.949 *** 0.916 0.841 0.164 5.600 ***
2012 0.257 0.980 0.017 15.568 *** 0.226 0.863 0.028 8.101 *** 0.576 2.153 0.021 26.862 *** 0.242 0.239 0.081 2.968 ***
2013 0.320 1.169 0.015 21.379 *** 0.301 1.098 0.023 13.131 *** 0.532 1.893 0.028 19.159 *** 0.309 0.309 0.073 4.247 ***
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Appendix Table 7.3 Results of firm size à firm performance relationship in the industry and three era models tested from 1985 – 2013. β – 
value: unstandardized regression weight, b – value: standardized regression weight and corresponding p-value are mentioned where <0.05 (***) 
are significant and insignificant values are mentioned. 
 
 
 
 
 
 
 
β - value b - value S.E. t - value p - value β - value b - value S.E. t - value p - value β - value b - value S.E. t - value p - value β - value b - value S.E. t - value p - value
1995 -130.148 -1.518 7.606 -17.112 *** -131.21 -1.528 8.147 -16.104 ***
1996 -14.553 -0.245 3.061 -4.755 *** -14.873 -0.243 3.382 -4.397 *** 74.887 1.076 24.824 3.017 ***
1997 -20.968 -0.313 3.315 -6.326 *** -17.79 -0.254 3.5 -5.083 *** -40.104 -1.141 28.159 -1.424 0.154
1998 -23.795 -0.221 6.138 -3.877 *** -13.396 -0.103 9.926 -1.35 0.177 6.467 0.813 1.573 4.111 ***
1999 -76.500 -0.500 15.179 -5.040 *** -139.59 -0.78 27.498 -5.076 *** -15.972 -0.619 3.433 -4.653 ***
2000 -43.757 -0.335 9.465 -4.623 *** -112.55 -0.799 15.829 -7.11 *** -7.775 -0.102 8.246 -0.943 0.346
2001 -37.192 -0.356 6.144 -6.054 *** -138.58 -1.223 9.54 -14.527 *** -2.583 -0.051 3.979 -0.649 0.516
2002 3.613 0.029 11.333 0.319 0.750 59.02 0.413 31.166 1.894 0.058 -2.617 -0.041 4.809 -0.544 0.586
2003 -160.099 -1.054 9.618 -16.647 *** -152.46 -0.998 10.074 -15.133 *** 29.637 0.152 27.219 1.089 0.276 -318.72 -4.277 84.655 -3.765 ***
2004 -116.762 -0.854 5.820 -20.062 *** -112.48 -0.787 7.38 -15.24 *** -147.68 -1.968 25.262 -5.846 *** -112.48 -0.787 7.38 -15.24 ***
2005 -98.809 -0.526 8.176 -12.086 *** -105.02 -0.536 13.363 -7.859 *** -93.826 -0.899 24.483 -3.832 *** -22.629 -0.676 12.738 -1.777 0.076
2006 -118.450 -0.748 16.931 -6.996 *** -81.459 -0.507 30.294 -2.689 *** -177.07 -0.98 76.13 -2.326 *** 52.471 0.487 7.496 7 ***
2007 -103.801 -0.547 7.556 -13.738 *** -116.13 -0.591 12.489 -9.299 *** -103.67 -0.586 31.01 -3.343 *** -48.756 -1.023 8.407 -5.8 ***
2008 -41.140 -0.166 15.620 -2.634 *** 20.494 0.08 24.446 0.838 0.402 -119.87 -0.568 58.655 -2.044 *** 42.861 1.34 8.701 4.926 ***
2009 -104.608 -0.428 7.034 -14.872 *** -102.9 -0.404 10.388 -9.906 *** -145.25 -0.673 24.958 -5.82 *** -28.438 -0.503 21.235 -1.339 0.181
2010 -106.245 -0.416 9.211 -11.535 *** -117.68 -0.438 15.199 -7.743 *** 10.601 0.048 35.136 0.302 0.763 29.587 0.676 9.947 2.975 ***
2011 -196.172 -0.819 18.697 -10.492 *** -292.34 -1.198 30.875 -9.468 *** -165.24 -0.645 25.723 -6.424 *** -79.374 -0.597 19.107 -4.154 ***
2012 -13.971 -0.051 13.861 -1.008 0.313 -9.47 -0.034 22.042 -0.43 0.667 -135.43 -0.56 23.216 -5.833 *** -56.406 -0.101 55.098 -1.024 0.306
2013 35.052 0.123 11.788 2.973 *** 42.105 0.146 18 2.339 *** -66.07 -0.239 26.491 -2.494 *** -33.644 -0.233 9.046 -3.719 ***
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Appendix Table 7.4 Results of R&D expenditure à firm performance relationship in the industry and three era models tested from 1985 – 2013. 
β – value: unstandardized regression weight, b – value: standardized regression weight and corresponding p-value are mentioned where <0.05 
(***) are significant and insignificant values are mentioned. 
 
β - value b - value S.E. t - value p - value β - value b - value S.E. t - value p - value β - value b - value S.E. t - value p - value β - value b - value S.E. t - value p - value
1985 1 0.723 1 0.723
1986 1 0.175 1 0.175
1987 1 0.180 1 0.180
1988 1 0.306 1 0.306
1989 1 0.227 1 0.227
1990 1 0.196 1 0.196
1991 1 0.061 1 0.061
1992 1 0.108 1 0.108
1993 1 0.089 1 0.089
1994 1 0.164 1 0.164
1995 1 0.118 1 0.118
1996 1 0.109 1 0.109 1 0.178
1997 1 0.123 1 0.117 1 0.396
1998 1 0.112 1 0.089 1 0.923
1999 1 0.091 1 0.071 1 0.6
2000 1 0.084 1 0.074 1 0.164
2001 1 0.107 1 0.102 1 0.19
2002 1 0.117 1 0.092 1 0.055
2003 1 0.132 1 0.125 1 0.083 1 0.563
2004 1 0.168 1 0.153 1 0.362 1 0.153
2005 1 0.123 1 0.113 1 0.2 1 0.779
2006 1 0.126 1 0.121 1 0.073 1 0.24
2007 1 0.129 1 0.123 1 0.083 1 0.672
2008 1 0.101 1 0.095 1 0.075 1 0.639
2009 1 0.104 1 0.097 1 0.064 1 0.739
2010 1 0.113 1 0.107 1 0.064 1 0.894
2011 1 0.124 1 0.126 1 0.066 1 0.121
2012 1 0.138 1 0.142 1 0.07 1 0.126
2013 1 0.128 1 0.131 1 0.089 1 0.22
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CHAPTER 8 
 
8 CONCLUSIONS, CONTRIBUTIONS AND 
OUTLOOK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“I shall be telling this with a sigh  
Somewhere ages and ages hence:  
Two roads diverged in a wood, and I—  
I took the one less travelled by,  
And that has made all the difference.” 
The Road Not Taken, Mountain Interval 
Robert Frost, Poet (1974 – 1963) 
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8.1 OVERVIEW 
 
The biotechnology industry has been in existence for more than four decades, and 
both its importance and contribution to improving human health remain 
unprecedented. Academics, government and industry have worked extremely hard 
towards harnessing its potential to serve and benefit humanity. The significant 
improvements in the healthcare sector have generated expectations from this industry, 
however there are problems associated with declining innovation and performance in 
the drug discovery process. Rather than rapid revolutionary changes, the 
biotechnology industry shows slow and incremental technology diffusion. 
Consequently, consultants, industrialists, policy makers and academics have promoted 
the idea of technical change in terms of revolutionizing drug discovery and 
development (Nightingale et. al., 2004). The driving factor behind my PhD was the 
burning desire to provide potential solutions relating to the increasing number of drug 
failures and enormous amount of resources lost in the drug development process. 
Biotechnology has two arms, science and business; therefore isolating them would not 
provide a comprehensive solution.  
 
This interdisciplinary thesis was designed to address the gaps in the drug-
development process, from its discovery in the lab to commercialisation by 
biotechnology firms. Analysis of naturally occurring disulfide-rich cyclic peptides 
from plants and frogs led to the discovery and development of molecules that have 
therapeutic significance to treat several major diseases. Further, understanding the 
biosynthesis of cyclic peptides in plants generated information that would be 
beneficial in tailoring the plants for the production of pharmaceutically relevant 
peptides. Following the discovery of a potential therapeutic use in the lab, the next 
phase of drug development is undertaking stringent clinical trials and obtaining 
approval to test and develop such drugs from regulatory bodies. Biotechnology firms 
largely carry the responsibility of turning molecules into drugs. As such, failure of 
business processes within the biotechnology firms lead to the failure of drug 
development. As such, a BM was developed that harmonised with the nature of the 
biotechnology industry. This model was empirically tested for its viability. This BM 
was used to study the evolution of the biotechnology industry to gain an 
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understanding of the factors that have contributed to sustainability of this industry 
over the past three decades. Overall, this thesis examined the biotechnology industry 
as a whole and attempted to provide solutions to some of the issues faced in the 
discovery and development of novel therapeutics. 
  
8.2 DEVELOPMENT OF PEPTIDE-BASED THERAPEUTICS  
  
One of the main strategies implemented by researchers in the development of novel 
drugs is discovering natural products (ranging from proteins to small molecules) and 
modifying them for drug efficacy. In this thesis, 14 – 34 amino acid peptides were 
screened and modified to develop molecules of therapeutic significance for treating 
breast cancer, Staphylococcal infection, acne and obesity. 
 
8.2.1 Chapter 2 – Cyclic plant peptides as matriptase inhibitors 
 
Two intriguing seed derived cyclic peptides that are also potent serine protease 
inhibitors, MCoTI-II and SFTI-1, have been studied for their inhibitory activity 
against trypsin and matriptase. Matriptase is a cell surface serine protease that had 
been reported to play a significant role in the breast cancer cell progression (Benaud 
et. al., 2002). Studies have shown that administration of a matriptase inhibitor 
counteracted the oncogenic effects, suggesting that matriptase inhibitors offer a 
potential therapeutic strategy to prevent the progression of carcinoma (Galkin et. al., 
2004; Parr et. al., 2007). 
 
Mutagenesis studies on SFTI-1 and MCoTI-II were conducted to study their 
structure–activity relationships (SAR) with matriptase and trypsin. Amino acids 
crucial for their inhibitory activity were identified for both peptides. Ile-10 in SFTI-1 
was found to be at the enzyme-inhibitor interaction site. Similarly, an alanine scan of 
selective MCoTI-II residues showed that Lys-6 and Lys-9 are important residues for 
the interaction of MCoTI-II with both trypsin and matriptase. MCoTI-II was found to 
be a significantly more potent matriptase inhibitor than SFTI-1. An interesting finding 
was the role of Val-3 that sits within the reactive site. A V3A mutation increased the 
inhibitory activity against matriptase by 17% while decreasing it for trypsin by 
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6000%. Based on the importance of Arg-2 in SFTI-1, Val-3 was mutated to arginine 
and this resulted in one of the most potent inhibitors of matriptase known, with sub-
nanomolar activity of 0.29 ± 0.054 nM.  
 
The large amount of SAR data generated for SFTI-1 and MCoTI-II is now available 
for designing more selective and potent inhibitors. In the future, additional 
mutagenesis studies on both SFTI-1 and MCoTI-II could help in developing 
matriptase specific inhibitors. For example, SFTI-1 I7A and P13A mutants both 
resulted in higher matriptase inhibitory activity relative to the native peptide; 
therefore mutations at these points could be used to determine their influence on 
activity. In MCoTI-II, loop 5 and loop 6 have been found to interact with trypsin 
hence residues in these loops could be mutated to reduce their interaction against 
trypsin whilst increasing matriptase inhibitory activity. Overall, promising matriptase 
inhibitory activity for SFTI-1 and MCoTI-II mutants has provided insight into the 
development of a potential potent matriptase inhibitor based therapeutics to halt the 
progression of cancer cells.  
 
8.2.2 Chapter 3 - SFTI-1 like frog peptides to treat Staphylococcal infection 
 
Staphylococcus aureus is one of the most notorious and virulent pathogens, with its 
resistance against existing antimicrobial drugs of global concern (Mera et. al., 2011). 
Due to the failure of current small molecules in combating S. aureus infections, 
antimicrobial peptides (AMPs) have been proposed as a potential solution to this 
problem. Peptides derived from frog skin secretions with high structural and sequence 
similarity to SFTI-1 were found through extensive literature and database searches, 
and they were termed SFTI-Like Frog (SLF) peptides These peptides had been 
reported to have in vitro antimicrobial activity against a range of microbes, along with 
trypsin inhibitory and immunomodulatory activity (Graham et. al., 2004, 2005; Li et. 
al., 2007; Mangoni et. al., 2003; Salmon et. al., 2000). However, unlike SFTI-1, these 
peptides were open chain making them less stable and prone to proteolytic cleavage. 
Consequently SLF peptides along with SFTI-1 were tested for the antimicrobial 
properties against S. aureus in mice, and the impact of cyclization on biological 
activity was also investigated. 
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Specifically, the peptides were tested using a mice wound infection model to 
determine their efficacy to treat Staphylococcal skin infection. Several peptides 
showed potent antibacterial activity against S. aureus, which was comparable to the 
positive control - neomycin sulphate, a broad-spectrum antibiotic used to treat skin 
infection. SFTI-1 was found to have no antimicrobial activity under the conditions 
examined. To determine if improving stability of the SLF peptides influenced 
bioactivity, the peptides were backbone cyclised. Although cyclisation improved 
serum stability, antimicrobial activity decreased. Overall, analysis of the SLF peptides 
in the in vivo infection model indicates that some of the peptides display promising 
antimicrobial properties against S. aureus.  
 
Further mutagenesis studies are required to improve the most active peptide, pYR. 
The reason for the negative impact of cyclization on antimicrobial properties is yet to 
be deciphered, however other strategies such as peptidomimetics could be used to 
improve the stability rather than backbone cyclization. The pre-clinical studies on 
SLF peptides are needed to understand the pharmacokinetics and pharmacodynamic 
properties in order to develop a safe and potent molecule. The ultimate objective of 
current antimicrobial research is to develop molecules active against the resistant S. 
aureus strain, therefore SLF peptides should be evaluated for their efficacy against the 
clinically most relevant strains such as methicillin resistant strains. Overall, AMPs are 
one of the most promising therapeutic strategies for combating infections and this 
work could offer therapeutic solutions against the clinically resistant microbes. 
 
8.2.3 Chapter 4 – SFTI-1 like frog peptides as melanocortin subtype selective 
antagonists 
 
In the current study I have shown that SFTI-1 is not only a potent serine protease 
inhibitor, but is also active in melanocortin receptor (MCR) binding assays and cAMP 
activity assay that measures the agonist and antagonist response of the compounds 
towards MCRs. This led us to investigate the response of SFL peptides to MCRs. The 
melanocortins are a family of structurally related protein hormones that play a 
significant role in numerous physiological processes, ranging from energy 
metabolism to skin pigmentation and memory functions (Hruby et. al., 2011a). Their 
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roles in these processes are controlled by highly conserved melanocortin receptors 
that are expressed in various human tissues in varying numbers. The development of 
potent and subtype selective ligands that have either agonist or antagonist responses 
to MCRs are required to conduct SAR studies. In addition, such ligands have 
pharmaceutical significance for the development of molecules that could moderate 
abnormal biological processes.  
  
Five SLF peptides showed selective antagonistic activity towards either MC4R or 
MC5R, which are linked to obesity and acne, respectively. Cyclization of two SLF 
peptides - ORB and ORB2K, resulted in a change of selectivity from MC4R to MC5R, 
but the reason for this change is not well understood. Further SAR studies for SFL 
peptides at MCRs are essential to understand the influence of amino acid content and 
cyclization. Because of the selectivity and moderate potency of native SFL peptides, 
further optimization of this group of peptides could potentially transform them into 
peptide-based drug leads. 
 
8.2.4 Chapter 5 - Understanding biosynthesis of naturally occurring cyclic 
plant peptides 
 
Cyclic peptides, such as cyclotides, have potential in drug design, but despite the 
discovery of more than 250 naturally occurring cyclotides, little is known about the 
mechanism of biosynthesis. Vacuolar processing enzyme (VPE) (asparaginyl 
endopeptidase (AEP)/legumain) has been proposed to play an important role in the 
maturation of particular cyclic peptide from plants, by mediating the transpeptidation 
of the precursor. However, direct evidence of the involvement of this enzyme in 
cyclization has not previously been shown. In the current study I have used purified 
AEP enzyme and a range of precursor peptide constructs based on the MCoTI-II gene 
to confirm that AEP is capable of cleaving and cyclizing the precursor protein to 
produce the mature peptide. The C-terminal pro-peptide region was found to play a 
more crucial role compared to the N-terminal region in the production of the cyclic 
peptide. Furthermore, the cyclization reaction appears to be less efficient than 
previously thought. This conclusion is based on the discovery of full-length acyclic 
variants of cyclic peptides in the seeds of M. cochinchinensis.  
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This study broadens our understanding of the processing and maturation of cyclotides. 
The pharmaceutically essential properties of these peptides has manoeuvred the 
research in this field towards better understanding of the structure-function 
relationships of cyclotides, gene structure, biological functions and therapeutic 
applications (Daly et. al., 2003). Knowledge gained from this study could be 
employed to produce cyclic peptide based therapeutic molecules in plants.  
 
8.3 BUSINESS MODEL AND PERFORMANCE OF BIOTECHNOLOGY 
INDUSTRY 
 
An analysis from the Food and Drug Administration (FDA) database, in the year 2011 
– 2012 showed that a disturbingly high proportion of drug failures occurred in clinical 
trial phase II (59 %) and phase III (52 %) trial. Such failure has a direct implication 
for the performance of biotechnology and pharmaceutical firms, particularly smaller 
more economically fragile ones (Arrowsmith et. al., 2013; DiMasi et. al., 2003). The 
reality is that biotechnology is driven by innovation in science; however, it needs 
industry to reach the market. Since the inception of this industry, modifying the BM 
for better performance, determining the success of this science-driven industry, and 
studying the evolution of this industry has remained a hot topic among analysts, 
pundits and scholars. The usual accounting measures to study the BM of firms cannot 
be used because the biotechnology industry does not earn revenue during its first few 
years of operation. The success of a biotechnology firm can be related to its survival 
based on its revenue growth, employment growth and patenting rate. This study is 
guided by the central research question: ‘To what extent has the change experienced 
in the biotechnology industry impacted on and been impacted by BMs in their 
operation over time?’  
 
To understand the evolution of the biotechnology industry, I needed a tool that could 
empirically evaluate change. After extensive literature research, to create the tool, I 
predominantly combined the organisational structure visualisation tool, BM canvas 
with the analytical technique, structural equation modelling, to observe quantitatively 
the dynamics of this industry. The US’s biotechnology industry was selected to be 
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observed, as it forms the core of modern medical biotechnology, and has a dominant 
presence in the global biotechnology sector. 
 
8.3.1 Chapter 6 – Understanding business model concept – from its genesis and 
development to continued reinterpretation 
 
After extensive literature screening, it was proposed that a BM could be better 
understood and defined if viewed through the lens of evolutionary economics, using 
the incorporation of scientific concepts such as evolution to study organisational 
change over time. This would employ the principles of change, dynamism, survival, 
adaptation and selection into the BM concept, which could assist in explaining the 
constant momentum observed in an organisation. After systematically screening the 
literature, a typical BM framework was found that is widely used in IT firms, mobile 
companies and e-businesses. However, this model could not be directly employed into 
the biotechnology industry due to the R&D-intensive nature of this industry, with its 
high ‘cash-burn’ rate. Therefore, the knowledge gained in the literature screening was 
used to propose key factors that influence the workings of biotechnology firms, and 
these components were combined to propose a BM framework for the biotechnology 
industry. 
 
The gaps identified in the literature on BMs were the absence of an evolutionary and 
dynamic concept that could illustrate the changes in the organisational processes, and 
the presence of five typical component-based BM frameworks that have been 
reinvented over the years. The literature was also screened to analyse the occurrence 
of the evolutionary concept in the BM publications. The keyword-based search was 
initially used with the aim of accessing a wider pool of publications; however, this 
method led to the capture of irrelevant articles. Therefore, a combination of keyword-
based and citation-based methodology was used to complete this study successfully. 
An evolutionary lineage of the BM concept was created that demonstrated the 
influence and interdependency of other closely related concepts (i.e. strategy and BM 
innovation). A more dynamic approach to this concept has led to the formation of 
another area of research: BM innovation. Gaps in the theoretical foundation of the 
BM concept and empirical proof for proposed frameworks are addressed in the 
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following chapter to build a BM framework for the biotechnology industry and 
observe its evolution over the years. 
 
8.3.2 Chapter 7: Effect of business-model changes on performance in the 
biotechnology industry  
 
To understand the success and failures of the biotechnology industry, I first need to 
understand the evolutionary changes since the inception of modern medical 
biotechnology industry. This thesis has studies the dynamics of this industry by 
observing its organisational inertia and adaptability in using the BM concept. This 
study emphasises the importance of R&D and revenue within the biotechnology 
industry, as well as their effect on firm performance. However, it does not address 
how firm performance could be improved or the connection of biotechnology firm 
performance to its external environmental factors. Further research could identify 
additional components of BMs specifically for the biotechnology industry to construct 
a more comprehensive framework for individual firms and the industry as a whole. 
For example, many studies explore one type of biotechnology firm to understand its 
BM, and test this BM in various organisational circumstances (Huelsbeck et. al., 
2011), however this addresses only one small section of a large industry. Future 
research could be conducted to compare the BMs of various types of biotechnology 
firms based on products, services or a hybrid-based value chain. This study is limited 
to the effect on firm performance of four key BM components – revenue, R&D 
expenditure, firm size and financial position, in the biotechnology industry. However, 
population study of the publicly listed biotechnology firms using key BM components 
resulted in a better understanding of the temporal change in their influence on 
performance over time.  
 
As biotechnology and pharmaceutical companies are becoming increasingly 
interdependent, it is important to test the effect of this relationship on the performance 
of each. Mergers and acquisitions among biotechnology firms are increasing, and are 
influencing firm performance. As such, it would be interesting to understand the 
changing landscape of these firms. It would also be highly informative to conduct 
cross-national studies to compare BM frameworks to assess their applicability and 
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generalizability across varying markets and organisational forms. Such research is 
important for the continuous advancement of business modelling in biotechnology. 
 
8.4 CONCLUDING REMARKS 
 
This research was driven by the need to address the problem of the continuously 
declining number of approved therapeutics worldwide. This decline is greatly due to 
failures of researchers to deliver novel and effective molecules to clinical trials, the 
incapability of bioentrepreneurs to meet the challenges of the drug-development 
process, and volatile market conditions. Therefore, this thesis amalgamates both 
components of drug discovery, that is, the science behind the creation of a drug in the 
laboratory and the business that delivers the drug to the market. The ultimate 
objectives were to generate peptide-based molecules with therapeutic potential, and 
assist biotechnology firms and venture capitalists by providing a tool to help them 
analyse an organisation’s profile. Such a tool can eventually be employed to alter the 
BM to ensure more profitability, sustainability and success.  
 
Disulfide-rich peptides from plants and frog-skin secretions reported in this thesis 
demonstrate potential as a drug candidate to treat cancer, Staphylococcal infection, 
obesity and acne. However, these molecules still require an enormous amount of 
optimisation to prove their competency and improve their potency. I propose to 
continue the developmental process on these peptides with the objective of 
transforming them into pharmaceutically significant therapeutics. biotechnology firms 
are the principal carriers of drug candidates to market, and they require the ability to 
learn and change in response to market needs to improve their chances of success. A 
BM-based tool offers an excellent platform from which to evaluate the state of a firm 
and its industry. After being used for evaluation, this tool can be used to ensure 
dynamic adjustment of the organisational environment to improve firm performance. 
The merger of promising science and a well-established business plan as presented in 
this thesis can improve the chances of attaining a greater number of novel therapeutics, 
which ultimately benefits society as whole.  
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The  main  bacterium  associated  with  skin  infection  is Staphylococcus  aureus,  occurring  especially  in  infec-
tions  acquired  via  surgical  wounds,  commonly  leading  to lethal  hospital-acquired  infections,  emphasizing
the  importance  of  identifying  new  antimicrobial  compounds.  Among  them,  cyclotides  have  gained  inter-
est  due  to  their  high  stability  and  multifunctional  properties.  Here,  cycloviolacin  2  (CyO2)  and  kalata
B2  (KB2)  were  evaluated  to determinate  their  anti-staphylococcal  activities  using  a subcutaneous  infec-
tion  model.  Anti-staphylococcal  activities  of 50  mM  for  KB2  and  25  mM  for  CyO2  were  detected  with  no
cytotoxic  activities  against  RAW  264.7  monocytes.  In  the  in  vivo  assays,  both  cyclotides  reduced  bacterial
load  and  CyO2  demonstrated  an increase  in the  phagocytosis  index,  suggesting  that  the  CyO2  in vivo  anti-
staphylococcal  activity  may  be  associated  with  phagocytic  activity,  additionally  to  direct  anti-pathogenic
activity.
©  2014  Elsevier  Inc.  All  rights  reserved.
Introduction
The skin is the largest and the most exposed organ of the human
body [26]. Although it is extremely effective in protecting host-
organisms against external environmental threats, skin infections
are common and may  be caused by bacteria, fungi or viruses [26,28].
The main bacterium associated with skin infections is Staphy-
lococcus aureus [2,27]. The majority of infections can be simply
treated, but some are less tractable, especially those associated with
surgical wounds, which are the most common hospital-acquired
infections and a major cause of morbidity and mortality [9,16].
These infections are increasingly caused by pathogens that are
resistant to conventional treatments, which highlights the impor-
∗ Corresponding author at: Centro de Análises Proteômicas e Bioquímicas, Pós-
Graduac¸ ão em Ciências Genômicas e Biotecnologia, SGAN 916 Av., W5  Norte –
Modulo C – Sala 222, CP 70790-160 Brasilia, DF, Brazil. Tel.: +556134487220 and
Fax: +55 61 33474797.
E-mail address: ocfranco@gmail.com (O.L. Franco).
tance of identifying new and more effective antimicrobial therapies
[1,32].
Antimicrobial peptides (AMPs) have emerged as a promising
new therapy with potential for the treatment of infectious dis-
eases [1,32]. Among AMPs, cyclotides have shown great promise
in a range of drug design applications. These head-to-tail cyclized
peptides, originally isolated from plants, incorporate six conserved
cysteine residues in their structure, which form three intercon-
nected disulfide bonds organized in a cyclic cystine knot (CCK)
motif. This motif makes cyclotides highly stable and has generated
interest in them as peptide-based scaffolds for designing medicines
[6,10,19]. The cyclotides can be divided into mainly two subfam-
ilies known as Möbius (Fig. 1A) and bracelet cyclotides (Fig. 1B);
the main characteristic that distinguishes one from the other is the
presence of a conserved cis-proline residue in loop 5 of the Möbius
subfamily, creating a twist in the circular backbone [4,8,10,29,40].
Here, the cyclotides cycloviolacin O2 (CyO2) and kalata B2
(KB2), respectively members of the bracelet and Möbius sub-
families (Fig. 1), were evaluated to characterize their cytotoxic
and anti-staphylococcal activities against S. aureus in an in vitro
microdilution assay and also in vivo using in a subcutaneous wound
http://dx.doi.org/10.1016/j.peptides.2014.10.019
0196-9781/© 2014 Elsevier Inc. All rights reserved.
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Fig. 1. Sequences and structures of cyclotides – (A) cycloviolacin O2 (CyO2) and (B) kalata B2 (KB2). All cyclotides contain six cysteines (I-VI) connected by disulfide bonds
to  form six loops (1–6). CyO2 and KB2 belong to the bracelet and Möbius subfamily, respectively. The two  subfamilies differ by the presence of conserved cis-Pro in loop 5
in  Möbius cyclotides that gives a conceptual backbone twist resembling a Möbius strip.
infection model. This study is the first report defining the efficacy
of cyclotides in an in vivo infection model.
Materials and methods
Peptides
The peptides used in this study, CyO2 and KB2, were
extracted from the aerial parts of the plants Viola odorata
(CyO2) and Oldenlandia affinis (KB2) with a 1:1 solution of
dichloromethane/methanol for 12 h. The extract was  partitioned
with water and the methanol/water fraction was rotary evaporate
to remove the methanol and lyophilized. The dried product was
resuspended in water and purified by RT-preparative HPLC using a
C18 column. Peptide masses were analysed using an ES-TOF micro-
mass LCT mass spectrometer [7].
Bactericidal microdilution assays
Minimum inhibitory concentrations (MICs) of the cyclotides
against S. aureus ATCC 25923 were determined using a standard-
ized dilution method according to NCSLA guidelines [39]. A single
bacterial colony was inoculated in Mueller-Hinton broth (MH)
(Himedia, India) and incubated for 12 h at 37 ◦C. Overnight-cultured
S. aureus was transferred to MH medium and cultured to expo-
nential phase (OD600 of ∼0.6). The culture was  centrifuged and
resuspended in sterile PBS and adjusted to a final amount of
1 × 105 colony-forming units (CFU) mL−1 by use of the equation
CFU mL−1 = OD600 nm × 2.5 × 108 [35]. For MIC  determination, pep-
tides were applied at various concentrations (1–200 !M)  from a
stock solution. Ten microliters of each concentration of peptide
solution was added to each corresponding well of a 96-well plate
(Becton & Dickinson, USA) and 90 !L of bacteria (1 × 105) in MH
medium was added. The polypropylene plates (TPP, Switzerland)
were incubated at 37 ◦C for 24 h. MICs were determined as the low-
est tested concentration that leads to complete inhibition (100%)
compared to the negative control group [33].
Animals
C57BL/6 mice weighting 18–22 g were used in this study, pro-
vided by the animal facility of the Catholic University of Brasilia.
All animals were housed in separate cages under a constant
temperature (22 ◦C) and humidity, with a 12-h light/dark cycle and
access to food and water ad libitum throughout the study. The mice
were euthanized by CO2 or ether inhalation at the end of the exper-
iments. All procedures including care and handling of the animals
were approved by the Ethics Committee of the Catholic University
of Brasilia number 005/13.
Cell cytotoxicity assays
Murine monocytes RAW 264.7 cells (Rio de Janeiro Cell Bank)
were seeded in 96-well microtiter plates in a concentration
of 1.0 × 105 cells per well, in DMEM medium, supplemented
with various concentrations of the tested cyclotides (0.3–15 !M).
After 24 and 48 h incubation, a 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) cell viability assay was
performed. Briefly, 60% of the medium was removed, and 10 !L of
MTT  (5 mg  mL−1) (Sigma, USA) solution was  added to each well and
the plate was incubated for 4 h in 5% CO2 at 37 ◦C. The blue form-
azan product produced was dissolved by the addition of 100 !L
of 100% DMSO (Mallinckrodt, Germany) per well. Plates were then
gently swirled for 5 min  at room temperature to dissolve the precip-
itate. The absorbance was monitored at 575 nm using a microplate
spectrophotometer (Bio-Tek, USA). Cytotoxicity was  determined as
a percentage of the maximum value after subtracting the back-
ground. The results were stated as the percentage of each sample
matched to the negative control (PBS buffer, pH 7.4) and cell cul-
ture was incubated in a lysis buffer (10 mM Tris, pH 7.4, 1 mM
ethylenediamine tetraacetic acid (EDTA), and 0.1% Triton X-100)
[39].
Induction of peritonitis and peritoneal cell collection
Peritonitis was induced as described by Leendertse et al. [23].
Mice were injected intraperitoneally with 200 !L of 3% thioglycol-
late solution. Peritonitis was  induced 6 h after injection [23]. After
this period, mice were anesthetized by 10% ketamine (80 mg kg−1)
(Agener Union – Brazil) and xylazine (10 mg  kg−1) (Agener Union
– Brazil), euthanasiated, and a peritoneal lavage was performed
with 5 mL  of RPMI 1670 medium using an 18-gauge needle. After
collection of peritoneal lavage fluid (PLF), cellular content was
immediately placed on ice. The numbers of total cells and neu-
trophils were counted using a microscope.
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Phagocytosis assays
Phagocytosis assays were conducted using neutrophils (105
cells per well). Controls (untreated and treated with DMSO 2.5%
and gentamicin 15 !M)  and treatments with the previously deter-
mined cyclotide MIC  concentration were conducted in RPMI 1640
medium. The cells were infected with S. aureus at a multiplicity of
infection (MOI) of 1:1 and incubated for 90 min. Following incuba-
tion, the cells were centrifuged, placed on slides and stained with
fast panoptic dye [34]. For neutrophil phagocytosis assay assess-
ments, at least 100 cells on each slide with or without phagocytosis
were counted. Additionally, the number of phagocytosed particles
and phagocytic index was calculated. In all experiments the phago-
cytosis confirmatory counts were conducted by an independent
observer. The phagocytic index (PI) was calculated using the
formula: PI equals the percentage of cell phagocytosis multiplied
by the average number of particles phagocytosed by each cell.
Murine surgical wound infection model
The murine surgical wound infection model was  performed as
described by McRipley and Whitney [24] with minor modifications.
Mice (n = 5/group) were anesthetized, their dorsal surface shaved
and the surgical area disinfected with 70% ethanol. A puncture was
performed on the dorsal surface using 6-mm punch biopsy needles
(Stiefel Laboratories, UK), and then 10 !L of S. aureus ATCC 25923
suspension (2 × 109 mL−1; previously cultured as described in the
section on bactericidal microdilution assays) was introduced into
the puncture wound, and the skin was closed with one silk suture
[41]. Wounds were treated every 24 h with 20 !L of a solution
containing 0.75–3 mg  kg−1 of cyclotide. Vetaglos® (gentamicin
0.5%, sulfanilamide 5% and sulfadiazine 5%) ointment (Vetnil,
Brazil) was used as a positive control and PBS as negative control.
Mice were euthanized 7 days post-surgery; the wounded mus-
cle tissue was  excised, weighed, and homogenized in 1 mL  of PBS.
Serial homogenate dilutions were plated in triplicate on mannitol
salt agar (Himedia, India) and the results were stated as CFU g−1 of
tissue [18,35].
Statistical analysis
Data are presented as mean ± SD of all samples. Values of p < 0.05
were considered statistically significant. GraphPad Prism software
v5.0 (GraphPad Software, USA) was used for all statistical analyses
[33].
Results
In vitro antibacterial activity
The activities of the cyclotides against S. aureus were evalu-
ated in vitro and MICs determined by microdilution tests (data not
shown). The MIC  for KB2 was 50 !M and that for CyO2 was 25 !M.
Effects of cyclotides in cell viability/metabolism
Cytotoxicity evaluation against RAW 264.7 cells for CyO2
(Fig. 2A) and KB2 (Fig. 2B) did not show significant deleterious activ-
ities at the concentrations tested when compared with the control,
demonstrating that these peptides show no cytotoxicity to RAW
Fig. 2. Effect of cyclotides CyO2 (A) and KB2 (B) on viability of murine cell line RAW 264.7. Cells were incubated for 24 and 48 h with CyO2 (27–438 nM), and KB2 (29–465 nM).
Values represent the mean ± SD and data were analyzed by one-way ANOVA and Bonferroni test: * p < 0.5; ** p < 0.01; *** p < 0.001 compared to untreated group. Recovery of
bacterial load of the wound from the C57BL/6 mice infected with S. aureus ATCC 25923 after 6 days of treatment. The wounds were inoculated with 2×109 cells mL−1 of bacteria
and  treated with: DMSO 2.5%, Vetagls® (gentamicin 5 mg  kg−1, sulphanilamide 50 mg  kg−1, sulfadiazine 50 mg  kg−1); (C) CyO2 (0.75 mg kg−1, 1.5 mg kg−1, 3.0 mg  kg−1); (D)
KB2  (0.75 mg kg−1, 1.5 mg  kg−1, 3.0 mg  kg−1). Values represent the mean ± SD and data were analysed by two-way ANOVA and Tukey’s test, with p < 0.05 as significant: *
p  < 0.05; ** p < 0.01; *** p < 0.001 compared to the negative control. For the phagocytosis assay, neutrophils extracted from healthy animals were incubated for 1.5 h with
controls: DMSO (2.5%), gentamicin (15 !M) or DMEM;  and treated with: (E) CyO2 (25 !M)  or (F) KB2 (50 !M).  Values represent the mean ± SD and data were analysed by
one-way ANOVA and Bonferroni test: * p < 0.5; ** p < 0.01; *** p < 0.001 compared to untreated group.
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264.7 cells, at the evaluated concentrations (CyO2 ranging from
437.8 to 27.4 nM and KB2 ranging from 465.2 to 29.1 nM).
Verification of bacterial burdens recovered from wounds
Mice treated with 0.75 mg  kg−1 of CyO2 showed a slight reduc-
tion in bacterial load of 108 to ∼107. When treated with 1.5 and
3.0 mg  kg−1, the bacterial load was reduced to ∼106 (Fig. 2C). In ani-
mals treated with 6.0 mg  kg−1 of CyO2, a clear decrease in bacterial
load of 108–105 was observed (data not shown). The infected mice
treated with KB2 showed a decrease in bacterial load of 108 to ∼106
in all tested concentrations (0.75, 1.5 and 3.0 mg  kg−1) (Fig. 2D).
Evaluation of phagocytosis
To evaluate possible indirect antibacterial activity through stim-
ulation of the host, we measured the activity of cyclotides on
the phagocytic activity of neutrophils following S. aureus infec-
tion. Neutrophils treated with KB2 (Fig. 2E) showed no variation
in the phagocytic index compared with controls. However, CyO2
increased the phagocytic index by ∼545% (Fig. 2F), suggesting that
it has the capability of stimulating phagocytosis of S. aureus by
neutrophils.
Discussion
With the rapidly increasing prevalence of multidrug-resistant
bacteria and the scarcity of new antibiotic research in the pharma-
ceutical industry, the use of AMPs could be a promising alternative
to conventional antibiotic treatments. AMPs are multifunctional
mediators of the innate immune response with direct antimicrobial
and immunomodulatory activities. Among AMPs, cyclotides are
notable for being small cyclic peptides with six conserved cysteine
residues that form three interconnected disulfide bonds, thereby
giving them greater stability than linear AMPs [13,17,30]. Thus,
cyclotides could potentially overcome some of the limitations of
peptides as drugs, such as sensitivity to proteolytic degradation
[12,13,30].
In the present study the antibacterial activities of KB2 and CyO2
against S. aureus ATCC 25923 were evaluated. CyO2 had the best
anti-staphylococcal activity in vitro whereas KB2 had only slightly
lower potency. In the literature there are two  studies in which
cyclotides were tested against S. aureus.  Tam et al. [36], reported
that KB1, circulin A and B, and cyclopsychotride showed MICs
against S. aureus of 0.26 !M,  0.19 !M,  13.5 !M and 39 !M,  respec-
tively under low salt conditions but no activity under physiological
salt conditions [36]. Pranting et al. [31] evaluated CyO2, KB1, KB2,
Vaby A and D for activity against S. aureus,  but no deleterious activi-
ties against S. aureus were obtained using the radial diffusion assay,
performed with 4 × 106 CFU in a culture medium based on sodium
phosphate buffer containing 0.03% (w/v) trypticase soy broth and
1% agarose, with wells made using a 3 mm gel punch added 5 !L of
sample, then incubated for 18–24 h, 37 ◦C. However, in microdi-
lution assays, these cyclotides inhibited S. aureus growth: CyO2
(>50 !M),  KB1 (>100 !M),  KB2 (35 !M),  Vaby A and D (>90 !M)
[31].
Given the confirmation in our study of the anti-staphylococcal
activity of cyclotides KB2 and CyO2, we tested them for effects
on cell viability of murine RAW 264.7 monocytes and found
that low doses did not cause any harmful effect. Otherwise any
evaluation was performed at higher concentrations. Only KB2
showed slight cytotoxicity at higher doses (>15 !M)  (data not
shown). Similar data were obtained by Grundemann et al. [11],
where O. affinis extract and KB1 (1.8–14.0 !M)  reduced peripheral
blood mononucleated cell (PBMC) proliferation. That study showed
that at concentrations of 1.8–14 !M a dose-dependent correlation
decrease in cell proliferation was  observed.
Since in vitro antibacterial activity, but no mammalian cytotox-
icity, was observed in the two cyclotides tested here, the next step
was to evaluate their in vivo anti-staphylococcal activity using a
surgical S. aureus wound infection model. To our knowledge, there
has been no previous report of cyclotide antimicrobial activity in an
animal infection model. The cyclotides showed similar responses,
and both decreased bacterial load. Interestingly, a progressive dose
response was  not observed, probably due to the low concentrations
tested. A similar phenomenon was  observed with the antimicrobial
peptide PXL150, which all tested concentrations showed activity
toward S. aureus [25].
A number of other studies have reported in vivo antibacterial
activity of AMPs using the surgical wound model used here. For
example, coprisin (5 mg  kg−1), in addition to reducing the bacte-
rial load, accelerated the wound healing process [21]. In another
study, PEP35 exhibited poor antimicrobial activity in vitro, with
MIC50 values for various clinical strains of S. aureus isolates of
approximately 500 !g mL−1. Nevertheless, this peptide showed
immunomodulatory activity, and when tested in vivo in the sur-
gical wound model, reduced the bacterial load to approximately
102 CFU g−1 tissue, probably recruiting neutrophils to the infection
site [22]. In another study, epinecidin peptide-1 (EPI-1) was  evalu-
ated against MRSA (106 CFU), with treatments placed on the wound
5 min  after infection, which was covered after 30 min to prevent
interference by the animal [15]. Groups treated with EPI-1 showed
an improved survival rate with a decrease in bacterial load of 106 to
∼20 to CFU g−1 tissue [15]. In a study using the same methodology,
the pardaxin peptide (GE33) led to complete bacterial clearance in a
surgical wound model infected with 106 CFU of S. aureus.  The activ-
ities of the cyclotides tested here are comparable to those reported
in these previous studies.
To observe whether the in vivo effects of the cyclotides could
be related simply to direct antibacterial activity or also to addi-
tional indirect host activity, a phagocytosis assay was performed
to assess the stimulation of neutrophils to increase S. aureus
phagocytosis. KB2 showed no change compared with the controls,
suggesting that the mechanism of action is based predominantly
on bactericidal activity. By contrast, CyO2 showed an increase
in phagocytic index of approximately 550%, suggesting that its
in vivo activity against S. aureus might be associated with both
bactericidal and phagocytic induction in the host animal. It is
interesting that this dual strategy is not seen with KB2. Other
antimicrobial peptides have been reported to induce phagocytic
activity, such as LL-37, which was  able to enhance phagocytosis
of opsonized Gram-negative and Gram-positive bacteria, besides
improving the phagocytosis of non-opsonized Escherichia coli in
human macrophages [38]. Another peptide that leads to improved
phagocytic activity in macrophages is hLF1-11, which was shown
to improve the phagocytosis of not only S. aureus,  but also Candida
albicans [37].
In conclusion, CyO2 and KB2 might represent a starting point
for a novel therapeutic approach for the local treatment of infec-
tions. Cyclotides can be produced recombinantly [3] or chemically
[5], which opens new frontiers for the production of cyclotide-
based medicines. The exceptional stability and cell penetrating
properties of cyclotides make them possible scaffolds for the
grafting of known active peptides for the engineering of peptide-
based drugs [20]. Such an approach might be used to enhance
the natural antimicrobial activity of the cyclotide framework,
which appears to be driven mainly by membrane binding and
disruption [14]. However, more studies are needed to evalu-
ate the applicability of these cyclic AMPs as well as to shed
additional light on their in vivo antibactericidal mechanism of
action.
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Cyclotide biosynthesis
David J Craik and Uru Malik
Cyclotides are bioactive macrocyclic peptides from plants that
are characterized by their exceptional stability and potential
applications as protein engineering or drug design frameworks.
Their stability arises from their unique cyclic cystine knot
structure, which combines a head-to-tail cyclic peptide
backbone with three conserved disulfide bonds having a
knotted topology. Cyclotides are ribosomally synthesized by
plants and expressed in a wide range of tissues, including
leaves, flowers, stems and roots. Here we describe recent
studies that have examined the biosynthesis of cyclotides and
in particular the mechanism associated with post-translational
backbone cyclization.
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Introduction
Cyclotides [1!] are head-to-tail cyclic mini-proteins of
approximately 30 amino acids that incorporate a cystine
knot motif built from their six conserved cysteine resi-
dues. They occur in a range of plant families, including
the Rubiaceae (coffee), Violaceae (violet), Fabaceae
(legume), Solanaceae (nightshade) and Cucurbitaceae
(cucurbit). Dozens to hundreds of different cyclotides
occur in leaves, flowers and other tissues of individual
plants [2], where their natural function is thought to be
host defense agents [3,4]. They were originally discov-
ered on the basis of the pharmaceutically interesting
bioactivities of extracts from a few medicinal Rubiaceae
and Violaceae plants, but the number of known cyclotides
has dramatically increased over the last few years since
focused discovery efforts have been directed at them
[5!,6!,7!,8!,9,10]. Cyclotides have attracted interest
because of their unique topology, exceptional stability
[11], and potential applications as protein engineering
or drug design frameworks [12–16]. It has also been
reported recently that they might have immunosuppres-
sive properties [17].
Cyclotides are just one class of a growing number of
circular proteins found in nature [5!,18!,19,20,21!!,22].
Until a decade or so ago, most known naturally occurring
cyclic peptides were small (<12 amino acids) and thought
to be non-ribosomally synthesized, as exemplified by the
well-known fungal cyclic peptide, cyclosporine [23].
However, it is now clear that all kingdoms of life produce
ribosomally synthesized cyclic peptides [24]. They range
in size from around six to 80 amino acids [25] and so far
little is known about their biosynthesis, other than that
they are gene-encoded, expressed as precursor proteins
and post-translationally processed to produce a cyclic
backbone. Cyclotides are the largest family of circular
proteins, with more than 250 sequences reported so far
[26]. In this article we review progress in delineating their
biosynthesis, focusing on articles published over the last
two years. Other recent reviews provide background on
their discovery, characterization and applications [5!,27–
32], and CyBase [26,33] is a regularly updated database
where information on cyclotides and other circular
proteins can be found.
Figure 1 shows selected cyclotide sequences, highlights
some properties that make them of interest, and sum-
marizes their prevalence among the five major plant
families in which they have been discovered so far. It
also shows the structure of the prototypic cyclotide, kalata
B1, and gives an overview of the standard nomenclature
used to define the six conserved Cys residues (I–VI) and
six backbone loops (1–6) between them. Figure 1 also
highlights the location of the ligation point where the
proto-termini are joined to form the circular backbone,
and shows the cystine knotted structure at the core of
cyclotides, linking CysI–CysIV, CysII–CysV and CysIII–
CysVI. Cyclotides have been divided into three subfami-
lies, the Mo¨bius, bracelet and trypsin inhibitor subfami-
lies, on the basis of structures and activities [32].
Cyclotide precursor sequences
The first indication that cyclotides are ribosomally syn-
thesized came when the precursors for several cyclotides,
including kalata B1, B2, B6 and B7, were deduced from a
cDNA library prepared from Oldenlandia affinis (Rubia-
ceae) leaves [34!]. This African plant was the first species
in which cyclotides were discovered, on the basis of their
role as uterotonic agents in a medicinal tea used to
accelerate childbirth [35]. Since then a large number
of cyclotides and their precursor sequences have been
reported from Rubiaceae and Violaceae plants [8!,36,37]
and some common features of the gene architectures have
become apparent. The most recently discovered cyclo-
tide precursors are from the Solanaceae [7!], Fabaceae
Available online at www.sciencedirect.com
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[38!!,39!!], and Cucurbitaceae plant families [40!], some
species of which are widely used in human and animal
diets. The discovery of cyclotide genes in plants from
these families places additional prominence on cyclo-
tides; in particular, suggesting the possibility that humans
might have routinely ingested cyclotides, thus providing
confidence that they might have a good safety profile in
pharmaceutical applications. Furthermore, the new pre-
cursor protein architectures suggest diversity in the way
cyclotides are biosynthesized.
Figure 2 shows representative structures of the precursor
proteins of cyclotides from various plant families. The
precursors typically incorporate an endoplasmic reticu-
lum (ER) signal sequence, which is followed by an N-
terminal propeptide, part of which is often classified as an
N-terminal repeat (see below). This is followed by the
cyclotide domain and a C-terminal pro-peptide. In some
cases elements of this modular structure are repeated,
namely the cyclotide-encoding domain and its flanking
N-terminal and C-terminal regions, referred to as the
N-terminal repeat (NTR) and C-terminal repeat
(CTR) respectively. For example, the first cyclotide gene
discovered, Oak1 (O. affinis kalata B1) encodes a single
copy of kalata B1, whereas the Oak4 gene encodes three
copies of kalata B2. Interestingly, different genes can
produce the same cyclotide. For example Oak1 and Oak10
both produce kalata B1. Multiple genes are present in a
given plant, and combined with the multidomain nature
of some of the genes, this accounts for the large number of
cyclotides expressed by an individual plant. Generally
there is little overlap in cyclotide content between differ-
ent species, but in some cases the same cyclotide is
produced in different species. Kalata B1, for example,
occurs in several plant species in addition to O. affinis,
including Viola odorata, whose Voc1 precursor is shown in
Figure 2.
As is apparent from the precursor sequences in Figure 2, a
conserved feature of all cyclotides, besides the six Cys
residues, is an Asn or Asp residue at the cyclotide proto C-
terminus. Also highly conserved is a small amino acid
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Cyclotide distribution in the plant kingdom, sequences and structures. (a) Representative examples of cyclotide sequences from each of the five major
plant families expressing cyclotides are shown; the total number of cyclotides reported in each family is in a box within each circular sequence. (b)
Cyclotides have highly conserved Gly and Asx (Asn or Asp) residues at their proto N-termini and C-termini, respectively; a selection of sequences
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(Ala or Gly) at the proto N-terminus. These features also
apply to the sunflower trypsin inhibitors [41!], another
family of plant-derived cyclic peptides. On the basis of
this Asn conservation, it was hypothesized that an aspar-
aginyl endopeptidase (AEP) might be involved in C-
terminal processing of cyclotides [34!]. So far, nothing
is known about processing events, assumed to be enzy-
matic, at the N-terminus but it is assumed that N-term-
inal processing occurs first, which then exposes the amino
group of the N-terminal Gly or Ala to act as a nucleophile
for an intramolecular transpeptidation reaction mediated
by AEP. Transpeptidation is, in principle, more efficient
than the alternative of N-terminal cleavage, followed by
C-terminal cleavage and then ligation, and is strongly
supported by a range of mutagenesis studies.
Before describing these mutagenesis studies, we note that
the majority of cyclotide genes reported so far can be
regarded as ‘dedicated’ specifically to producing cyclo-
tides, but surprisingly, those from the Fabaceae plant
Clitoria ternatea (butterfly pea) are somewhat unusual
(Figure 2). In these precursors, the cyclotide domain
appears to have hijacked an albumin gene, replacing
one domain of a two-domain albumin sequence with a
cyclotide sequence [38!!,39!!]. Interestingly, the
replaced albumin domain has a cystine knot structure
but with a sequence quite different from the cyclotide
domain that takes its place. An analogous hijack event
occurs for the precursor of the small cyclic peptide SFTI-
1 in another type of albumin [41!]. The evolutionary
origins of these unusual events are not yet understood,
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Selected cyclotide precursors from five cyclotide-positive plant families. Sequences of cyclotide precursor proteins from plants in the Asterid and
Rosid dicot lineages and from a monocot (Poaceae family) plant are shown. The color coding is: signal sequence (blue), N-terminal repeat — NTR (red),
cyclotide domain (green), acyclotide domain (light green), C-terminal repeat — CTR (pink), C-terminal propeptide — Ctpp (orange) and, in the case of
the Fabaceae gene, albumin (grey). The N-terminal propeptide region Ntpp is represented by a black line with a break to aid alignments; the number of
residues in this domain is shown above the breakpoint. Some precursors like Oak10, Vok1 and TIPTOP 1–3, contain multiple cyclotide domains, which
can contain different cyclotides or repeats of the same cyclotide, as indicated with a bracket ( )n, where n is the number of repeated domains. The
sequences below the ( ) region indicate the repeated domain with or without (black font) the variation in the residues. Some cyclotides are present in
multiple precursors (e.g. kalata B1 in Oak 1 and Oak10), or in different plant families (kalata B1 in Oak 1 and Vok1).
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but they indicate that alternative biosynthetic starting
points are available to make cyclotides.
Mutagenesis studies to explore biosynthesis
Support for the AEP hypothesis has been generated by
recent mutagenesis studies in transgenic tobacco and
Arabidopsis [42,43!,44!]. Neither plant naturally pro-
duces cyclotides, but does so after transfection with
cyclotide genes. Figure 3 summarizes the effects of
mutations in the genes for two prototypical cyclotides,
kalata B1 from the Mo¨bius subfamily and MCoTI-2 from
the trypsin inhibitor subfamily [40!,45!!]. Single site
mutations near the N-termini or C-termini dramatically
modulate the production of cyclotides and in particular,
substituting the Asn to any other residue abrogates the
production of cyclic peptide, strongly supporting the AEP
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Summary of in vivo mutagenesis studies undertaken to help unravel the cyclization mechanism of cyclotides. Perturbations were induced in cyclotide
genes or in AEPs: AEP1 represents enzyme or gene silencing using a caspase inhibitor or virus induced gene silencing, respectively, and AEP2 denotes
AEP-null transgenic plants into which cyclotide genes were transfected. Various versions of Oak1 (encoding kalata B1) and TIPTOP2 (encoding MCoTI-
2) cDNA were cloned into the non-cyclotide producing plants Nicotiana benthamiana (Nb) and/or Arabidopsis thaliana (Ab) to observe production ( ),
no production ( ), an increase ( ) or decrease ( ) in the amount of respective cyclotides using matrix-assisted laser desorption/ionization (MALDI)
mass spectrometry (MS). For clarity, only residues that were mutated are shown; D represents a truncated CTR/Ctpp. The bracketed region ([ ])
corresponds to both truncated and mutated Ctpp domains. References a–d are: (a) Saska et al. [44!]; (b) Gillon et al. [43!]; (c) Conlan et al. [45!!]; and
(d) Mylne et al. [40!].
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hypothesis. A number of other interventions, aside from
substrate mutations, have been made in these trans-
genic plant experiments, including the use of gene
silencing to knock down expression of AEP [44!] and
also the use of AEP-null plants for studying expression
of MCoTI-2 [40!]. Reduced, or no, production of cyclic
peptide is observed, respectively, following these inter-
ventions, consistent with a role for AEP in cyclotide
biosynthesis.
C-terminal residues flanking the cyclotide domain also
appear to be important, with the apparent requirements
being a small amino acid at S1’ and a Leu at S2’.
Truncation studies have also established that a minimum
of two amino acids is required in the C-terminal propep-
tide (or CTR) for cyclization to occur, consistent with the
reaction being a transpeptidation rather than simple
ligation [45!!]. This transpeptidation hypothesis is sup-
ported by the existence of the naturally occurring chassi-
tide C2 peptide, whose precursor (Figure 2) contains just
two residues (Glu-Ile) in its C-terminal propeptide [46!],
and is effectively a naturally occurring example having a
partially truncated CTR.
Further evidence for a transpeptidation reaction can be
seen from the fact that recently a number of linear
cyclotide derivatives have been discovered
[7!,10,47,48!]. We have suggested the term ‘acyclotide’
for these molecules [7!] reflecting that they are cyclotide-
like, but lack one or more features required for cycliza-
tion. In our opinion acyclotide is preferred over the term
‘uncyclotide’ [46!], which implies that these peptides
were once cyclic but no longer are. Inspection of the
genes for these linear cyclotide derivatives shows that
they lack either the vital Asn/Asp [10], or sufficient CTR
residues, and thus are unable to be cyclized by an AEP-
mediated transpeptidation reaction. These natural
mutations thus provide further support for AEP being
centrally involved in biosynthesis.
Biosynthetic mechanism: repurposing an
existing enzyme
Figure 4 summarizes a mechanism that has been pro-
posed for cyclization [43!]. It initially follows a classic
cysteine protease cleavage reaction involving the for-
mation of an acyl enzyme intermediate. Normally this
intermediate would be resolved by hydrolysis. However,
in the case of cyclic peptide production, it appears that
the N-terminal (small) amino acid of the partly processed
cyclotide precursor is able to act as a nucleophile and
complete a cyclization rather than hydrolysis reaction.
This mechanism also applies to SFTI-1 [41!], which has
an Asp residue at the C-terminus and a Gly at the N-
terminus of the relevant region of the precursor. We
speculate that the conformations of SFTI-1 and cyclotide
precursors are held in place by their disulfide bonds,
leaving the N-termini and C-termini in close proximity
to facilitate these reactions.
Figure 4 also provides a broader overview of the whole
biosynthetic process, showing the presumed intracellular
locations of key steps in the pathway. A recent study
showing that the Oak1 precursor is trafficked to the
vacuole [49!!], is consistent with the AEP hypothesis,
given that AEPs are alternatively known as vacuolar
processing enzymes in view of their vacuolar location.
In that study it was found that the N-terminal propeptide
was sufficient to target the Oak1 precursor to the vacuole.
As illustrated in Figure 4, it is proposed that the cyclotide
precursor is folded in the ER and then targeted (via the
NTR) to the vacuole for cyclization and storage. A
number of auxiliary proteins probably play a role in this
process as tentatively identified in transcriptome studies
[50], but there is still more to be done to identify their
roles. A protein disulfide isomerase (PDI) was recently
isolated from O. affinis [51] and shown, in vitro, to facili-
tate the production of cyclic peptide from an artificial
linear precursor. There is no evidence yet to determine
whether this PDI is involved in the in vivo biosynthesis
but it seems probable, as is schematically illustrated in
Figure 4.
Although there is little knowledge of how cyclization
evolved, we have suggested [52] that fortuitous acquisition
of the key Asn/Asp mutations predisposed cyclotide-like
precursors to processing by already existing AEPs which
are ubiquitous in plants. Such linear cyclotide precursors
were first found from bioinformatics studies [53] and more
recently as isolated peptides in a Poaceae family plant
[48!]. In some plants, gene duplication appears to have
played a role in facilitating cyclization. The Cucurbitaceae
family plant family, Momordica cochinchinensis, shows the
greatest duplication of cyclotide-like sequences, with
recently reported genes [40!] encoding 4–7 cyclotide
domains. Uniquely, the C-terminal domain of these genes
encodes a linear cyclotide-like molecule. For example, the
TIPTOP1 gene encodes one copy of the cyclotide MCoTI-
1, four copies of MCoTI-2 and one copy of MCoTI-5, an
acyclic peptide that is cyclotide-like in every way apart
from the circular backbone (Figure 2). TIPTOP2 and TIP-
TOP3 encode even more cyclotide domains.
A wide range of chemical [54–56] and biological [57–60]
studies on the synthesis of cyclotides have been carried
out recently and these typically involve the formation of a
head-to-tail cyclic backbone before disulfide bond for-
mation, rather than the reverse, as is thought to occur in
nature, that is, disulfide bond formation followed by
cyclization via the AEP as described above. The closest
mimic to the natural biosynthesis is perhaps a chemo-
enzymatic approach in which a linearized version of
MCoTI-2 was chemically synthesized and then enzy-
matically cyclized using trypsin [61!!]. Plant cell culture
550 Mechanisms
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systems have also been extensively applied for the pro-
duction of cyclotides [62,63].
Outlook
There has been significant progress made in recent years
in our understanding of the biosynthesis of cyclotides, but
much remains to be discovered. In particular nothing is
known about the nature of N-terminal processing.
Furthermore, the role of PDI, if any, remains to be
confirmed in vivo. In early studies, cyclic versions of
cyclotides were discovered almost exclusively in the
absence of linear homologues, reflecting the efficiency
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Schematic representation of the major steps thought to occur in cyclotide processing inside a plant cell. Panel (a) shows the structure of a generic
cyclotide precursor protein (prepropeptide) using the same color coding as in Figure 2 and highlights proposed N-terminal and C-terminal enzymatic
processing points. A series of in vivo mutagenesis and transfection studies [43!,44!,45!!,49!!,50] is schematically illustrated below the precursor,
which led to: (b) the hypothesized steps involved in the intracellular processing of cyclotides and (c) a proposed mechanism for the AEP-mediated
cyclization reaction. In panel (b) the various steps in the biosynthesis pathway are highlighted, including: (i) transcription of cyclotide DNA into RNA and
translation to the prepropeptide [34!]; (ii) targeting of the prepropeptide to the ER, removal of the signal sequence and folding of the cyclotide
precursor, possibly assisted by PDI [51]; (iii) targeting of the propeptide to the vacuole, presumably by the NTR (or Nttp) [49!!]; (iv) cleavage at the N-
terminus of the cyclotide domain by an unknown enzyme to release the NTR and expose a small amino acid (Gly/Ala) as the proto N-terminus of the
cyclotide domain; (v) transpeptidation to release the Ctpp [43!,44!]; and (vi) form cyclic peptide [45!!]. The last two steps probably occur in a concerted
manner. In panel (c) the proposed mechanism of cyclization of a cyclotide by AEP is shown: (i) AEP cleaves and releases the CTR or Ctpp (depending
on whether the cyclotide is from a terminal or internal domain) leading to formation of an acyl enzyme intermediate via attack of the AEP active site thiol
on the carbonyl of the scissile bond; (ii) the excised Cttp exits the enzyme active site and is replaced by a sterically homologous region from the N-
terminus of the cyclotide domain; (iii) the primary amine of the N-terminal Gly (or Ala) acts as a nucleophile to attack the acyl enzyme intermediate; and
(iv) the enzyme is regenerated and the cyclized product (cyclotide) exits the active site. The middle panel of the diagram schematically represents the
process of mutating selected residues in the cyclotide precursor (a), transfecting the modified genes into model plants and detecting the presence of
cyclic product using mass spectrometry. A lack of production of cyclic peptide can be used to draw conclusions about the importance of individual
residues in the cyclization process. Examples are shown for transfection of two mutants into wild-type plants, leading to cyclic products and into an
AEP-null plant where no cyclization occurs.
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of processing from linear precursors. However, recently
there have been increasing discoveries of acyclotides,
whose corresponding genes lack the vital Asn or key
flanking residues in the precursor. These and other dis-
coveries confirm that the cyclization process in vivo
appears to be a transpeptidation reaction rather than a
simple ligation of a segment excised from the precursor,
but raise questions about the functions of cyclic versus
acyclic homologues.
Another question that remains unresolved, is since cyclo-
tides are stored in intracellular vacuoles but are known to
disrupt membranes, why do they not leach out of vacuoles
and exhibit toxicity against their host plants? Recent
studies suggest that cyclotides interact with specific lipids
[64,65] and the vacuolar membrane composition might be
tailored to resist disruption, but this has not yet been
investigated. Alternatively, it has been suggested that
cyclotide self association might be a way of deactivating
them under conditions of high concentration storage such
as would occur in vacuoles [66].
Cyclotides have been demonstrated to be stable templates
for the insertion (grafting) of a wide range of pharmaceu-
tically relevant epitopes, including angiogenic, anti-angio-
genic, analgesic and protease inhibitory epitopes, among
others. Should these drug leads advance to the clinic then
the cost-of goods needs consideration, and an understand-
ing of biosynthesis could greatly facilitate the use of plant-
based expression systems for the production of inexpen-
sive cyclotide-based pharmaceuticals [67!]. Such appli-
cations would complete a cycle of first using plants to
discover novel protein frameworks, adapting them to
stabilize pharmaceutical epitopes, and then adapting the
natural biosynthetic machinery of crop plants to make the
designer pharmaceutically active cyclotides.
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